The Marketing Group Makes Two Senior Appointments to Strengthen Communications Team

· Phillip Lord appointed as a senior investor relations advisor and Stella Tan appointed as Director of Communications · Appointments significantly strengthen the Group’s investor relations and communications capabilities Stockholm, 2nd December 2016 – THE MARKETING GROUP PLC (“the Group”) (ST: TMG, FRANKFURT: 2MG), the world’s leading digital marketing and advertising agglomeration, is pleased to announce the strengthening of its investor relations and communications organization with two senior appointments, effective immediately.  Phillip Lord has been appointed as a senior advisor to the Board of Directors, with responsibility for expanding the Group’s institutional ownership and brokerage relationships and advising on its investor relations strategy. Stella Tan, who replaces Hannah Middleton as Director of Communications, will lead The Marketing Group’s investor relations and corporate communications activities aimed at reinforcing the Group’s reputation among key stakeholders.  Adam Graham, Chief Executive Officer, The Marketing Group PLC said: “I am delighted to welcome Phillip Lord and Stella Tan to The Marketing Group. Phillip’s relationships with the global institutional investor and private client communities built up over a long career working in the capital markets will prove highly valuable as the Group looks to expand its shareholder base. Stella’s appointment to lead our communications team is another important step to improving our investor relations structure and I am confident that together, they will significantly strengthen the Group’s capabilities to manage and expand our relationships with the investment community.”  Phillip Lord has more than 20 years of experience working in the equity and debt capital markets. Since 2011 Phillip has served as Managing Director of Montreux Capital Group, a Swiss investment advisory firm with a global institutional and private client base. Prior to that, he held senior positions in the capital markets teams of leading international banks and investment firms including Queen Street Capital, Jefferies LLC, Nomura, HSBC and Capital Group.  Stella Tan has more than ten years of experience working in investor relations and as an equities research analyst. She joins The Marketing Group with experience from global corporate and financial communications agencies, where she held senior positions in Singapore. Earlier in her career Stella spent six years as a sell-side equities analyst at banks and research firms including Standard Chartered Bank and UOB Kay Hian Research. For more information, please contact Malcolm Robertson / Tom Evrard Phone: +65 6831 7829 / 6831 7801 E-mail: ftiunitygroup@fticonsulting.com  This information is information that The Marketing Group plc is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 7am CET on 2nd of December 2016. The Marketing Group in brief  The Marketing Group plc is a global marketing and advertising company that brings together a portfolio of successful and independent digital marketing businesses, each offering unique and complementary products and services. Together these businesses make up a global network offering a full suite of digital marketing and advertising services. The consolidated group supports its subsidiaries with management and coordinating activities as well as a common operating platform. The Marketing Group was incorporated in May 2015 and listed on Nasdaq First North Stockholm on 8 June 2016. Mangold Fondkommission AB, +46 8-5030 15 50, is the Company’s Certified Adviser and liquidity provider. For more information, please visit the Company’s website www.marketinggroupplc.com. 

ICA Real Estate to sell ICA Eiendom Norge AS

The sale of the company ICA Eiendom includes a property portfolio as well as the existing organisation. In all, the sale covers 58 properties in Norway, and the transaction is expected to close in February 2017. The sale of ICA Eiendom will generate a capital gain of approximately SEK 400 million¹ for ICA Gruppen, which will be recognised during the first quarter of 2017. With this sale the entire property portfolio in Norway will have been divested. A total of 73 properties have been sold for SEK 2.8 billion, generating a capital gain of slightly more than SEK 430 million. “Interest in the properties has been great,” comments Per Strömberg, CEO of ICA Gruppen. “We are satisfied with the purchase price and that our employees at ICA Eiendom are being offered continued employment. It feels good that we can now conclude the process of leaving Norway that we began in 2014.” For the sale of ICA Eiendom, Pangea Property Partners has served as financial advisor, Advokatfirmaet Haavind has served as legal advisor, and Handelsbanken Capital Markets has served as debt financial advisor.  EBITDA for ICA Eiendom was SEK 159 million in 2015 and SEK 91 million on a rolling 12-month basis. For more informationICA Gruppen press service, Telephone number: +46 10 422 52 52 This information is such that ICA Gruppen is obligated to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication at 07:45 CET on Friday, 2 December 2016. ¹ At an exchange rate of NOK 1/SEK 1.08

Tobii Announces Prospectus and Updated Financial Goals in Connection with Preferential Rights Issue

Tobii AB (publ) (the “Company” or “Tobii”) announced on November 7, 2016 that the Board of Directors had resolved to, subject to the approval by an Extraordinary General Meeting, launch a preferential rights issue (the “Rights issue”) for large-scale initiatives on eye tracking in virtual reality and smartphones. The Rights Issue was approved by the Extraordinary General Meeting on November 30, 2016. In connection with the Rights Issue, the Board of Directors has prepared a prospectus, which has been approved and registered by the Swedish Financial Supervisory Authority (“SFSA”) and is now available Tobii’s website, and adopted updated financial goals. Prospectus The prospectus and the application form can be obtained from Tobii and Carnegie. The prospectus and the application form will also be available on Tobii’s website (www.tobii.com (http://www.tobii.com/group/investors/rights-issue-2016/)), Carnegie’s website (www.carnegie.se) and, within a few days, the SFSA’s website (www.fi.se).   Updated financial goals The updated financial goals adopted by the Board of Directors in connection with the Rights Issue are linked to the Company’s updated business plan for large-scale initiatives on eye tracking in virtual reality and smartphones. The financial goals for Tobii Dynavox and Tobii Pro remain unchanged while the goal for Tobii Tech has been updated. ·  Tobii Dynavox's long-term goal is to deliver revenue growth in excess of 10% per year and to reach an EBIT margin of 20%. ·  Tobii Pro's long-term goal is to deliver revenue growth in excess of 15% per year and to reach an EBIT margin in excess of 15%. ·  Tobii Tech's long-term goal is to be the leading provider of eye-tracking technology for integration into high-volume products. Since the market for integration of eye tracking in volume products is at an early stage, the Company has chosen not to present a specific financial goal for Tobii Tech, but instead expresses a strategic long-term goal for the business unit's market position. This objective is complemented by the Company's assessment of market developments that are included in the prospectus prepared in connection with the Rights Issue. The Board considers that the Company, with the proposed Rights Issue, is fully funded to implement the updated business plan. Timetable The Board of Directors has decided to extend the subscription period with two days. The dates for the rights issue are set out below. December 2, Record date for the preferential rights issue, i.e. holders2016 of shares who are registered in the share register on this date will receive subscription rights for participation in the preferential rights issueDecember 2, Publication of the prospectus2016December 6 – Trading with subscription rightsDecember 20,2016December 6 – Subscription periodDecember 22,2016December 29, Estimated date for announcement of outcome of the2016 preferential rights issue Advisors in connection with the preferential rights issue Carnegie Investment Bank AB is financial advisor to Tobii and Baker & McKenzie Advokatbyrå KB is legal advisor in connection with the Rights Issue. This information is information that Tobii AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on December 2, 2016, at 8:00 a.m. CET. 

GE Aviation controls 76.15 percent of the shares in Arcam and does not further extend the acceptance period

Stockholm, December 2, 2016. On September 6, 2016, GE Sweden Holdings AB (“GE”), a Swedish company within the GE Aviation operating unit and an indirectly wholly-owned subsidiary of General Electric Company[1], announced a recommended public cash offer to acquire all ordinary shares[2] in Arcam Aktiebolag (publ) (“Arcam”) for a consideration of SEK 300 per ordinary share in cash (the “Offer”). On November 14, 2016 GE declared the Offer unconditional and that the Offer will be completed. The acceptance period for the Offer ended on November 29, 2016. The ordinary shares in Arcam[3] tendered up until the end of the second extension of the acceptance period on November 29, 2016, together with the ordinary shares in Arcam acquired by GE on the market, correspond to approximately 76.15 per cent of the total number of outstanding shares and votes in Arcam on a fully diluted basis.[4] GE has decided not to further extend the acceptance period. Tendered ordinary shares and GE’s ownership in Arcam At the time of announcement of the Offer, GE did not own or control any shares in Arcam. The Offer has been accepted by shareholders holding an aggregate of 9,537,047 ordinary shares in Arcam, corresponding to approximately 45.97 per cent of the total number of outstanding shares and votes in Arcam on a fully diluted basis. GE has, after announcement of the Offer, acquired 6,260,530 ordinary shares in Arcam on the market, corresponding to approximately 30.18 per cent of the total number of outstanding shares and votes in Arcam on a fully diluted basis. No such acquisitions have been made at prices higher than SEK 300 per ordinary share in Arcam. Settlement Settlement in respect of ordinary shares in Arcam duly tendered by November 29, 2016 is expected to begin on or around December 6, 2016. In accordance with, and subject to the restrictions under, applicable laws, rules and regulations, GE Group and any advisor, broker or other person acting as the agent for, or on behalf of, GE Group may make arrangements to purchase shares in Arcam, including purchases in the open market at prevailing prices or in private transactions at negotiated prices. Such purchases or arrangements to purchase may be made following completion of the Offer. Additional information The information was submitted for publication on December 2, 2016 at 8.00 am CET. For additional information about the Offer, please visit www.geaviation.com/additive. All media inquiries should be directed to: Rick Kennedy, Executive, GE Aviation Communication, +1 513 607 0609.  Important information Important Information for U.S. persons The Offer has not been, and will not be, submitted to the review or registration procedures of the U.S. Securities and Exchange Commission or any other regulator outside of Sweden. The Offer has not been approved or recommended by any governmental securities regulator. The Offer is being made in the United States in compliance with Regulation 14E under the U.S. Securities Exchange Act of 1934, as amended, and in reliance on the Tier II exemption from certain requirements of the U.S. Securities Exchange Act of 1934. The Offer is principally governed by the regulations and procedures of Sweden, which are different from those of the United States, including with regard to extension, withdrawal rights and timing of payments. To the extent that the Offer is subject to the U.S. securities laws, they apply only to holders of shares in Arcam in the United States and no other person has any claims under such laws. This press release is not an offer to purchase or a solicitation of an offer to sell shares and ADSs of Arcam. The solicitation and the offer to purchase shares and ADSs of Arcam is made in the U.S. pursuant to the U.S. Offer to Purchase, dated September 6, 2016, as may be amended or supplemented from time to time and including Amendment No. 1 to the U.S. Offer to Purchase, dated October 31, 2016 (the “U.S. Offer Document”). Shareholders of Arcam resident in the U.S. are advised to read the U.S. Offer Document, because such document contains important information about the Offer and the parties thereto. Investors and shareholders may obtain free copies of the U.S. Offer Document (as amended) and the Swedish offer document relating to the Offer dated September 6, 2016, as may be amended or supplemented from time to time and including the supplement to such offer document dated October 31, 2016 (the “Swedish Offer Document”), at the website of GE Aviation, www.geaviation.com/additive. Free copies of the Swedish Offer Document may also be obtained at the website of Handelsbanken Capital Markets, www.handelsbanken.se/investeringserbjudande. Other important information The Offer is not being made to, and acceptances are not approved from, persons (other than U.S. persons) whose participation in the Offer requires that an additional offer document is prepared or registration effected or that any other measures are taken in addition to those required under Swedish law, except where there is an applicable exemption. This press release and any related offer documentation will not be distributed and must not be mailed or otherwise distributed or sent in or into any country in which the distribution or offering would require any such additional measures to be taken or would be in conflict with any law or regulation in such country – any such action will not be permitted or sanctioned by GE. Any purported acceptance of the Offer resulting directly or indirectly from a violation of these restrictions may be disregarded. The Offer is not being made, directly or indirectly, by use of mail or any other means or instrumentality (including, without limitation, facsimile transmission, electronic mail, telex, telephone and the Internet) in or into Australia, Hong Kong, Japan, Canada, New Zealand or South Africa, and the Offer cannot be accepted by any such use, means, instrumentality or facility of, or from within Australia, Hong Kong, Japan, Canada, New Zealand or South Africa. Accordingly, this press release and any related offer documentation are not being and should not be mailed or otherwise distributed, forwarded or sent in or into Australia, Hong Kong, Japan, Canada, New Zealand or South Africa. GE will not deliver any consideration from the Offer in or into Australia, Hong Kong, Japan, Canada, New Zealand or South Africa. This press release is not being, and must not be, sent to shareholders with registered addresses in Australia, Hong Kong, Japan, Canada, New Zealand or South Africa. Banks, brokers, dealers and other nominees holding shares for persons in Australia, Hong Kong, Japan, Canada, New Zealand or South Africa must not forward this press release or any other document received in connection with the Offer to such persons. This press release has been published in English and Swedish. In the event of any discrepancy in content between the two language versions, the English version shall prevail. Forward-looking statements This press release contains "forward-looking statements" – that is, statements related to future events that by their nature address matters that are, to different degrees, uncertain. For details on the uncertainties that may cause GE Group’s actual future results to be materially different than those expressed in the forward-looking statements, see the Swedish Offer Document at www.geaviation.com/additive and GE Group’s website at www.ge.com/investor-relations/disclaimer-caution-concerning-forward-looking-statements as well as GE Group’s annual reports on Form 10-K and quarterly reports on Form 10-Q. GE Group do not undertake to update the forward-looking statements. This press release may also include certain forward-looking projected financial information that is based on current estimates and forecasts. Actual results could differ materially. ---------------------------------------------------------------------- [1] General Electric Company, together with its subsidiaries, are referred to as “GE Group”. [2] The Offer also includes a public offer to tender to GE all American depositary shares (each an “ADS”), each ADS representing the right to receive one ordinary share in Arcam. [3] Including ordinary shares in Arcam represented by ADSs. [4] Based on 20,746,585 shares and votes in Arcam (including 152 ordinary shares and 200,000 preference shares of Class C held by Arcam).

EQT VII to Acquire AutoStore

· EQT VII to acquire Norway based AutoStore – a unique automated storage and retrieval system with more than 130 installations to date in 22 countries · The company has experienced an annual topline growth of ~50% and an annual EBITDA growth of ~80% since 2013 · EQT will support AutoStore in continuing its growth trajectory through further expansion internationally and through continued high focus on R&D and technology leadership The EQT VII Fund (“EQT VII) has entered an agreement to acquire AutoStore (or “the Company”) from Jakob Hatteland Holding AS and other minority owners. AutoStore is a unique automated storage and retrieval system (“ASRS”) which uses robotics for collecting stored goods in a warehouse. From the origin of the idea by Ingvar Hognaland in the Hatteland Group in the 1990s and delivery of the first commercialized system in 2005, AutoStore has experienced strong growth and is today a unique and leading automated material handling solution. AutoStore provides significant improvements in capacity, performance and cost and represents an optimal solution for meeting the growing demands for automated and efficient warehousing. Global megatrends, including increasing focus on automation and robotization, urbanization and need for space efficient solutions, as well as the demands for increased delivery speed and accuracy, are all expected to continue to fuel AutoStore’s growth globally. AutoStore employs approximately 140 people and has to date more than 130 installations in 22 countries. In 2016 it is expected to generate approximately NOK 500 million in Sales and NOK 240 million in EBITDA. Ingvar Hognaland, inventor of AutoStore, says: “I am very proud of what we have achieved with AutoStore – it has been developed from a simple idea into a leading product on the marked today.” Jakob Hatteland, serial entrepreneur, adds: “Through the innovative thinking and drive of everyone involved, AutoStore has grown to be a unique Norwegian company with truly global potential. EQT is a great partner with an eye on long-term goals. This will enable us to continue to develop AutoStore and we are excited to partner with EQT for the continued journey.” “We are really excited to have EQT as our new owner and are happy to be a part of the EQT family. We strongly believe that EQT’s industrial approach, global presence and network will be of valuable support in our next growth phase and future success.” says AutoStore CEO Karl Johan Lier. Anders Misund, Partner at EQT Partners, Investment Advisor to EQT VII, says: “We are impressed with AutoStore’s unique solution offering and leading position in the market. Karl Johan and his team have built an excellent platform that has grown consistently over time. EQT’s strong expertise in the industrial sector, alongside EQT’s global network, will support AutoStore´s further international expansion and growth.” The transaction is expected to close in early 2017. The parties have agreed not to disclose the transaction value. Contacts: Anders Misund, Partner at EQT Partners, Investment Advisor to EQT VII, +47 232 37 567 Kerstin Danasten, EQT Press Contact, +46 8 506 55 334 About EQT EQT is a leading alternative investments firm with approximately EUR 30 billion in raised capital. EQT Funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 15 billion and approximately 100,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. More info: www.eqtpartners.com About AutoStore AutoStore is a unique world-wide patented warehouse system proven to be the ideal small-goods handler for any warehouse, old or new. With standardized boxes stacked in a cube, it is easily the most space-efficient goods-to-man system on the market and can double storing capacity without increasing footprint. AutoStore is sold via a global multi-distribution network.   More info: www.autostoresystem.com                 https://www.youtube.com/watch?v=Xnyn9l0hxSs

Evac Group and Uson Marine join forces to provide their customers with an improved service network and enlarged offering

Uson Marine provides dry and wet waste management systems, including food waste systems, for maritime and offshore industry customers. The company was established in 1983 and its sales turnover was 6.6 MEUR (64 MSEK) in 2015. Uson Marine has offices in Stockhom, Sweden and Oslo, Norway, as well as representatives in 21 countries on five continents. The company has a very strong market share and excellent customer relationships, especially within the merchant, passenger, navy, and special vessel segments, offshore vessels, and rigs.  Market Growth The need for cleantech solutions that support the sustainable and environmentally friendly operations of offshore, marine, and river vessel operators is increasing due to tighter legislation and increased public awareness. This increasing demand has supported the growth of Evac and led to an increase in turnover for the company of almost 40% last year. The acquisition of Uson Marine supports this growth by bringing in new resources and knowledge to serve customers better. “Demand is not just associated with new build vessels, as new, updated equipment is also retrofitted to existing vessels. Uson Marine has extensive experience in dry and food waste retrofit projects for cargo vessels, for example, which supports the expertise of Evac Group,” explains Tomi Gardemeister, President and CEO of Evac Group. “Evac is a market leader in terms of providing dry and wet waste management systems for marine and offshore industry customers. Thanks to this acquisition, our position has become even stronger,” continues Gardemeister. An increased offering for small and medium-sized vessels The Evac Complete Cleantech Solution covers all marine and offshore cleantech needs, including vacuum collection and wastewater treatment, dry, wet, and food waste management, and fresh water generation. “Uson Marine’s offering brings in new, compact units for food and galley waste collection and treatment, as well as different equipment for treating dry solid waste. These systems complement Evac’s existing offering and are an excellent strategic fit,” says Claes Rudling, CEO of Uson Marine. “Dry and wet waste management systems help customers to minimize the costs and labor requirements of waste handling onboard their rig or vessel by collecting, sorting, compacting, and storing waste. This helps customers to comply with relevant rules and regulations, and minimize the environmental impact of their operations.” Uson Marine CEO Claes Rudling will continue in his present role. Evac in brief Evac is the world’s leading provider of integrated waste, wastewater, and water management systems for the marine, offshore, and building industries. The company has executed over 20,000 marine, 1,500 offshore, and 2,000 building projects worldwide. Evac has employees in Brazil, China, Finland, France, Germany, Korea, Norway, and the USA, and representatives in more than 40 countries. The company’s turnover was 98 million euros in 2015. For more information, contact: Tomi GardemeisterCEO and President, Evac GroupMobile: +358 405 590746email: tomi.gardemeister (at) evac.com

Sverre Munck will not stand for re-election as Chairman of the Board at the Annual General Meeting 2017

Since the sale of the Consumer unit the Board of Directors has worked, together with the Nomination Committee, to ensure a Board size and composition that reflects that Opera Software now is a holding company with its main activity, Opera Mediaworks, based in the US, and with less than 30 employees in Norway.  Consequently, a proposal will be presented to the Shareholders Meeting on Dec 15th, 2016 allowing the number of shareholder elected board members to be reduced to 3. At the same time, the employees at Opera have decided in a company-wide election not to be represented at the Board of Directors.  Sverre Munck has informed the Opera Nomination Committee that he will notstand for re-election at the ordinary shareholders´ meeting in June 2017. Hefurther informed the committee that as Election to the Board of Directors ison the agenda at the extraordinary shareholders´ meeting on Dec 15th 2016 heis willing to resign already at this meetingshould the Nomination Committeedecide on a new board composition in the best interest in the company. Sverre Munck has served as Chairman of the Board since June 2014. "Opera is today, after the sale of the Consumer division, a substantiallydifferent and more streamlined company than it was 2 years ago", says MrMunck. "The company´s balance sheet is strong, and the 5 remaining businessunits all operate in dynamic and growing markets. The substantial part of thebusiness, Opera Mediaworks, is based in the US. The future composition of theBoard of Directors needs to reflect the importance of the mobile advertisingtechnology unit within Opera, as well as its US base. My experience is mainlywithin the consumer part of Opera´s business, and I think the time is right togive the Nomination Committee the necessary flexibility in findingpersons with specific knowledge within the Ad Tech industry". Jakob Iqbal, Chairman of the Nomination Committee, commented that "SverreMunck has chaired the Board during an important transition phase for Opera,culminating in the successful sale of the Consumer division after a thoroughStrategic Review process. The Nomination Committee respects his decision.  Petter Lade, Investor Relations  Tel: +47 2369 2400

Oatly, Sweden’s fast growing lifestyle brand of plant-based products

Malmö, 2nd December 2016 – Oatly, Scandinavia’s leading lifestyle brand of plant-based products, is pleased to announce that it can now count a newly established Joint-Venture between Verlinvest, the international consumer-focused investor, and China Resources as shareholders. Under the terms of the transaction, China Resources and Verlinvest will invest alongside the Founders and existing shareholders to expand Oatly’s manufacturing footprint in Sweden and fund the Group’s entry into new markets including China and the US.Oatly is Scandinavia’s leading brand of plant-based, dairy-free products, with a c.40% market share in Sweden. The Company is a pioneer in the Swedish food industry and, through its sustainable high-fibre dairy-free oat-based range, empowers consumers to eat in an ethical and environmentally-friendly way. This new partnership with Verlinvest and China Resources will enable further investment in the group’s R&D facilities and bring new opportunities to offer Oatly’s unique brand of simple, natural Swedish liquid oat goodness to new consumers worldwide.“Oatly’s mission is to make it easy for people to eat the healthy food they love, without recklessly taxing the planet’s resources in the process. In China Resources’ and Verlinvest’s Joint-Venture we have found a highly experienced global-minded partner who understands this unique heritage and brings to Oatly a valuable network as well as operational expertise in key markets. It will help us bring Oatly’s values and unique patented oat-based technology to new consumers across the world. The investment enables us to add further production capacity and product development resources in Landskrona, creating job opportunities and strengthening our presence globally”, says Toni Petersson, CEO at OatlyFrédéric de Mévius, Chairman of the Board of Verlinvest, said: “We have been very impressed by what the team at Oatly has achieved so far in building the Swedish market leader and we are excited to join them, alongside the existing shareholders, to bring the brand, an icon of Swedish health and sustainability, to a global audience”Kerry Zhang, Deputy General Manager of China Resources Holdings Strategy Department commented: “Oatly has built a differentiated lifestyle brand with an ethical approach which we believe will strongly appeal to the Chinese consumer. The business has developed world class R&D expertise and production facilities in its Landskrona site. We will invest further to ensure that Oatly remains at the leading-edge of oat research, and continues to develop new innovative products for many years to come.” ABOUT OATLYFounded in 1990, based on Swedish research from Lund University, Oatly is Sweden’s leading dairy-free brand, with a broad range of healthy and sustainable oat-based products. The company’s patented enzyme technology copies nature’s own process and turns fiber-rich oats into nutritional liquid food that is perfectly designed for humans.Based in the south of Sweden with headquarters in Malmö and a production & development center in Landskrona, Oatly currently employs about 120 people and its products are available in more than 20 countries throughout Europe and Asia.ABOUT CHINA RESOURCES-VERLINVEST JOINT VENTURE The China Resources-Verlinvest Joint Venture was established in 2016 to invest in mid-sized, high-growth businesses in the healthy branded Food & Beverage and Senior Care sectors. The Joint Venture marries Verlinvest’s deep consumer expertise in growing international F&B brands with China Resources’ broad distribution capability to bring innovative and high potential brands to a global audience.Verlinvest is a Belgian, family-owned investment company focused on international high-growth consumer businesses, with offices in Brussels, New York and Singapore. Verlinvest’s mission is to empower business leaders over the long term with a ‘hands-with’ approach to build global consumer brands across distribution channels and geographies.China Resources is a holding company with a diverse range of business interests, including over 4,700 food retail outlets and coffee shops in 280 cities across China, under brands including Vanguard, Tesco Vanguard, Olé and Pacific Coffee.

Second AP Fund furthers integration of sustainability in asset management activities

The Second AP Fund makes sustainability an integral part of its asset management activities by incorporating sustainability factors into its analytical and decision processes. This enables the Fund to reduce risk and improve the potential for an increased return on investment. The Fund is convinced that companies committed to long-term sustainability are also those that generate solid long-term returns.“One reason for making the integration of sustainability a priority in our asset management strategy is the conviction that it generates better long-term returns. Consequently, we have a comprehensive understanding of this area and a large number of staff who are keenly interested in these issues,” states Eva Halvarsson, CEO of the Second AP Fund.Breadth of decision dataDuring the autumn, ESG factors have gradually been integrated into the Second AP Fund’s in-house developed mathematical model for asset class global equities. The implementation process is scheduled for completion before the end of the year, when ESG considerations will become integral to investment decisions, in conjunction with the other factors on which the model is based.“We are one of few players in the industry to have taken this process to the next level, by analysing the basic data instead of relying on pre-determined ESG factors. It is vital to get as close to the basic data as possible, a recognition that is fully in line with the Fund’s overall approach to quantitative asset management,” notes Tomas Morsing, Head of Quantitative Strategies at the Second AP Fund.On the one hand, the Second AP Fund’s ESG model comprises environmental factors of a concrete nature, such as the level of companies’ carbon emissions or how much energy they consume. On the other hand, the model also comprises data and indicators relating to social and corporate governance factors that may be said to provide an impression of the company.Importance of values and corporate cultureAn interesting observation made by the Fund is that companies featuring a high proportion of women in leading positions also note stronger growth, regardless of size or type of company. One possible explanation is that these companies are more focused on issues relating to values and corporate culture. This is reflected in the Fund’s measurable indicators, such as the proportion of women in leading positions or the range of in-company training.The next stage of this process is to get still closer to a strategic working approach by developing an ESG-weighted index for quantitative equities management. Furthermore, in our management of global corporate bonds, we also plan to integrate ESG factors in the same way as we now do for equities.For further details, please contact CEO Eva Halvarsson, Second Swedish National Pension Fund, or Ulrika Danielson, Head of Corporate Communications, on +46 31 704 29 00.

Industrifonden in partial exit from leading lifestyle brand Oatly

Oatly was founded in the 1990s, and is based on Swedish research from Lund University. Industrifonden joined the company in 2002, and has since 2006 been one of the major shareholders. Today the company has established itself as one of the Nordic’s leading ethical and sustainable lifestyle brands and a leader among Nordic foodtech companies. With its unique patented oat-based technology and product range, the company is available in more than 20 countries across Europe and Asia. Oatly had a turnover of SEK 369 million last year. – Oatly has rewritten the rules in a competitive market dominated by large players. As a value-driven company with the aim of enabling people to make healthy and sustainable choices in food, we are very proud of what the Oatly team has achieved to date. It’s been a fantastic journey – and it has also been a very successful investment so far for Industrifonden, says Thomas Carlström, Investment Manager at Industrifonden. – The relation with Industrifonden has been a truly valuable partnership, and we are happy that they remain as shareholders in the company. Our new partner adds a valuable network and industrial operational expertise in new key markets, especially in China and US. In addition, the partnership will enable investments in further production capacity and product development resources in Landskrona and creating job opportunities, says Toni Petersson, CEO at Oatly. A joint venture between international investors Verlinvest and China Resources, will assist the current management team and existing owners in bringing Oatly to new audiences across the world. Both companies have a wealth of experience in developing high-growth, innovative lifestyle brands. – After an extensive search we are delighted to have found new partners in an ideal position to support Oatly in the next stage of development. We are confident of the future prospects of Oatly, and therefore we are excited to remain as partners, says Thomas Carlström. Other existing shareholders including Östersjöstiftelsen, founders, private investors and employees will also retain stakes in Oatly.

Finnish Music Hall of Fame to open up at Mall of Tripla

The Finnish Music Hall of Fame – a museum showcasing the history of Finnish music as well as contemporary Finnish music – is set to open in Pasila in October 2019, simultaneously with the Mall of Tripla, parking facilities and the new Pasila station. The complex, covering nearly a thousand square metres, will offer a broad view into the Finnish music scene in an innovative, interactive and technologically advanced environment.  “The goal is to provide a living room where music lovers from all over the world can return to again and again,” says Mikko Vanni, the project’s leader and Managing Director of Life Style Invest Oy.    Along the lines of the other Music Hall of Fame museums in Sweden, Norway and Denmark, the museum will cover music from different decades, and focus on the entire spectrum of Finnish music. It will present profiles through films, videos, photographs as well as various items, interiors and infotainment elements.  The content design is the work of the awarded Berlin-based media artist Christopher Bauder and Whitevoid Interactive Art and Design, a design studio founded by Bauder. Whitevoid has designed and implemented several well-known art projects and light installations around the world. Staffan Holm and Mattias Hansson, who founded and still run Stockholm’s Abba the Museum, have also taken part in the project’s conceptualisation and design. The total investment in the concept and content of the Finnish Music Hall of Fame amounts to about five million euros.   Tripla offers the museum a unique setting. The museum can be entered either through the shopping mall or directly from outdoors, through the terrace square. The Mall of Tripla also houses a one-of-a-kind event area of approximately 3,000 square metres which the museum can use, providing year-round program to residents and travelers alike.  This location is ideal for the museum, since it is easy to reach from anywhere in Finland. In addition to the shopping mall’s estimated 40 million visitors, who will bring a flow of customers to the museum, the museum itself will attract visitors and out-of-towners. “For Tripla, the Finnish Music Hall of Fame means more events and experiences and a touch of originality,” says Commercial Development Director Pirjo Aalto.  Life Style Invest Oy’s partners in the project are More On Ltd and Custodian Oy.   The Mall of Tripla is a shopping mall to be constructed as the centre of Central Pasila. In terms of the number of retail spaces, it will be the largest in Finland and have the best commercial location in the country. The Mall of Tripla offers a total of 85,000 m2 of rentable space for some 250 operators. The shopping mall will be opened in the autumn of 2019, at the same time as the parking facilities and the new Pasila station. The project venture company developing the Mall of Tripla is owned by YIT, Etera, Onvest and Fennia.  For further information, please contact: Pirjo Aalto, Commercial Development Director, YIT Construction Ltd, tel. +358 50 500 2013, pirjo.aalto@yit.fi  Mikko Vanni, Managing Director, Life Style Invest Oy, tel. +358 400 422 751, mikko.vanni@lifestyleinvest.fi  Olli Ilmolahti, Chairman of the Board, More On Ltd, tel. +358 40 528 9005, olli.ilmolahti@moreon.fi  YIT creates better living environment by developing and constructing housing, business premises, infrastructure and entire areas. Our vision is to bring more life in sustainable cities. We want to focus on caring for customer, visionary urban development, passionate execution and inspiring leadership. Our growth engine is urban development involving partners. Our operating area covers Finland, Russia, the Baltic countries, the Czech Republic, Slovakia and Poland. In 2015, our revenue amounted to nearly EUR 1.7 billion, and we employ about 5,300 employees. Our share is listed on Nasdaq Helsinki. www.yitgroup.com

Automotive: Cold-forming returns

More and more automotive manufacturers are realizing that hot forming is a costly process and not so favorable from the sustainability perspective. To date, there has not been a range of cold-forming steels with the right properties available in the market. Now SSAB’s cold-formed Advanced High Strength steels (AHSS) offer car manufacturers a cost-efficient and environmentally sound alternative. Of course, sometimes hot forming is the only option allowing parts with a complex geometry and SSAB can provide solutions for this too. Alexander Vigander and Johan Eriksson from Ortic. New cold-forming steels have been developed that can live up to the high strength and geometric demands of modern automotive applications. Those companies in the forefront will have a competitive cost advantage. Easier to weld and join Cold- forming steels are easier to weld and join due to their leaner alloy composition. Cold-formed applications can also help to avoid some of the challenges with different kind of embrittlement. Cold-forming steels are also a more environmentally sound alternative – without the need for energy-intensive heating processes. The main advantages of cold forming are lower processing costs, including tooling costs, productivity, and energy consumption. With hot forming there is also the need for more expensive laser trimming. Higher crash test ratings “With component innovations matching the properties of the steel, a car body made up mostly of cold-formable Docol can be expected to obtain high crash test ratings, while being also lightweight,” says business development specialist Kenneth Olsson from SSAB. Really high-strength steel should be used where it makes sense in a car. SSAB can contribute to the automotive industry with our extensive knowledge and experience of cold-forming steels. Using AHSS for selected applications costs only a third of the price of aluminum, for example.  By increasing the share of AHSS steel in components, car manufacturers can both lower vehicle weight and increase the percentage of recyclable parts. Docol’s high strength-to-weight ratio means that thinner steel can be used without sacrificing strength. This boosts fuel efficiency, improves driving performance and cuts costs. Docol in bumpers help shed weight and improve bumper performance (https://www.ssab.com/products/industries/automotive#!pi=discover3E56B26705CF4288B753808E6D6C2024)

Eltel decides on immediate operational actions in its project business

Started in October 2016, Eltel’s management is carrying out a thorough review of the project related part of Eltel’s business. The review has covered both an in-depth project-by-project analysis of current risk exposure as well as an ambition to identify measures to further strengthen overall governance and processes in the project business. An internal review of all projects, with a value at a minimum of EUR 2 million, has been conducted. The analysis of the review has now resulted in several decided planned actions. Håkan Kirstein, Eltel’s President and CEO comments:“The underperformance in certain of our larger projects has clearly affected our profitability and showed that the risk exposure in current environment is too high. In order to reduce the risk level of our project business we have identified certain areas were we need to make changes and improvements. These decided actions are the important first steps in ensuring stable and strong project performance in both the short and long term and are likely to have implications on both size and mix of Eltel’s project portfolio going forward. In parallel with the operational review and planned actions we have initiated a review of Eltel’s project business strategy. Despite the current challenges in certain projects, it is important to emphasise that Eltel’s overall operations are performing well and the underlying drivers of the Infranet industry remain strong.” The decided operational actions in the project business, which are started immediately and carried out during 2017, include the following: Organisational enforcementsEltel has established a Group Project function with dedicated focus on governance and structure in running Eltel’s project business. As of 1 December, a new Director has been recruited for this function, who will report to Håkan Kirstein, CEO of Eltel. The task of this new function will be to implement and follow-up on the decided new governance and processes described below. Strengthening of governance and processesThe strengthening of the project business’ governance and processes includes several actions related to governance, risk assessments, reporting, audits and tools covering the process from tendering to execution of a project. A new governance work stream – the Project Board - regarding special project governance will be implemented, with the purpose of making thorough risk assessment starting from the tender phase. A new improved reporting model will also be implemented throughout Eltel’s project portfolio, cascading from project level with consolidation up to board level. In addition, Eltel’s guidelines regarding project tendering are also being renewed. For further information:Ingela UlfvesVP – IR and Group CommunicationsTel: +358 40 311 3009, ingela.ulfves@eltelnetworks.com This information is information that Eltel AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 2 December 2016 at 12.00 CET. About EltelEltel is a leading European provider of technical services for critical infrastructure networks – Infranets – in the segments of Power, Communication and Transport & Security, with operations throughout the Nordic and Baltic regions, Poland, Germany, the United Kingdom and Africa. Eltel provides a broad and integrated range of services, spanning from maintenance and upgrade services to project deliveries. Eltel has a diverse contract portfolio and a loyal and growing customer base of large network owners. In 2015 Eltel net sales amounted to EUR 1,255 million. The current number of employees is approximately 9,600. Since February 2015, Eltel AB is listed on Nasdaq Stockholm.

MADDY PRIOR AND THE CARNIVAL BAND On Tour December 2016 with Carols & Capers

It was a series of happy accidents that led to Maddy Prior and the Carnival Band being thrown together for a Radio 2 Christmas broadcast.  Such a success was this pairing that it has become an ongoing concern, both in the festive season and beyond, resulting in numerous sell-out tours, and six albums. A mixture of early music, hymnal settings, ribald reeling,  trouser-bursting exuberance and quiet a lot of accomplished musicianship, the union has led to a clutch of albums celebrating Yuletide, the works of Methodist composers, and the Bacchanalian pleasures of life. "I love working with the chaps," Maddy muses, "it's just so different and they're so off the wall.  Coming from a folk background I can relate to a lot of their dances and early music, but anything less like serious academic concerts when we tour you can't imagine.  When we go out at Christmas, it's all streamers, balloons and lunacy. But behind it there’s a lot of talent." MADDY PRIOR A hugely influential figure in British folk music, Maddy Prior has made 40 plus  albums in as many years, and in 2001 was awarded an MBE in recognition of services to folk music.  Maddy came to international prominence as the voice of folk-rock pinoeers Steeleye Span.  Through 45 years with Steeleye, Maddy kept up a variety of extra-curricular activities, most notably The Silly Sisters (with June Tabor), and since 1987, The Carnival Band. Maddy’s reputation as a solo artist and songwriter has gone from strength to strength, with regular tours in the UK and abroad and several highly-acclaimed albums. THE CARNIVAL BAND have been together for over twenty five years. Highly accomplished musicians, the band, and in particular leader Andy Watts have a burning desire to restore energy into the medieval and  renaissance music they tackle.  Dry, academic and authentic they are definitely not!  Mixing ancient, modern and ethnic instruments, their emphasis on celebration, festivity, irreverence and exuberence has earned them the description “Henry VIII’s rock ‘n’ roll band”. Between them The Carnival Band play over 25 instruments from shawms, lutes, and Flemish bagpipes to more familiar instruments such as violin, clarinet and guitar. Appealing to folk, classical and medieval audiences alike, they have taken the spirit of carnival to venues from village halls to cathedrals, and have featured on Classic FM as well as BBC Radio 1,2,3 and 4! The Carnival band are:  Andy Watts, Steve Banks, Giles Lewin and Andrew (Jub) Davis , Guy Schlom,  “Maddy’s voice is clear as a bell. It actually sounds as if there’s a celebration going on” THE GUARDIAN “a truly superb pack of musicians” DIRTY LINEN “if you haven’t seen them before you’re in for a treat!” OXFORD MAIL MADDY PRIOR AND THE CARNIVAL BAND Carols & Capers 2016 Thurs 1st December Borough Theatre Abergavenny Friday 2nd December Sundial Theatre Cirencester Sat 3rd December Theatre Royal Margate Sun 4th December Queen’s Theatre Hornchurch Tue 6th December The Platform Morecambe Wed 7th December Huddersfield Town Hall Huddersfield Thurs 8th December ARC Stockton Arts Centre Stockton On Tees Fri 9th December The Atkinson Southport Sun 11th December Cast Doncaster Mon 12th December Majestic Theatre Retford Tue 13th December Roses Theatre Tewkesbury Wed 14th December Theatre Royal Winchester Thurs 15th December St George’s Bristol Fri 16th December St Mary In The Castle Hastings Sun 18th December The Stables Milton Keynes Mon 19th December Cadogan Hall London Tue 20th December The Apex Bury St Edmunds Wed 21st December SJE St John’s The Evangelist Church Oxford Thurs 22nd December Birmingham Town Hall Birmingham

Festive music resounds around the halls of Castle Howard

Carols and choirs have become synonymous with Christmas and live music will add to the festive feel at Castle Howard, where visitors enjoying the exquisitely decorated house can enjoy live performances from top musicians every day until the historic house closes its doors to the public on 23 December. Among the performers is international broadcast pianist, Emmanuel Vass, who will entertain visitors with a collection of seasonal and popular music each weekend, with further musical treasures to be found in the house courtesy of some of North Yorkshire’s finest choirs.  Each weekday, there will be live music from a different band, string quartet, singer, soloist or duo to continue the festivities right up until Christmas. “Visiting Castle Howard at Christmas is an experience not to be missed – the gingerbread house and decorations this year look absolutely stunning and complement the architecture and furnishings in each room to create a wonderfully immersive festive event, and having live music every day really is the icing on our Christmas cake,” comments marketing manager, Rachel Underwood.  “Many of our visitors pause their visit around the house to enjoy listening to the performers.” An extended performance by Emmanuel Vass and the Cantar Choir will take place on Sunday 18 December, when Castle Howard is extending its Christmas opening into the evening with last admissions to the house at 7.00pm, and all of the stalls in its Christmas marquee and Courtyard shops, café and gift outlets open until 8.00pm. Castle Howard is open daily from 10.00am until 4.00pm (5.00pm at the weekend) until Friday 23 December.  Tickets can be bought on the day from the ticket office, or bought in advance via the Castle Howard website to save 10%, and are priced at £18.95 for adults, £17.50 for concessions and £9.95 for children.  A family ticket (two adults and two children) is £47.85, and annual pass holders get in free.  For more details or to prebook tickets, please visit www.castlehoward.co.uk or call 01653 348333. ENDS Notes to editors: December performers are as follows: Thursday 1 December Two for Tea Duo (Piano) Friday 2 December Pavilion String Quartet Saturday 3 December Emmanuel Vass (Piano) | Chanticleer Singers Sunday 4 December Emmanuel Vass (Piano) | Track 29 Choir Monday 5 December Two for Tea (Piano) Tuesday 6 December Kevin Leach Band Wednesday 7 December Paula Marie Vintage Vocalist Thursday 8 December Two for Tea Duo (Piano) Friday 9 December Catherine Strachan (Cello) & David Hammond (Piano) Saturday 10 December Emmanuel Vass (Piano) | Ampleforth Choir Sunday 11 December Emmanuel Vass (Piano) | Track 29 Choir Monday 12 December Emmanuel Vass (Piano) Tuesday 13 December Kevin Leach Band Wednesday 14 December Key Largo Trio Thursday 15 December Lucy Philips (Violin) & Laura Jones (Piano) Friday 16 December Lucy Philips (Violin) & Laura Jones (Piano) Saturday 17 December Emmanuel Vass (Piano) | Harmoniae Quartet | Pavilion Duo Sunday 18 December (Daytime) Emmanuel Vass (Piano) | York Tutti Amici Choir |Harmoniae Quartet Sunday 18 December (Twilight) Emmanuel Vass (Piano) | Cantar Choir Monday 19 December Lucy Philips (Violin) & David Hammond (Piano) Tuesday 20 December Kevin Leach Band Wednesday 21 December Pavilion String Quartet Thursday 22 December Lucy Coleman (Soprano) & David Hammond (Piano) Friday 23 December Lucy Coleman (Soprano) & David Hammond (Piano) +----------+-----------------------+|Issued by:|Jay Commins, Pyper York|+----------+-----------------------+|Date: |1 December 2016 |+----------+-----------------------+|Telephone:|01904 500 698 |+----------+-----------------------+|Email: |jay@pyperyork.co.uk |+----------+-----------------------+

Nuevolution receives research grant and enters collaboration on development of new tailored cancer therapeutics

Stockholm, 2 December 2016. Nuevolution AB (publ) (NUE.ST), a leading small molecule drug discovery biotech company, today announced that it has received a three-year grant, in accordance with the details below, from Innovation Fund Denmark together with professor Kristian Helin, Biotech Research and Innovation Center (BRIC) at University of Copenhagen, to pursue discovery and development of therapeutics directed towards specific cancer types for which there is no efficient treatment today. The three-year project has a budget of DKK 24.4 million (SEK 32.2 million) and Innovation Fund Denmark contributes with DKK 16.4 million (SEK 21.6 million) in financial support to the involved parties. Nuevolution will contribute with in-kind investments and is to receive up to DKK 5.2 million (SEK 6.8 million) in funding over the project period. The funding is only guaranteed if the project is not terminated prematurely, which in turn depends on the progress of the project. Furthermore, Nuevolution will have the lead in commercializing the results from the project. The grant from the Innovation Fund Denmark has been awarded in acknowledgement of the unique and complementary competencies represented by Nuevolution and professor Helin’s research group. The Helin Group is a renowned world class research laboratory within epigenetic enzymes, a class of enzymes often associated with the development and progression of cancer. Together, Nuevolution and the Helin research group will address the identification of therapeutic small molecules for NSD proteins (histone methyltransferase enzymes), a group of proteins that is observed to be hyper-activated in specific cancers such as e.g. multiple myeloma, acute myeloid leukemia and acute lymphatic leukemia. Although these proteins represent some of the best validated epigenetic cancer targets, no small molecule drugs have yet been identified. The joint research project aims to change this. The well characterized association of NSD proteins with very specific and highly deadly cancers will ideally lead to the development of therapies applicable in personalized treatment for such cancers. Professor Kristian Helin comments, “I am very happy for the funding we have received from the Innovation Fund Denmark making it possible to work together with a world leading biotech company like Nuevolution. Without this funding it would not have been possible.” “We are thrilled about this new collaboration with Kristian Helin and his research group, a recognized world leading capacity within cancer research and histone methyl transferases” says Thomas Franch, Nuevolution’s Chief Scientific Officer, and continues “Nuevolution seeks to realize personalized medicine within cancer therapy and the collaboration with professor Helin and his group has exactly this scope.” For more information, please contact: Thomas Franch, CSO Phone: +45 3913 0922 Email: tf@nuevolution.com  Henrik D. Simonsen, CFO Phone: +45 3913 0947 Email: hs@nuevolution.com  About Nuevolution Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology. This information is information that Nuevolution AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Market Act. The information was sent for publication, through the agency of the contact persons set out above, on Friday 2 December 2016, 13:30 (CET). Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm, Sweden (ticker: NUE.ST). Redeye AB acts as Certified Adviser to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com

Rejlers wins assignments as the Aviapolis region grows

One of the assignments involves Rejlers being responsible for the planning of electrical, telecommunications and security systems in conjunction with the building of the service centre in Aviapolis. The building will have a floor space of 12,300 m2 and the client is the real estate company LAK Oy, which is owned by Finavia. Rejlers has also been engaged by Skanska Talonrakennus Oy for the planning of electrical, telecommunications and security systems for the office building Aviapolis II, which will measure 9,660 m2. Skanska is one of Finland’s largest construction companies working with building and construction, housing development, commercial development and infrastructure development."Being a part of the development of the Aviapolis Area is an exciting possibility to see one of the major investment areas in Helsinki metropolitan to grow. We were also involved as technical consultants when Clarion Hotel Helsinki Airport was built. New hotels and offices bring so much energy and possibilities to the area" says Timo Tenninen, Business Area Director Rejlers Finland. For further information, please contact:Peter Rejler, President and CEO, e-mail: peter.rejler@rejlers.seTimo Tenninen; Business Area Director Rejlers Finland, tel. +358 40 040 3902,e-mail: timo.tenninen@rejlers.fiRejlers is one of the Nordic region’s major technical consultants. A total of 2,000 experts working on projects in construction and property, energy, industry and infrastructure. We have specialist engineers with both broad and specific expertise, coupled with energy that creates results. We are continuing to expand rapidly, and currently have offices in 80 locations throughout Sweden, Finland and Norway. In 2015, Rejlers achieved sales of SEK 1.9 billion and its B share is listed on NASDAQ Stockholm.

Messiah in the Minster: Handel's best known composition returns to York

There can be few better known pieces of choral music than the Hallelujah Chorus from Handel’s Messiah, and on Saturday 10 December, the people of York can enjoy the famous composition sung by the York Minster Choir and guest soloists. The performance of Handel’s Messiah during Advent has become a recent tradition for the choir, which will welcome Darren Jeffery Bass, Thomas Elwin, Julia Doyle and Michael Chance CBE as guest soloists for this year’s rendition.  Performed within the Nave of the great cathedral, the size and scale of the building serves to amplify the sound of the massed voices. “For many people, hearing Messiah performed has become as much a part of their preparations for Christmas as hearing carols or wrapping presents, and this year, we welcome four superb guests to perform the solo roles within the concert,” explains director of music, Robert Sharpe.  “When it was first written, many in the Anglican church were appalled by the drama and passion that this composition used to present Christ’s life story, but it is precisely this emotion that makes it so popular today.” Handel’s Messiah takes place at 7.00pm on Saturday 10 December 2016.  Tickets cost £25 for seats in the Front Nave, £18 for the Rear Nave and £12 for the side aisles.  “With all the tickets sold out for our annual Christmas Carol Concert, this is a wonderful opportunity to hear the York Minster Choir singing something slightly different from their usual sacred repertoire,” adds Robert. For more details, or to book, please visit www.yorkminster.org.  Tickets can also be purchased from York Theatre Royal’s Box Office. Ends For further media information or photographs, please contact: Jay Commins Pyper York Limited Tel:         01904 500698 Email:    jay@pyperyork.co.uk

The new moovel app simplifies the daily commute in the Greater Helsinki area

  moovel Group has introduced the moovel (http://www.moovel.com/intl/fi) mobile application to make it easier to move around in the city. The users of the transit application may for example search for clear and precise information on routes from A to B, stop-specific schedules and store their favorite destinations. The application can be installed on iPhone (https://itunes.apple.com/app/id1134449799?mt=8) and Android (https://play.google.com/store/apps/details?id=com.moovel.na.mint&referrer=adjust_reftag=cQMRcXmtCYJ4g&utm_source=Mint+Website) phones for free. It is based on reliable and up-to-date open data provided by HSL (Helsinki Region Transport). “moovel develops services to make mobility in cities smarter. Our products are designed to simplify the shared transportation experience around the world. The Helsinki area is at the forefront of transit services. We are really excited to launch the moovel application as a useful travel companion in this innovative city”, says CEO Jörg Lamparter, moovel Group GmbH. In the Greater Helsinki area moovel helps you to choose the best route: whether you’re using public transport or Uber, and situated at home, work or on route. In the future, shared cars, taxis and city bikes can be included in the service. “HSL has paved the way for open data since 2009. We want to share real-time data for developers and companies. We are delighted that the data is used for making transits easier in the capital area”, says communications and marketing director Mari Flink, HSL. The new moovel app has been developed together with inhabitants of the capital area in a facebook beta testing group. The facebook group serves as a continuous feedback channel unveiling the pain points of a local commuter’s life, which are then picked up by the moovel developers and translated into new app features, such as the following: Many vehicles used in public transport in the capital area lack stop-specific displays at the moment. That is why a feature has been added into moovel notifying the user when it is time to leave the vehicle.   In addition to Helsinki, moovel is currently working on simplifying the local commute in eight cities around the world, for example, Boston, Amsterdam and Sydney. With public transit being the backbone of a city’s mobility infrastructure and commuting playing an important role in our daily routine, moovel aims to make public transit in cities smarter.   Contact information and interviews: San Francisco Agency Olli-Joonas Juusoolli@sanfrancisco.fi+358 40 773 2467   moovel Group GmbH  Mirjam Osswaldmirjam.osswald@moovel.com                                                                       +49 176 3093 6148                                                        Helsinki Region Transport (HSL) Mari Flink, Communications and Marketing Directormari.flink@hsl.fi+358 40 715 0440   Additional material for media (https://www.moovel.com/intl/fi/cities/helsinki)   About moovel Group GmbH      moovel Group GmbH is a subsidiary of Daimler that develops and markets the moovel application. The application brings together all the local transport, timetables and means of transport. moovel makes it possible to search for schedules from A to B. It is possible to store favorite destinations to make searching easier. moovel can be used in the Helsinki capital area. It can be downloaded for free in the App Store and Google Play Store. Further information: www.moovel.com/intl/fi  

Kährs Group in research project aimed at developing smart floors

Spring 2016, Kährs turned to Ideon Open, an open and neutral meeting place for business and academia. The object was to tap from new, creative thinking when it comes to integrating smart functionalities in floors. Ideon Open, located in the university city of Lund in the south of Sweden, is part of Ideon Science Park, Scandinavia’s leading forum for innovation and entrepreneurship. Ideon encourages companies to reignite entrepreneurship and to break conventional thinking. This makes it an interesting partner for an innovation driven company like Kährs Group. “We have always been good at developing wood floors, both when it comes to the aesthetics and the production process. But we also wanted to get some inspiration to identify future requirements and opportunities enabled by new technology,” says Emanuel Lidberg, Creative Design Manager at Kährs Group. The collaboration project started with Ideon Open setting up a workshop on “floors of the future”, bringing together Kährs and a group of international students with different backgrounds and competencies, including design, economy and production. The goal was to evaluate new, potential development areas with focus on aesthetics, health, suitability, comfort and sustainability. Discussions spanned from how the world is changing to what impact this will have on requirements and opportunities when it comes to floors. The thoughts and ideas that came out of this were later grouped and evaluated. “We picked out 15 exciting ideas linked to companies operating in technology and development. Then we let them elaborate on their ideas. Out of these 15, we have picked a number of particularly interesting potential partners,” Emanuel Lidberg says. Ideas span from smart ways to solve everyday problems, where the technology is already available but need to be adapted to new use, to more visionary ideas regarding future, smart floors. “By bringing together the challenges facing wood flooring with creative, bright young minds and technology from other industries, this project has a potential to make way for the development of new, smart wood flooring solutions”, says Emanuel Lidberg.  For further information, please contact:Emanuel Lidberg, Creative Design Manager, Kährs Group tel: +46 73 804 63 05Helén Johansson, Corporate Communication, Kährs Group, tel: +46 70 364 60 30Mats Dunmar, Open Innovation Navigator/Manager Ideon Open, tel: +46 73 512 04 22, www.ideonopen.com  About Kährs GroupKährs Group is a world-leading flooring manufacturer in hardwood and resilient flooring with a number of strong brands in its product portfolio, including Kährs, Karelia and Upofloor. The Company's innovations have shaped the industry throughout history and Kährs Group is dedicated to providing the market with innovative new flooring solutions. Kährs Group, which delivers products to more than 70 countries, is the market leader in Sweden, Finland, Norway and Russia and holds a strong position in other key markets, such as the UK and Germany. The Group has approximately 1,600 employees and annual sales of EUR 300 million. www.kahrsgroup.com 

Farstad Shipping ASA – Contract Award

Farstad Shipping ASA has been awarded the following contract: Ocean Farming AS, a subsidiary of the SalMar Group, has awarded Farstad Offshore AS, a wholly owned subsidiary of Farstad Shipping ASA, a contract for the complete mooring installation and hook-up of Ocean Farming’s Semi-submersible Offshore Fish Farm. The scope involves project management as well as execution of the offshore operations. The project will utilize AHTS vessels from the Farstad Shipping fleet trading the spot market in the North Sea. Operations are scheduled to take place during first half of 2017. The commercial terms of the agreement will be kept private and confidential between the parties. This award is a strong demonstration of the capacities and capabilities in the Farstad Shipping organization, both onshore and offshore. - Within the company, we have an extensive track record and knowledge base related to offshore mooring and hook-up operations, and this has been key factors enabling us to secure this contract. We highly appreciate Ocean Farming’s confidence in Farstad Shipping as demonstrated by the award of this interesting contract in this new market segment, says Karl-Johan Bakken, CEO of Farstad Shipping ASA. - The introduction of Offshore fish farms of this size and specification is also opening a new market for utilization of large AHTS vessels and we are excited to take part in making this first pilot a success, and look forward to further developments in this market, Bakken concludes. Contacts: CEO Karl-Johan Bakken tel. +47 901 05 697 CFO Olav Haugland tel. +47 915 41 809 Farstad Shipping’s fleet currently consists of 55 vessels (27 AHTS, 22 PSV and 6 SUBSEA) and 1 SUBSEA vessel under construction. The company’s operations are managed from Aalesund, Melbourne, Perth, Singapore, Macaé and Rio de Janeiro with a total of 1,725 employees engaged onshore and offshore. The company’s strategy is to be a leading quality provider of large, modern offshore service vessels to the oil industry. www.farstad.com http://www.salmar.no/en/offshore-fish-farming-a-new-era

Tradedoubler has repurchased Bonds

Tradedoubler has repurchased  SEK 19M of the nominal value of its own Bond. The transaction has taken place after the release of the interim report for the third quarter. For further information, please contact:Matthias Stadelmeyer, CEO TradedoublerPhone: +46 8 405 08 00Email: matthias.stadelmeyer@tradedoubler.com OtherThis information is information that Tradedoubler AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16.30 CET on December 2, 2016. About TradedoublerTradedoubler is an international leader in performance-based digital marketing, dedicated to the success of digital marketers through traffic, technology and expertise. Founded in Sweden in 1999, Tradedoubler pioneered affiliate marketing in Europe and has since developed its offering to include a suite of solutions that help digital marketers succeed.  TD CONVERT is Tradedoubler’s affiliate solution where advertisers pay only for results delivered.  TD CONNECT is a white label global partner management platform that advertisers can use to manage their digital marketing activity.  TD ENGAGE is Tradedoubler’s full service programmatic solution. TD ADAPT is a market-leading business intelligence tool that enables advertisers to visualise their digital marketing data to get the insights they need to ensure that all activity is optimised.  Tradedoubler is committed to close collaboration with each customer, helping them to generate revenue and succeed on a national and international scale. The share is listed on Nasdaq OMX on the Stockholm Exchange. More information can be found on www.tradedoubler.com 

Paradox Interactive Partners with Tencent to Publish Cities: Skylines and Stellaris on Chinese Language Platform

STOCKHOLM — Dec. 2, 2016 — Paradox Interactive, a Stockholm-based publisher and developer of games, today announced a new partnership with Tencent, a leading provider of Internet value added services in China. As part of the partnership, Paradox will publish Cities: Skylines, the award-winning game of city-building and management from developer Colossal Order, for players in China using Tencent’s proprietary platforms. In addition, following the release of Cities: Skylines, Paradox will continue to bring its iconic strategy titles to China, beginning with its recently released sci-fi grand strategy game Stellaris and following with several more. “Paradox is a company whose games possess universal appeal, and I’m eager for the chance to share our games with a broader audience in China,” said Fredrik Wester, CEO of Paradox Interactive. “It’s important to us that gamers everywhere have the same high-quality experience with our titles. Tencent is the biggest game publisher in the world, and we’re glad to have such a capable partner -- we know their platforms and their expertise will achieve excellent things for games like Cities: Skylines, Stellaris, and many others to come.” Cities: Skylines, the best-selling City-building strategy game from Colossal Order, was released to widespread critical acclaim in March 2015. The game allows players to design, build, and manage a city of their own creation, from layout to services and policies. Since the game’s launch, it has gone on to sell millions of copies, and dedicated fans have built over 90,000 pieces of community-contributed content. For more information on Cities: Skylines, visit https://www.paradoxplaza.com/cities-skylines.

Spreading the news: Vikings visit Westminster ahead of their return to York

News of the flooding of JORVIK Viking Centre made international headlines and prompted Parliamentary debate last December, so a small horde of Vikings – accompanied by archaeologists and museum bosses - headed down to Westminster yesterday (Friday 2 December) to a reception in the Palace of Westminster to update politicians and supporters on the plight of one of the world’s most famous attractions. The reception was organised by Baroness Harris of Richmond.  Representatives of York Archaeological Trust, including chief executive David Jennings and director of attractions, Sarah Maltby, explained the work that has gone into not only re-imagining the JORVIK Viking Centre experience for its re-opening on 8 April 2017, but also the measures put in place to protect against future flooding.  They also explained how York Archaeological Trust’s educational remit has been met through a series of innovative exhibitions with key partners in the city, a touring exhibition and working closely with schools and educational groups to support curriculum studies on the Viking era. “York Archaeological Trust is a small charity which runs one of the best-known visitor attractions in the country.  Despite the flooding irreparably damaging most of our Viking city recreation and artefact galleries, we have still welcomed thousands of school children to our temporary exhibitions – especially in the adjacent York St Mary’s in partnership with York Museums Trust and the treasury of York Minster – and kept some of the most important Viking artefacts ever found in this country on public display,” comments David Jennings.  Baroness Harris raised the plight of York Archaeological Trust in the House of Lords following her visit in January, particularly requesting funding from the Government to help re-open JORVIK Viking Centre, and indeed, the Trust has received financial support from many different sources, from individuals to Arts Council England, to help re-imagine the Viking attraction with the latest technology and archaeological discoveries when it re-opens in time for Easter 2017. Significantly, funding from insurers has enabled York Archaeological Trust to retain all members of staff who work at JORVIK Viking Centre throughout the period of closure.  With the Viking interpreters playing a key role in the educational message, three York-based exhibitions and educational outreach programmes have ensured that their skills have been retained, alongside those of the front-of-house and technical staff who keep the Trusts five visitor attractions running smoothly. “Our fundraising efforts top up the monies received from our insurers which would have enabled us to re-build the original displays.  However, with technology and our understanding of Viking-age York moving on since our last major refurbishment, we’ve taken the opportunity to re-imagine the Viking city, and to improve the specification of our galleries so that we can welcome touring collections from other museums alongside our own internationally-acclaimed collection of Viking artefacts,” explains Jennings.  The campaign to celebrate the re-opening of JORVIK Viking Centre has now begun, with hundreds of booking already received for the opening weeks, and educational visits returning to the attraction from 1 May 2017.  The annual JORVIK Viking Festival (20 – 26 February) – which is entirely funded and organised by York Archaeological Trust – will tell the prequel story to the new displays, focusing on the last days of King Eric Bloodaxe, whose departure from York signalled a brief period of decline before a resurgence in trade and commerce in the city to restore it for another 100 years as the capital of Viking Britain. For more information, please visit www.returnofthevikings.co.uk ENDS Notes to editors: House of Lords Question regarding flooding and tourist attractions, 12 January 2016 at 2.59pm Baroness Harris of Richmond raised the issue of Jorvik Viking Centre’s flooding in the House of Lords on 12 January 2016, calling for HM Government to urgently match any funding from City of York Council and North Yorkshire County Council to bring the centre back to life as soon as possible. Her appeal was supported by the Earl of Courtown, who advised that Arts Council England was in active discussions with museums affected by the December 2015 flooding. Lord Campbell-Savours spoke appealing to Ministers to re-examine insurance flood cover to ensure that businesses in flood areas would be able to seek flood insurance for their commercial premises, with the Earl of Courtown confirming that Ministers were in discussions with the insurance industry. Baroness Afshar recognised the extraordinary generosity of the citizens of York during the floods, and also called for funding to help renovate the museum to extend tourism in the city. Lord Cormack highlighted not only the tourist attraction aspect of Jorvik Viking Centre’s work, but also the real scholarship that supports it.  Lord Stevenson of Balmacara praised the heroic efforts of the workers of Jorvik, in particular in saving key artefacts including the last remaining Viking sock.  He also asked what measures would be taken to ensure that the artefacts that had been put in storage were still available, during the closure of the Jorvik Viking Centre, for education and other purposes. A full transcript of the question can be found at: https://hansard.digiminster.com/Lords/2016-01-12/debates/16011273001363/FloodingTouristAttractions#contribution-16011273000043 For further media information or photographs, please contact: Jay Commins Pyper York Limited Tel:         01904 500698 Email:    jay@pyperyork.co.uk

Data reinforcing the long-term safety and efficacy of extended half-life haemophilia therapies Elocta® and Alprolix® highlighted at 58th ASH meeting

Biogen  (http://www.biogen.com/)(NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (http://www.sobi.com/) (Sobi™) (STO: SOBI) will present new data, including updated longitudinal safety and efficacy findings from phase 3 and extension studies, on the companies’ extended half-life therapies, Elocta® (efmoroctocog alfa)( marketed as Eloctate® in the United States and certain other countries) for haemophilia A and Alprolix® (eftrenonacog alfa) for haemophilia B, at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego, California, from 3-6 December. The presentations include efficacy data, which show low target joint annual bleeding rates and effective target joint resolution (≤2 spontaneous bleeding episodes over one year) in pediatric, adolescent and adult patients on long-term prophylaxis with Elocta/Eloctate. Target joints occur when people with haemophilia experience frequent bleeds in the same joint, and can lead to chronic joint disease. An 18% improvement in haemophilia-related quality of life measures (Haem-A-QOL) was seen in adolescents and adults who experienced target joint resolution with prophylactic treatment with Elocta/Eloctate as compared to baseline measurements at phase 3 study entry, with the most impact (≥ 20%) in areas such as physical health, sports and leisure, and work and school. Biogen will also present preclinical data on recombinant FIXFc-XTEN, a fusion protein being investigated for once-weekly, subcutaneous treatment of haemophilia B. The rFIXFc-XTEN program is currently being developed solely by Biogen and utilizes XTEN® technology licensed from Amunix. Depending on Biogen’s development activities and other factors, it is subject to an opt-in right by Sobi in the future. “The data presented at ASH, coupled with the real-world experience of Eloctate/Elocta and Alprolix, may help patients, clinicians and policymakers better understand the long-term safety and sustained efficacy profile for these therapies,” said Maha Radhakrishnan, MD, vice president, medical, at Biogen and head of medical at Bioverativ Inc., a spin-off of Biogen’s haemophilia business that is on track to launch in early 2017. “We also remain deeply committed to developing new treatments that can make a meaningful impact in the lives of people with haemophilia.” “We are encouraged to see data that show Elocta/Eloctate can improve the quality of life for people with haemophilia A,” said Krassimir Mitchev, MD, PhD, vice president and medical therapeutic area head of Haemophilia at Sobi. “Sobi, together with Biogen, is strongly committed to ensuring sustainable access to Eloctate/Elocta for people living with haemophilia A across our respective markets. “ Elocta/Eloctate and Alprolix have more than two years of real-world experience and are the only haemophilia therapies developed using Fc fusion technology, which enables them to use the body's natural pathway to prolong the time the therapies remain in the body. These therapies and rFIXFc-XTEN are part of Biogen’s haemophilia business, which Biogen plans to spin off into Bioverativ, an independent, public company focused on the discovery, research, development and commercialization of treatments for haemophilia and other rare blood disorders. Bioverativ will continue to collaborate with Sobi on their joint development programmes. Selected presentation information: Elocta/Eloctate and Alprolix focused · Longitudinal Analysis of Long-term Safety and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Adults/Adolescents with Severe Hemophilia A – Session: 322, Disorders of Coagulation or Fibrinolysis: Poster I - #1413 - Saturday, December 3, 5:30-7:30 PM PST · Longitudinal Analysis of Long-term Safety and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Children with Severe Hemophilia A – Session: 322, Disorders of Coagulation or Fibrinolysis: Poster I - #1414 - Saturday, December 3, 5:30-7:30 PM PST · Clinical Outcomes in Adults/Adolescents with Hemophilia B Treated Long Term with Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis: Interim Results of the B-YOND Extension Study – Session: 322, Disorders of Coagulation or Fibrinolysis: Poster I - #1416 - Saturday, December 3, 5:30-7:30 PM PST · Long-term Efficacy and Quality of Life With Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia A – Session: 322, Disorders of Coagulation or Fibrinolysis: Poster III - #3791 – Monday, December 5, 6:00-8:00 PM PST Biogen’s rFIXFc-XTEN: Evaluation of rFIXFc-XTEN bleeding efficacy in Hemophilia-B mouse models – Session: 321, Blood Coagulation and Fibrinolytic Factors: Poster III - #3757 – Monday, December 5, 6:00-8:00 PM PST ----------About haemophilia A and BHaemophilia is a rare, genetic disorder in which the ability of a person's blood to clot is impaired. Haemophilia A occurs in about one in 5,000 male births annually, and more rarely in females. Haemophilia B occurs in about one in 25,000 male births annually, and more rarely in females. The World Federation of Hemophilia estimates that approximately 180 000 people are currently diagnosed with haemophilia A and B world-wide[vii] (http://connect.ne.cision.com#_edn1). People with haemophilia A or B experience bleeding episodes that can cause pain, irreversible joint damage and life-threatening haemorrhages. Prophylactic injections of factor VIII or IX can temporarily replace the clotting factors that are needed to control bleeding and prevent new bleeding episodes[viii] (http://connect.ne.cision.com#_edn2). The World Federation of Hemophilia recommends prophylaxis as the optimal therapy as it can prevent bleedings and joint destruction[ix] (http://connect.ne.cision.com#_edn3). About Elocta®/Eloctate®Elocta® (efmoroctocog alfa), is a recombinant clotting factor VIII therapy developed for haemophilia A with prolonged circulation in the body using Fc fusion technology. It is engineered by fusing factor VIII to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body), enabling Elocta to use a naturally occurring pathway to extend the time the therapy remains in the body. While Fc fusion technology has been used for more than 15 years, Sobi and Biogen have optimized the technology and are the first companies to utilize it in the treatment of haemophilia. Elocta is manufactured in a human cell line, using an environment free of animal and human additives. Elocta is approved for the treatment of haemophilia A in the European Union, Switzerland, Iceland, Liechtenstein, Norway and Kuwait, marketed by Sobi and in the United States, Japan, Canada, Australia, New Zealand, Brazil, and other countries as Eloctate and Biogen has the marketing rights in these regions As with any factor replacement therapy, allergic-type hypersensitivity reactions and development of inhibitors may occur in the treatment of hemophilia A. Inhibitor development has been observed with Eloctate/Elocta, including in previously untreated patients. For more information, please see the full U.S. prescribing information (http://www.eloctate.com/pdfs/full-prescribing-information.pdf) for Eloctate. Note that the indication for previously untreated patients in not included in the EU Product Information (http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003964/human_med_001928.jsp&mid=WC0b01ac058001d124) for Elocta. About Alprolix®Alprolix® (eftrenonacog alfa), is a recombinant clotting factor therapy developed for haemophilia B using Fc fusion technology to prolong circulation in the body . It is engineered by fusing factor IX to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body), enabling Alprolixto use a naturally occurring pathway to extend the time the therapy remains in the body (half-life). While Fc fusion technology has been used for more than 15 years, Biogen and Sobi have optimized the technology and are the first companies to utilize it in the treatment of haemophilia. Alprolix is manufactured using a human cell line in an environment free of animal and human additives. Alprolix is approved for the treatment of haemophilia B the European Union, Iceland, Liechtenstein, Schweiz and Norway marketed by Sobi, as well as in the United States, Canada, Japan, Australia, New Zealand, Brazil and other countries and Biogen has the marketing rights in these regions. Allergic-type hypersensitivity reactions and development of inhibitors have been observed with Alprolix in the treatment of hemophilia B, including in previously untreated patients. For more information, please see the full U.S. prescribing information (http://www.alprolix.com/pdfs/PrescribingInformation.pdf) for Alprolix. Note that the indication for previously untreated patients is not included in the EU Product Information (http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004142/human_med_001973.jsp&mid=WC0b01ac058001d124). About BiogenThrough cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies, and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com. Follow us on Twitter. (https://twitter.com/biogen)  About Sobi™Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and about 700 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com. About the Biogen and Sobi CollaborationBiogen and Sobi collaborate on the development and commercialisation of Elocta/Eloctate and Alprolix. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia and most Middle Eastern markets). Biogen has manufacturing responsibility for Eloctate/Elocta and Alprolix and has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory. For more information please contact Media relations   Investor relationsLinda Holmström, Senior Jörgen Winroth, ViceCommunications Manager  President, Head of Investor RelationsT: + 46 708 73 40 95, + T: +1 347-224-0819, +1 21246 8 697 31 74   -579-0506, +46 8 697 2135linda.holmstrom@sobi.com jorgen.winroth@sobi.com  Media Contact Biogen Investor relations Biogen:Tracy Vineis Susan Altschuller+1-781-464-3260 +1-781-464-2442public.affairs@biogen.com IR@biogen.com ---------------------------------------------------------------------- [vii] (http://connect.ne.cision.com#_ednref1) World Federation of Hemophilia, Annual Global Survey 2015, published in October 2016. Available at: http://www.wfh.org/en/data-collection [viii] (http://connect.ne.cision.com#_ednref2) World Federation of Hemophilia. About Bleeding Disorders – Frequently Asked Questions. Available at: http://www.wfh.org/en/page.aspx?pid=637#Difference_A_B. Accessed on: June 17, 2016. [ix] (http://connect.ne.cision.com#_ednref3) Guideline for the management of hemophilia, World Federation of Hemophilia, 2nd edition, http://www1.wfh.org/publication/files/pdf-1472.pdf. Accessed on December 2015

Nordic Nanovector: Single-dose Betalutin® shows promising efficacy, improved duration of response and favourable safety in relapsed NHL patients

Oslo, Norway, 4 December 2016 Nordic Nanovector ASA (OSE: NANO) presented today the updated results from its ongoing Lymrit 37-01 Phase 1/2 clinical trial of Betalutin® (177Lu-satetraxetan-lilotomab) in subjects with relapsed non-Hodgkin lymphoma (NHL) at the 58th Annual American Society of Hematology (ASH) meeting (San Diego, CA, USA). The updated data confirm Betalutin®’s promising efficacy and favourable safety profile as a single agent in 38 relapsed NHL patients, having failed multiple prior regimens and being eligible for assessments. The results, based on the data cut-off date of 31 October 2016, were presented by the study’s Principal Investigator Dr. Arne Kolstad from the Department of Oncology at the Oslo University Hospital, Radiumhospitalet. Key conclusions: • In the 35 patients evaluable for efficacy, the Overall Response Rate (ORR) was 63%, with 29% Complete Responses (CR) • The 21 evaluable patients in the study who received Betalutin® at the dose of 15 MBq/kg with 40 mg/m2 lilotomab pre-dosing had an ORR of 62% and a CR of 38%; of these, the 16 patients enrolled in the Phase 2 expansion of Arm 1, had an ORR of 69% and a CR of 38% • Durable responses have been observed with a median duration of response of 20.7 months for all patients in Arm 1 • Betalutin® is well tolerated, with a predictable and manageable safety profile: most adverse events are haematological in nature, and all have been transient and reversible • No dose-limiting toxicity (DLT) was reported in Arm 4 (15 MBq/kg Betalutin® plus 100 mg/m2 lilotomab pre-dosing) and this regimen demonstrated lower bone marrow toxicity than Arm 1, 2 and 3. Arm 4 is now enrolling patients to evaluate the higher dosing regimen of 20 MBq/kg Betalutin® plus 100 mg/m2 lilotomab. The Lymrit 37-01 study is a Phase 1/2 open label, dose escalation study investigating the optimal lilotomab pre-dosing and Betalutin® regimen in patients with relapsed NHL. Data from 38 patients are presented. Dr. Arne Kolstad, MD commented: “The results we are presenting today are very encouraging and continue to highlight the potential of Betalutin® to provide a new treatment option for NHL patients. These patients, particularly those who fail standard CD20-targeted immunotherapy and/or are too frail to receive chemotherapy, are desperately in need of alternative therapies that work through different and complementary mechanisms and are well tolerated. Betalutin® is showing exciting promise in an increasing number of NHL patients and we look forward to the results from future studies that will hopefully confirm its attractive profile.” Dr. Lisa Rojkjaer, MD Nordic Nanovector’s Chief Medical Officer, commented: “These new data confirm the promising results for Betalutin®, including durable responses in a number of patients, which were presented earlier this year at the AACR meeting, and continue to demonstrate an encouraging clinical profile as a single agent for treating patients with relapsed NHL. The results also support escalating to a higher dosing regimen in the final stages of this Phase 1/2 study that will allow us to decide an optimal dosing regimen for the pivotal Phase 2 study, PARADIGME, expected in Q1 2017.” The poster (abstract 1780) is available at: http://www.nordicnanovector.com/product-info/scientific-posters. Conference call details A conference call will take place on Monday 5 December at 11 am CET. Please make sure to dial in 5-10 minutes prior to scheduled conference call start time using the number and confirmation code below: Local – Norway +47 2350 0296Local – UK +44 (0)330 336 9411Local – USA and International +1 719 457 1036 Conference ID: 2949173 The conference call presentation will be available at www.nordicnanovector.com in the section: Investor Relations/Reports and Presentation/2016 from 10 am CET on Monday 5 December 2016. For further information, please contact: For Nordic NanovectorIR enquiries:Luigi Costa, Chief Executive OfficerCell: +41 79 124 8601Tone Kvåle, Chief Financial OfficerCell: +47 91 51 95 76Email: ir@nordicnanovector.com Media enquiries:Mark Swallow/David Dible (Citigate Dewe Rogerson)Tel: +44 207 282 2948/+44 207 282 2949Email: nordicnanovector@citigatedr.co.uk About Nordic Nanovector:Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously referred to as HH1), conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications. Further information about the Company can be found at www.nordicnanovector.com This information is subject to the disclose requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Nordic Nanovector: Single-dose Betalutin® shows promising efficacy, improved duration of response and favourable safety in relapsed NHL patients

Oslo, Norway, 5 December 2016 Nordic Nanovector ASA (OSE: NANO) presented yesterday the updated results from its ongoing Lymrit 37-01 Phase 1/2 clinical trial of Betalutin® (177Lu-satetraxetan-lilotomab) in subjects with relapsed non-Hodgkin lymphoma (NHL) at the 58th Annual American Society of Hematology (ASH) meeting (San Diego, CA, USA). This press release was previously issued on Sunday 4 December at 2:30am CET. A conference call will be held today at 11 am CET. Please see conference call details below. The updated data confirm Betalutin®’s promising efficacy and favourable safety profile as a single agent in 38 relapsed NHL patients, having failed multiple prior regimens and being eligible for assessments. The results, based on the data cut-off date of 31 October 2016, were presented by the study’s Principal Investigator Dr. Arne Kolstad from the Department of Oncology at the Oslo University Hospital, Radiumhospitalet. Key conclusions: • In the 35 patients evaluable for efficacy, the Overall Response Rate (ORR) was 63%, with 29% Complete Responses (CR) • The 21 evaluable patients in the study who received Betalutin® at the dose of 15 MBq/kg with 40 mg/m2 lilotomab pre-dosing had an ORR of 62% and a CR of 38%; of these, the 16 patients enrolled in the Phase 2 expansion of Arm 1, had an ORR of 69% and a CR of 38% • Durable responses have been observed with a median duration of response of 20.7 months for all patients in Arm 1 • Betalutin® is well tolerated, with a predictable and manageable safety profile: most adverse events are haematological in nature, and all have been transient and reversible • No dose-limiting toxicity (DLT) was reported in Arm 4 (15 MBq/kg Betalutin® plus 100 mg/m2 lilotomab pre-dosing) and this regimen demonstrated lower bone marrow toxicity than Arm 1, 2 and 3. Arm 4 is now enrolling patients to evaluate the higher dosing regimen of 20 MBq/kg Betalutin® plus 100 mg/m2 lilotomab. The Lymrit 37-01 study is a Phase 1/2 open label, dose escalation study investigating the optimal lilotomab pre-dosing and Betalutin® regimen in patients with relapsed NHL. Data from 38 patients are presented. Dr. Arne Kolstad, MD commented: “The results we are presenting today are very encouraging and continue to highlight the potential of Betalutin® to provide a new treatment option for NHL patients. These patients, particularly those who fail standard CD20-targeted immunotherapy and/or are too frail to receive chemotherapy, are desperately in need of alternative therapies that work through different and complementary mechanisms and are well tolerated. Betalutin® is showing exciting promise in an increasing number of NHL patients and we look forward to the results from future studies that will hopefully confirm its attractive profile.” Dr. Lisa Rojkjaer, MD Nordic Nanovector’s Chief Medical Officer, commented: “These new data confirm the promising results for Betalutin®, including durable responses in a number of patients, which were presented earlier this year at the AACR meeting, and continue to demonstrate an encouraging clinical profile as a single agent for treating patients with relapsed NHL. The results also support escalating to a higher dosing regimen in the final stages of this Phase 1/2 study that will allow us to decide an optimal dosing regimen for the pivotal Phase 2 study, PARADIGME, expected in Q1 2017.” The poster (abstract 1780) was presented on Saturday, 3 December 2016 between 5:30PM–7:30PM Pacific Standard Time (Oslo: Sunday 4 December, 2:30AM–4:30AM CET) and is available at: http://www.nordicnanovector.com/product-info/scientific-posters. Conference call details A conference call will take place today, Monday 5 December at 11 am CET. Please make sure to dial in 5-10 minutes prior to scheduled conference call start time using the number and confirmation code below: Local – Norway +47 2350 0296Local – UK +44 (0)330 336 9411Local – USA and International +1 719 457 1036 Conference ID: 2949173 The conference call presentation will be available at www.nordicnanovector.com in the section: Investor Relations/Reports and Presentation/2016 from 10 am CET today, Monday 5 December 2016. For further information, please contact: For Nordic NanovectorIR enquiries:Luigi Costa, Chief Executive OfficerCell: +41 79 124 8601Tone Kvåle, Chief Financial OfficerCell: +47 91 51 95 76Email: ir@nordicnanovector.com Media enquiries:Mark Swallow/David Dible (Citigate Dewe Rogerson)Tel: +44 207 282 2948/+44 207 282 2949Email: nordicnanovector@citigatedr.co.uk About Nordic Nanovector:Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously referred to as HH1), conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications. Further information about the Company can be found at www.nordicnanovector.com This information is subject to the disclose requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Alimak Group acquires Avanti Wind Systems and intends to propose a rights issue of up to 800 MSEK

Avanti offers vertical access solutions to the wind industry that are permanently installed, have a long lifecycle and are based on high safety requirements. Avanti was established in 1885 and has more than 30,000 service lifts installed globally. In 2016, Avanti´s net sales is expected to be 98 MEUR and it operates globally with six production facilities in Denmark, Spain, China, US and Brazil. “The demand for service lifts for wind turbine towers is expected to grow the coming years due to increased heights of the towers and increased safety requirements. The acquisition expands and diversifies our offering of vertical access solutions for industrial customers globally, enables cross selling opportunities and adds an opportunity to expand after sales well in line with Alimak´s strategy and business model”, says Tormod Gunleiksrud, CEO of Alimak Group.  “Becoming part of Alimak Group enables Avanti to continue its development of best in class safety products and solutions to the benefit of our customers within the wind industry. I see this acquisition as the perfect strategic fit for Avanti, and we look forward to becoming part of the global leader in vertical access systems” says Erik Laursen, CEO of Avanti Group.  Through the acquisition, Alimak Group takes another step forward in the global vertical access industry and the annual group net sales will increase from approximately 3,200 MSEK to 4,200 MSEK, while the number of employees will rise from 1,900 to 2,300. The globally installed base will increase from around 36,000 to 66,000 units. The acquisition is subject to customary regulatory approvals and is expected to close in the first quarter of 2017. Synergies will primarily be found in the supply chain, through cross-selling and in expansion of the aftersales offering. The acquisition is expected to be EPS accretive and contribute positively to cash flow. Integration costs are estimated to approximately 43 MSEK. The acquisition will be financed through a bridge loan arranged by Alimak Group´s existing banks. Upon completion of the acquisition, Alimak Group will have a capital structure with an expected leverage (net debt/EBITDA) of around 3.7x, which exceeds the targeted leverage of 2.0x. In accordance with Alimak Group’s financial targets, Alimak Group’s capital structure shall enable a high degree of financial flexibility and allow for strategic initiatives. Therefore the Board of Alimak Group will call for an Extraordinary General Meeting of shareholders to be held in January 2017 in order to obtain an authorisation for the Board to resolve on a rights issue of up to 800 MSEK with preferential rights for existing shareholders. The rights issue will be launched sometime after the year-end report has been published and is expected to be completed during the beginning of the second quarter of 2017. Due to the recent acquisitions of Facade Access Group and Avanti during the fourth quarter, Alimak Group will postpone the release of the Year End report 2016 until February 23 2017 (initially scheduled for release on February 17). In the afternoon on February 23, Alimak Group will host an investor update which will include a presentation of revised financial targets for the Group.  A notice to the EGM will be published separately and will be made available at www.alimakgroup.com. A detailed time plan and conditions for the rights issue will be announced at a later stage. Alimak Group´s main shareholders, Triton, Lannebo Fonder, Swedbank Robur and York Capital Management, who together control close to 60% of the share capital and the votes, have indicated their intention to at the EGM vote in favor of authorizing the Board to resolve on the rights issue and declared their intent to subscribe for their respective shares in the rights issue.   Alimak Group was advised by Kirkland & Ellis in connection with the acquisition of Avanti. Telephone conference and audiocast: Alimak Group´s CEO, Tormod Gunleiksrud and CFO, Stefan Rinaldo, will present the acquisition at a telephone conference and audiocast on Monday December 5, 2016 at 11.00 CET. SE: +46 856642699  UK: +44 (0)2030089807 The presentation can also be followed via webcast:  https://wonderland.videosync.fi/alimak-group-press-conference  For further information:Sofia Wretman, Head of Communications & IR, Phone: +46 8 402 14 40 The information in this release is such that Alimak Group is obliged to make public pursuant to the EU Market Abuse Regulation and, as applicable, the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at December 5, 2016, 07.30 CET. Alimak GroupAlimak Group is a world-leading supplier of elevators, platforms and after-market service for the industrial and construction sectors. The Group has manufacturing operations in Sweden and China and a sales and servicing network in more than 90 countries supplying and maintaining vertical access solutions. At present, more than 22,000 elevators and platforms are installed globally. Alimak was established in Skellefteå in 1948 and has 1,200 employees around the world. The Group is listed on Nasdaq Stockholm. www.alimakgroup.com  Avanti Group Avanti is a world leading supplier of service lifts, safety ladder systems, safety equipment, tower internals and after-market service for wind turbine towers. The group has manufacturing facilities in Denmark, Spain, China, US and Brazil and sales offices in 9 countries supplying and servicing customers in all major markets for wind power. As of today Avanti has more than 30,000 service lifts installed globally. Avanti was established in Copenhagen in 1885 and today Avanti has more than 400 employees throughout the world.  www.avanti-online.com

NetEnt enters Mexico with Codere

NetEnt continues to expand globally on regulated markets with its innovative digital gaming solutions and has now signed an agreement with Spanish gaming operator Codere to enter the online market in Mexico. Codere is an existing customer of NetEnt and has a significant presence on the traditional land-based casino markets in Spain, Italy and Latin America. Codere is one of the largest casino operators in Mexico and has an operator license for both land-based and online casino operations. NetEnt will be able to provide its portfolio offerings to Codere through Codere’s existing operator license. ”I am really excited to enter the regulated online casino market in Mexico together with Codere. This is our first market entry in Latin America and marks another milestone as we follow our long-term strategy to enter and grow in new regulated markets. I’m convinced that we can support Codere’s online casino growth and that players in Mexico will enjoy our world-class thrilling games”, says Björn Krantz, Managing Director of NetEnt Americas LLC. For additional information please contact:Björn Krantz, Managing Director of NetEnt Americas LLCPhone +1 646 647 5670bjorn.krantz@netent.com Roland Glasfors, Investor Relations, NetEnt AB (publ)Phone +46 760 024 863roland.glasfors@netent.com This information is information that NetEnt AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07:30 CET on December 5, 2016. About NetEntNetEnt AB (publ) is a leading digital entertainment company, providing premium gaming solutions to the world’s most successful online casino operators. Since its inception in 1996, NetEnt has been a true pioneer in driving the market with thrilling games powered by a cutting-edge platform. NetEnt is committed to helping customers stay ahead of the competition, is listed on NASDAQ Stockholm (NET–B) and employs 900 people in Stockholm, Malta, Kiev, Krakow, Gothenburg, Gibraltar and New Jersey. www.netent.com

Senzime signs license agreement with Fukuda Denshi

Fukuda Denshi is one of the global market leaders in the field of patient monitoring. The company was founded in 1939 and reported global revenues in excess of JPY 100 billion in 2015. Pursuant to the Agreement, Fukuda licenses the TetraGraph technology to exclusively commercialize a handheld monitoring system under its own brand on the Japanese market. Furthermore, Fukuda is granted rights to develop, at its own expense, an integrated modular system based on the TetraGraph technology. This latter solution is to be offered as an accessory to Fukuda’s installed base of patient monitors in Japan. "This is a major milestone for Senzime and the first major commercialization step in our journey to become a leader in patient monitoring. Fukuda is one of the world's leading companies in this field and the joint long-term commitment proves the competitiveness of our product offering. It’s certainly a breakthrough for Senzime", says Lena Söderström, CEO of Senzime AB. The Senzime TetraGraph is a monitoring system developed to meet today's high standards of usability and reliability. Objective and preventive monitoring of patients undergoing anesthesia with neuromuscular blocking agents was proven to reduce the risk of complications by more than 50%, resulting in great benefits for patients and healthcare providers. The license agreement includes fixed milestone payments as well as fixed license fees based on actual sales. The license fees are not disclosed. The fist products are expected to be launched in Japan in late 2017, and for the fiscal year of 2017, Senzime expects fixed license fees of SEK 4 million. The license fees are paid to Senzime on a quarterly basis. Fukuda will source components directly from designated suppliers; hence, Senzime will not carry any inventory for Fukuda, have any cost of goods sold related to the license fees, or have any other working capital needs in relation to the agreement. In Japan, approximately 2.7 million patients undergo surgery and general anesthesia in approximately 13,500 operating rooms1. This represents approximately 2% of the global market2. The agreement with Fukuda spans 10 years and is expected by Senzime’s management and board to generate more than 100 MSEK in license revenues in the form of fixed and variable royalty payments based on sales of products with Senzime’s technology. The forecast is substantiated by Senzimes assumptions of increased volumes and the license fees agreed upon during the contract period, however, sales quota are not guaranteed by Fukuda. For further information, please contact: Lena Söderström, CEO of Senzime AB Tel: +46-708-16 39 12, email: lena.soderstrom@senzime.com 1. Yano Research Institute Ltd (report 2014), and Fukuda Denshi. 2. There are 405,000 operating rooms worldwide (Lancet 2010: Global operating theatre distribution and pulse oximetry supply: an estimation from reported data Funk LM, et al.) and 234.2 million patients (Lancet 2008: An estimation of the global volume of surgery: a modelling strategy based on available data. Weiser TG (https://www.ncbi.nlm.nih.gov/pubmed/?term=Weiser%20TG%5BAuthor%5D&cauthor=true&cauthor_uid=18582931) et al.) TO THE EDITORS About Senzime Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of $10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI) www.senzime.com About Fukuda Denshi FUKUDA DENSHI, which succeeded in 1939 in developing the first electrocardiograph (ECG) ever produced in Japan, has continued enhancing its know-how as a pioneer of the electrocardiograph in this country while building a firm foundation in the medical equipment industry and continuing to grow along with the daily-evolving health and medicine fields. The FUKUDA DENSHI Group is a manufacturer specialized in medical instruments, which provides products and services utilizing our accumulated wide-ranging resources in the medical field to offer total support "from medical examination to medical treatment and first aid, and even home medical care." FUKUDA DENSHI is publicly traded on JASDAQ. http://www.fukuda.co.jp

New weapon against the shadow economy - tax authorities to receive VAT information in real time

Tieto and the Federation of Finnish Financial Services have presented an initiative on digitalized value-added tax (VAT) reporting. The new standard would allow companies to report VAT information faster and facilitate real-time reporting. Adopting a uniform standard could help to increase European tax revenues by up to EUR 160 billion a year. The new ISO 20022 standard devised and developed by Tieto and the Federation of Finnish Financial Services will help to enable real-time value added tax (VAT) reporting. The standard allows the necessary information in each invoice to be reported to the tax authorities in digital form. Adopting the new standard across Europe could potentially increase tax revenues by up to EUR 160 billion through the collection of currently unreported VAT. - Digitalization is the best weapon for combatting the shadow economy. The newly published standard for easy VAT reporting will help to advance the transition towards electronic invoicing in Europe. It will also lighten the burden of reporting carried by the companies by means of automatization and real-time reporting. We are proud to have been able to contribute to the fight against the shadow economy by offering efficient new digital tools for companies and organizations, says Kimmo Hannus, Head of Business Integration Brokerage at Tieto. - Tieto is actively involved in the ecosystems of the financial sector. Together with the Federation of Finnish Financial Services, we played an active role in the specification work related to the new standard. We have also collaborated closely with the tax authorities to establish common ground rules, Hannus continues. - The implementation of the new standard will promote uniform VAT collection policies across Europe. The VAT deficit does not constitute a large problem in Finland. For Finnish companies, the most significant aspect is that implementing real-time VAT reporting at the European level would provide for a fairer competitive environment, says Pirjo Ilola, Head of Payments Standardisation and E-invoicing at the Federation of Finnish Financial Services. Pirjo Ilola notes that this new standard represents the third time the Federation of Finnish Financial Services has contributed to the creation of an ISO standard. Both Tieto and the Federation of Finnish Financial Services hope for fast and extensive adoption of the standard by the tax authorities, public sector and companies, so that its benefits can be claimed as quickly as possible. The standard is available free of charge on the ISO 20022 website (https://www.iso20022.org/trade_services_messages.page). Tieto is active in promoting digitalization in Finland and the development of the financial sector ecosystem. Among other things, Tieto has developed and implemented the Siirto payment platform, Finland's first real-time multi-banking platform for mobile payments. The company has also been strongly involved in advancing the digitalization of cash and card payment receipts as part of the TARU project (https://www.tieto.com/news/digitalization-of-receipts-can-bring-huge-savings). Tieto is involved in the ecosystems of the financial sector: Digitalization progressing in the banking sector – Tieto develops Finland's first real-time mobile payment platformhttps://www.tieto.com/news/tieto-develops-finlands-first-real-time-mobile-payment-platform-for-automatia The TARU project: Digitalization of receipts can bring huge savingshttps://www.tieto.com/news/digitalization-of-receipts-can-bring-huge-savings For further information, please contact: Kimmo Hannus, Head of Business Integration Brokerage, Tieto, +358 40 524 5203, kimmo.hannus[at]tieto.com Pirjo Ilola, Head of Payments Standardisation and E-invoicing, Federation of Finnish Financial Services, +358 20 793 4255, pirjo.ilola[at]finanssiala.fi Tieto aims to capture the significant opportunities of the data-driven world and turn them into lifelong value for people, business and society. We aim to be customers’ first choice for business renewal by combining our software and services capabilities with a strong drive for co-innovation and ecosystems. www.tieto.com 

BioGaia signs major distribution and license agreements with partner in Japan

The first agreement concerns the exclusive rights to sell probiotic supplements with BioGaia’s patented strains of Lactobacillus reuteri at drugstores, supermarkets and similar outlets. Depending on the product category, products will be sold under Kabaya, Ohayo and/or BioGaia brands and the main target segment is adults. The other agreement is an exclusive license, giving Ohayo Dairy Products the rights to use strains of Lactobacillus reuteri in food, such as drinks and dairy products. The agreements are long term and include exclusivity fees and minimum royalties over the term of the contracts, which will have a substantial effect on BioGaia’s Japanese business. Due to confidentiality, the amounts of the fees and the royalties cannot be disclosed. Nippon Kabaya Ohayo Holdings Inc. is a privately-owned company with headquarters in Tokyo and consisting of a group of 13 companies with more than 3,000 employees. Kabaya Foods and Ohayo Dairy, Japan´s 7th largest confectionary and dairy companies respectively, are both well-known brands with a strong presence in the confectionary and dairy markets. “Through these two milestone agreements with Nippon Kabaya Ohayo Holdings Inc. we have secured another trusted partner in the complex Japanese market. In addition to the marketing and sales of our supplements we look forward to the creation of innovative functional foods based on our Lactobacillus reuteri strains”, says Axel Sjöblad, Managing Director, BioGaia. Latest press releases from BioGaia 2016-11-30              BioGaia makes further investment in MetaboGen 2016-10-31              Disclosure notice in BioGaia 2016-10-25              BioGaia AB Interim management statement 1 January – 30 September 2016 This information is information that BioGaia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on 5 December 2016. 

Nettalliansen chooses Rejlers Embriq for IT- operation services

Through the agreement Rejlers Embriq will take responsibility for set-up and overall operation, as well as responsibility for integration support for future specialist applications that are part of Nettalliansen's digitalisation process.IT services from Rejlers Embriq – an important element of the digitalisation processNettalliansen is an expertise and purchasing alliance of small and medium-sized energy distribution companies that looks after its owners’ interests by establishing competitive and attractive shared services. The IT services that Rejlers Embriq will now supply are an important contribution to supporting the digitalisation process of the owner companies. Nettalliansen and Rejlers Embriq are already working in partnership to deliver and operate new smart electricity meters (AMS) for over 180,000 homes across Norway. Overall perspective on services“Rejlers Embriq has a good understanding of industry needs and fulfils requirements in terms of price and service quality, which is essential for us,” says Torgeir Brovold, Managing Director at Nettalliansen, and concludes: “Rejlers Embriq is way ahead when it comes to digitalisation and stands out as the most cost-effective partner for Nettalliansen.”Smart cooperation“We are pleased to be further strengthening Nettalliansen’s competitiveness,” says René Eriksen, Vice President Operations at Rejlers Embriq. “IT is becoming a very important means for achieving the objectives and overcoming the challenges facing the industry. Nettalliansen stands for smart collaboration in the power sector, and our services make modern and effective solutions available to them. This brings considerable synergies that will benefit all the owners, regardless of size or geography,” he says.  “Here at Rejlers Embriq we are delighted to be expanding our collaboration with Nettalliansen. Through our expertise within the power sector, substantial market share and solid IT expertise we can realise considerable potential together with Nettalliansen. We are looking forward to contributing in the form of flexible IT services, smart choices and strategic use of IT in the years to come,” says Thomas Pettersen, CEO of Rejlers Embriq.About the agreementThe duration of the agreement, including options, is a total of 5 years, with a value in the order of NOK 100 million for the period. The services are being set up and the first energy distribution companies will be switched to the new platform by the end of the year. About NettalliansenNettalliansen AS is an expertise and purchasing alliance owned by small and medium-sized energy distribution companies. Nettalliansen aims to look after its owners’ interests by establishing competitive and attractive shared services that contribute to increasing latitude for each local energy distribution company. Nettalliansen is experiencing strong growth and its ownership currently comprises 47 companies, with a total of 268,000 grid customers. Nettalliansen is aiming to ensure increased cost efficiency for its owners, and benefits of scale, cooperation and innovation are its focus areas. These will be the owners’ most important tools for increased competitiveness, development of new business areas and utilising the expertise of its owners through profitable coordination of resources.About Rejlers EmbriqRejlers Embriq is part of the Rejlers Group and is a business with 160 employees and an annual turnover of almost NOK 400 million. Rejlers Embriq helps to achieve business gains through digitalisation of physical infrastructure, smart choices and strategic use of IT. We design, develop and manage IT solutions and have a Nordic focus and strong roots with a presence in Oslo, Halden, Drammen, Gothenburg, Stockholm and Motala.For further information:Peter Rejler; President and CEO, email: peter.rejler@rejlers.seThomas Pettersen; CEO Rejlers Embriq, +47 950 22 323, email: thomas.pettersen@embriq.noRejlers is one of the largest engineering consultancy firms in the Nordic region. Our 2,000 experts work with projects in the areas of Building and property, Energy, Industry and Infrastructure. At Rejlers, you will meet specialist engineers with the knowledge, cutting edge expertise and energy to achieve results. We are still experiencing rapid growth and can now be found in 80 locations in Sweden, Finland and Norway. Rejlers recorded revenue of SEK 1.9 billion in 2015 and its class B share is listed on Nasdaq Stockholm.This information is information that Rejlers AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on December 5th 2016.

Lemminkäinen Corporation – Managers’ transactions

LEMMINKÄINEN CORPORATION  MANAGERS’ TRANSACTIONS  5 DECEMBER 2016 AT 9:02 A.M. LEMMINKÄINEN CORPORATION – MANAGERS’ TRANSACTIONS Lemminkäinen Corporation has received a disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Lemminkäinen Corporation made by managers and their closely associated persons. The essential content of the disclosure is as follows: Person subject to the notification requirement Name: Fideles Oy  Position: Closely associated person Person discharging managerial responsibilities in issuer Name: Forstén, Noora Position: Member of the Board of Directors Notification type: Initial Notification Reference number: 7437004WJ8GW8WTL8A35_20161202095231_2 Issuer Name: Lemminkäinen Corporation  LEI: 7437004WJ8GW8WTL8A35  Details of the transaction Transaction date: 1 December 2016 Venue: Nasdaq Helsinki (XHEL)  Nature of the transaction: Acquisition Instrument: Share ISIN: FI0009900336    Volume: 882,200  Unit price: 18,55000 Euro  Aggregated transaction Volume: 882,200  Volume weighted average price: 18,55000 Euro  LEMMINKÄINEN CORPORATIONCorporate Communications ADDITIONAL INFORMATION:General CounselJohan NyberghTel. +358 2071 54811johan.nybergh@lemminkainen.com DISTRIBUTION:Nasdaq Helsinki LtdKey mediawww.lemminkainen.com Lemminkäinen is an expert in complex infrastructure construction and building construction in Northern Europe and one of the largest paving companies in its market. Together with our customers and 4,800 professionals we employ, we build a sustainable society. In 2015, our net sales were EUR 1.9 billion. Lemminkäinen Corporation’s share is quoted on Nasdaq Helsinki Ltd. www.lemminkainen.com

National Test Results Released for 2016: Strong Results Show Value Added for Internationella Engelska Skolan Students Between Years 6 and 9.

Swedish education agency Skolverket has now published statistics from the 2016 national tests for middle schools. Internationella Engelska Skolan’s (IES) year 9 students have once again achieved significantly higher results than the national average. In the subject of mathematics the difference between IES and municipal schools has grown. Some 60 percent of year nine students at IES managed to achieve top grades(A-C) which compared with 35 percent of students in municipally run schools in Sweden. In Swedish, 72 percent of students in IES took top grades, against 51 percent in municipal schools. In English the difference was 97 percent against 69.As part of its quality assessment system, Internationella Engelska Skolan is now looking at the value added to its students. Irrespective of the socioeconomic composition, how much does the school help to raise the students' attainment level over a three-year period. This is a measure, which is strongly recommended by school researchers. Now, for the first time it is possible to compare the results achieved by students in grade nine in spring 2016 with the corresponding national tests that they undertook when they were in grade six in the spring of 2013. IES has found a way to statistically follow the students so that we can see the results for the exact same student body for both tests.Comparing these results to find the value added shows that Internationella Engelska Skolan has a significant positive effect on the education of students. On the national test in mathematics in year six, the gap between IES and municipal schools in terms of the percentage of students achieving top grades A-C was 11 percentage points. Three years later this gap had grown to 29 percentage points, meaning a value added by IES of 18 percentage points. In the subject of Swedish, the value added is 12 percentage points while in English the difference is one percentage point (this is because 95 per cent of IES students already received top grades in year six after most of them had studied with IES for three years).In the debate around education, it is often claimed that the positive outcomes from Internationella Engelska Skolan’s students are the result of the socioeconomic background of the students. This is said despite the fact that IES does not select its students, has many schools in poorer socio-economic areas and has a higher proportion of students with a foreign background than the average in Sweden. The new measure of value added validates that IES schools have a significant positive impact on students’ attainment. Students have shown a greater academic improvement, regardless of their background, at IES schools than they have in those run by municipalities.Damian Brunker, Head of Academics for Internationella Engelska Skolan, comments: “It is clear from the results that the calm teaching environment and the work ethic that we offer, combined with the recruitment of qualified teachers from other countries, drives positive results among students, irrespective of social background.”   For more information, please contact:   Johan Hähnel, IES’s IR ManagerTel: +46 (0)70 605 6334e-mail: johan.hahnel@engelska.se  This information is such that Internationella Engelska Skolan i Sverige Holdings II AB (publ) is obliged to publish pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the above contact, at 8:15 a.m. CET on 5 December 2016.   About Internationella Engelska Skolan  Internationella Engelska Skolan, IES, is one of the leading independent school organizations in Sweden, with 21 400 students in 30 schools during school year 2016/17. IES operates schools for students in grades 1-12. Its main focus is grade 4-9, what is often called “middle school”. Within the compulsory school system in Sweden, IES is the leading independent actor, operating nine of the ten largest free schools. IES results on the national tests in grade 9 are far above average in Sweden.Internationella Engelska Skolan was founded in 1993 and is in its 24th year of operation. It continues to be defined by three strong convictions, established by the founder, Mrs. Barbara Bergstrom: · A safe and orderly environment, where teachers can teach and students learn. · To command the English language—the key to the world. · High academic expectations. Up to half of the teaching in IES schools is performed in English, by native English speaking teachers. Over 600 teachers with qualified foreign teaching degrees are currently teaching in IES schools. They are mainly recruited from Canada, UK, USA and South Africa.IES has shown a strong and consistent growth for a number of years. Average growth during the last ten years is 19 % per year. Turnover during the latest concluded operational year, 2015/16, was 1 807 MSEK (growth of 17 % from previous year). The queue for admission for the current and coming years had 122 000 registrations as of September 30, 2016.Internationella Engelska Skolan has been listed on Nasdaq Stockholm Mid Cap with the ticker ENG since the end of September 2016. The largest shareholders of IES are TA Associates of the US, which has close affiliations to leading universities and foundations in the US, and IES’s founder Barbara Bergström. Other major shareholders at the time of the listing included Swedbank Robur funds, investment company Öresund, Norron Asset Management, the Third Swedish National Pension Fund, AMF Försäkring och Fonder and the Second Swedish National Pension Fund.

Yggdrasil Gaming strikes deal with Gaming Innovation Group

Yggdrasil’s portfolio of industry-leading games will be rolled-out across the operator’s B2C sites including its flagship online casino and sportsbook, Guts.com and Rizk.com, and its B2B network, iGaming Cloud. The operator will also gain access to Yggdrasil’s collection of in-game promotional tools, BOOST™, including the recently-launched Missions feature, as well as the social sharing tool BRAG. Fredrik Elmqvist, CEO at Yggdrasil Gaming, said: “We are thrilled to have joined forces with Gaming Innovation Group. Their deal to acquire Betit has made them one of the fastest growing and largest operators in Scandinavia, and it’s a major boon for us to be able to put our content in the hands of their players. We have rolled out some fantastic new games in recent months that we believe have really moved the needle. We remain committed to delivering our partners the best content on the market, and look forward to working more closely with GiG, particularly when it comes to gamification as it is an area where we are both excelling.” Read more at Yggdrasil (http://www.yggdrasil.com/).com TranslationThis is a translation of the Swedish original. For further information, please contact: Fredrik Elmqvist, CEO Yggdrasil Gaming, Telephone +356 996-25 104, fredrik@yggdrasilgaming.comFredrik Burvall, CEO Cherry AB (publ), Telephone +46 8-514 969 52, +46 709 279 632, Email: fredrik.burvall@cherry.se Cherry in brief  Cherry is a Swedish innovating and fast growing gaming company established in 1963. The business strategy is to create shareholder value by owning and developing fast-growing and profitable businesses within the gaming and casino industry. Cherry operates within five diversified business areas, Online Gaming through Cherry iGaming, Performance-based Marketing through Game Lounge, Gaming Technology through XCaliber. Game Development through Yggdrasil Gaming and Restaurant Casino through Cherry Spelglädje. The objective is to grow organic in combination with strategic acquisitions of fast-growing companies. Cherry employs around 900 people and has more than 4,600 shareholders. The Company’s B-shares are listed on AktieTorget.

Japan Patent Office intends to grant Idogen’s patent application

The Japan Patent Office has communicated its intention to grant Idogen’s Patent Application No. 2013-546073. The patent belongs to Idogen’s second patent family and broadly covers Idogen’s technology. Final grant of the patent by the JPO will take place following the payment of official fees by Idogen during the coming weeks. ”As another major market for our tolerogenic vaccine is now added to the patent portfolio, our future prospects are strengthened. The decision represents a clear increase in the value of our product portfolio.”, CEO Lars Hedbys comments. “It is very pleasing that the Japan Patent Office intends to grant this patent.” A granted patent protects the technology for 20 years from the date of PCT filing, which means that Idogen’s patent will provide protection in Japan until 2031. This patent is a member of Idogen’s second patent family and covers induction of IDO for treatment of autoimmune diseases and transplant rejection. Related patent applications in this family are pending in Canada, Europe and the USA. Idogen’s first patent family concerns additional aspects of using zebularine for the treatment of autoimmune diseases and rejection of transplanted organs and is so far granted in Europe.  For additional information about Idogen, please contact: Lars Hedbys, CEO Tel: +46 (0)46-275 63 30 E-mail: lars.hedbys@idogen.com This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that Idogen AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on the 5th of December 2016.

One of UK’s most experienced skippers launches exciting tuition opportunity for yacht and boat enthusiasts

Nautical enthusiasts can experience a unique opportunity to learn from one of the most experienced skippers in the UK as Seaway Deliveries expands its services to include own boat tuition. Simon Phillips, who has racked up an impressive 300,000 nautical miles ranging from the waters around Norway to the Galapagos Islands, is now available to instruct boat owners on the comfort of their own vessel as he expands his business.  Armed with a remarkable 27 trans-Atlantic crossings, including seven races, and an excellent track record for yacht racing, Phillips is set to impart his experience and passion to his customers. With an extensive list of places he’s visited by sea, boat and yacht lovers will be hard-pressed to find someone with more knowledge and insight than this skipper. As a Yachtmaster Instructor, customers can even gain formal training and certification as they learn from one of the most experienced in the business and become comfortable taking control of their own yacht. Simon Phillips, Managing Director of Seaway Deliveries, said, “Having been taken sailing on board the family yacht at only a few weeks old, I have been involved in sailing and boating all my life. There’s nothing like cruising the open waters to the next destination and the skills needed to act as a skipper of a yacht are something I love to teach. The freedom and excitement it offers our customers mean that working with them is always rewarding.” Seaway Deliveries has now been in operation for almost a decade, with its initial offering focussing on the delivery of yachts around the world. Its success has seen the business and its services rapidly grow to now include boat repairs and maintenance, skipper and crew hire and its Soft Landings packages, a bespoke service that aims to make every aspect of buying and setting out on a boat simple and stress free. It’s not just Phillips that has a high level of experience taking to the seas in the Seaway Deliveries company. The team of professional yacht skippers, first mates and crew members are carefully handpicked to ensure they maintain high standards of seamanship, professionalism and customer care and every skipper must have a minimum of 50,000 miles on a variety of yachts in differing conditions and locations around the world. The exacting standards mean customers will never be disappointed with the service they receive and have access to highly experienced professionals when they choose Seaway Deliveries. To find out more visit http://www.seawaydeliveries.com/.

Middle East Propulsion Company (MEPC) selects IFS Applications for engine MRO support

In 2012, MEPC opened its state-of-the-art, 194,000 square-foot MRO facility in Riyadh, close to the city’s King Khalid International Airport. MEPC is the sole military engine shop in the Kingdom of Saudi Arabia and provides MRO support for the Pratt & Whitney F100 engines powering the Boeing F-15 fighter aircraft operated by the RSAF. The IFS solution will allow MEPC to execute all aspects of its MRO operations, from hangar entry to exit—with integrated support for finance and HR. End-to-end visibility will extend across personal areas of responsibility, ensuring focus is kept on what is strategically important. Business intelligence is built into IFS Applications, enabling operators to analyze key performance indicators using predictive analytics to show the full impact of processes on overall MRO performance, as well as the effect a decision has on operations in real time. “Rather than continuing to use a combination of different business systems, we required a single, integrated solution to manage our complete business operations at the critically important Riyadh facility,” said Abdullah Al Omari, Chief Executive Officer at MEPC. “The 360-degree visibility provided by IFS Applications allows us to maximize maintenance efficiency and react quickly to potential performance issues, which is important in the fast-paced military support environment.” Luis Ortega, Managing Director for Middle East, Africa & South Asia at IFS added, “The selection of IFS Applications to support the MEPC facility, which is integral to military operations in the Kingdom of Saudi Arabia, demonstrates the strength of the engine MRO capability in IFS Applications. The RSAF is one of the most advanced fighting forces in the world, and we are delighted to be supporting MEPC with our market-leading engine MRO solution to keep its aircraft available and operational around the clock.”

Saab Receives Order for Carl-Gustaf M4

The new version has all the effectiveness and versatility of the proven Carl-Gustaf system but with enhancements. These include a lightweight design (weighing less than 7 kg), a round counter and intelligent features, such as compatibility with future innovations like the intelligent sighting systems and programmable ammunition, which collectively offer significant operational improvements for the soldier. “With the M4 version the customer will have a weapon with the latest technology and with improved ergonomics which will give them an increased tactical flexibility to deal with any situation on the battlefield”, says Görgen Johansson, head of Saab business area Dynamics. With this order, Saab has secured a new Carl-Gustaf customer and also its fourth customer of the new M4 system since the market debut in late 2014. In 2015, Saab received the first order of the new Carl-Gustaf M4 from the armed forces of the Slovak Republic. In addition, the system was acquired by two other countries for evaluation and qualification purposes. The industry’s nature is such that depending on circumstances concerning the product and customer, further information regarding the customer will not be announced. Saab’s world-leading weapon system Carl-Gustaf has a long and distinguished service history all around the world. It has been successively modernised and enhanced to meet the changing requirements of its users.For more information and videos (A- and B-rolls) for editorial use, see attached links:http://saabgroup.com/Media/media-videos/ For further information, please contact: Saab Press Centre, Helena Dahlberg, Media Relations Manager +46 (0)734 180 018 presscentre@saabgroup.com www.saabgroup.com  www.saabgroup.com/YouTube  Follow us on twitter: @saab  Saab serves the global market with world-leading products, services and solutions within military defence and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs. 

Lemminkäinen Corporation completes the tender offer of its outstanding hybrid bond issued on 11 March 2014

LEMMINKÄINEN CORPORATION  STOCK EXCHANGE RELEASE  5 DECEMBER 2016 AT 12:15 P.M LEMMINKÄINEN CORPORATION COMPLETES THE TENDER OFFER OF ITS OUTSTANDING HYBRID BOND ISSUED ON 11 MARCH 2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Lemminkäinen Corporation completes the partial repurchase of its hybrid bond (ISIN FI4000086665) issued on 11 March 2014. The company has agreed to repurchase notes to a nominal amount of EUR 34.8 million in exchange for cash which represents 49.7 per cent of the original EUR 70 million hybrid bond issued in 2014. All tenders from noteholders have been accepted in full. The purchase price for the notes is 107.85 per cent, amounting to EUR 107,850 per each EUR 100,000 nominal amount of the notes. Accrued and unpaid interest until the settlement date on 9 December 2016 will also be paid in accordance with the terms and conditions of the tender offer memorandum. The repurchased notes will be annulled, after which EUR 35.2 million of the hybrid bond issued in 2014 will remain outstanding. The company is entitled to redeem it on 30 March 2018 at the earliest. A hybrid bond is an instrument which is subordinated to the company’s other debt obligations and which is treated as equity in the IFRS financial statements. The hybrid bond does not confer to its holders the rights of a shareholder and does not dilute the holdings of the current shareholders. Nordea Bank Finland Plc is acting as the exclusive dealer manager and tender agent for the tender offer. LEMMINKÄINEN CORPORATIONCorporate Communications ADDITIONAL INFORMATION:Ilkka Salonen, CFOTel. +358 2071 54524ilkka.salonen@lemminkainen.com  DISTRIBUTION:Nasdaq Helsinki LtdKey mediawww.lemminkainen.com  Lemminkäinen is an expert in complex infrastructure construction and building construction in Northern Europe and one of the largest paving companies in its market. Together with our customers and 4,800 professionals we employ, we build a sustainable society. In 2015, our net sales were EUR 1.9 billion. Lemminkäinen Corporation’s share is quoted on Nasdaq Helsinki Ltd. www.lemminkainen.com

THQ Nordic AB (publ) Acquires Multiple Franchises - new additions to the THQ Nordic portfolio

Karlstad (Sweden), December 5: Today, THQ Nordic announced that an asset purchase agreement with Mobile Gaming Studios Ltd. and Enigma Software Productions S.L. has been closed. Here is an extract of the acquired franchises and brands: · Sphinx (and the Cursed Mummy); Mobile Gaming Studios Ltd. · War Leaders: Clash of Nations (Enigma Software Productions S.L.) · Legends of War (Enigma Software Productions S.L.) Lars Wingefors, founder and Group CEO, comments: “Due to our love for these types of games they were natural acquisition targets, however this financially a smaller acquisition it adds up to our portfolio” said Lars Wingefors Group-CEO, THQ Nordic. “Moreover, we also got a lot of messages from fans that encouraged us to add them to our portfolio. Among these titles, Sphinx (and the Cursed Mummy) is very well suited for the Nintendo audience – which we love to support. We are excited for Nintendo Switch, Nintendos new platform, and already have two other projects in development for it”, Wingefors continues. Sphinx (and the Cursed Mummy) is a third person action-adventure video game inspired by the mythology of Ancient Egypt. It was originally released for Xbox, PlayStation 2 and Nintendo GameCube. War Leaders: Clash of Nations is a turn-based global strategy game bundled with a real-time tactics game mode for PC. Legends of War is a turn-based strategy video game series franchise created in 2010. It was released for PlayStation 3, Xbox 360 and PlayStation Portable. For additional information, please contact:  Lars Wingefors, Group CEO Tel: +46 708 471 978 E-post: lwingefors@thqnordic.com About THQ  THQ Nordic acquires, develops and publishes PC and console games for the global games market. The core business model consists of acquiring established but currently underperforming franchises and successively refining them. The Company focuses on owning its own franchises and developing and publishing these, and as of 31 October 2016 had around 75 owned franchises in the portfolio. The Company has a global presence, with its Group head office in Karlstad, Sweden and its operational head office in Vienna, Austria. As of 31 October 2016 the Company had four internal game development studios – two in Sweden, one in Germany and one in the US – and contracts with 19 external game studios in a number of different countries. As of the same date the Company employed more than 370 people, of which around 30 personnel within the publishing business, around 70 personnel within internal game development and more than 270 contracted external game developers. THQ Nordic’s shares are listed at Nasdaq First North with FNCA Sweden AB as its Certified Adviser. This information is information that THQ Nordic AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13.00 CET on 5 December 2016.

Article from Placeringsguiden #12 December 2016: New stock market winners when banks are redefined / Nya börsvinnare när bankerna stöps om

The article gives a good description of the situation on the Swedish market and the changes that are taking place. The most important nisch actors are being described and among them are DDM Holding. "… DDM Holding listed on First North have found their own niche and specialized as investors in and managers of consumer receivables in Eastern Europe." “…management sees strong growth potential of loan portfolios to acquire in the region". Please find the full article in the magazine Placeringsguiden (is to be found in the magazines web shop www.privataaffarer.se/butik or app Placeringsguiden and will be sent to the subscribers of the magazine). In SwedishNya börsvinnare när bankerna stöps om Nyhetsmagasinet Placeringsguiden har i sitt decembernummer en omfattande kartläggning av den svenska bankmarknaden. “Storbankerna är under press av extremt låg ränta, nya regler och en snabb förändring av teknik och kundbeteenden. Men det öppnar även för uppköp och en rad framgångsrika nischaktörer som har kommit ut på börsen”. Artikeln ger en god beskrivning av situationen på den svenska marknaden och de förändringar som sker. De viktigaste nischaktörerna beskrivs i artikeln och bland dessa finns DDM Holding. ”… DDM Holding på First North har hittat en egen nisch och specialiserat sig som investerare i, och förvaltare av, konsumentfordringar i Östeuropa.” ”…ledningen ser stark tillväxt med möjliga låneportföljer att förvärva i regionen”. Hela artikeln finns i Placeringsguiden #12, december 2016, (som säljs tidningens webbshop www.privataaffarer.se/butik eller deras app Placeringsguiden samt distribueras till tidningens prenumeranter).

Trigon Agri A/S announces the completion of the debt to equity conversion

Trigon Agri A/S announces that it has successfully completed the conversion of its SEK 350,000,000 11% Bond Loan into equity. Comment from the Chairman of the Board, Mr. Johannes Bertorp: "I am very proud to announce that we have now finalised the full debt for equity swap. Without the debt burden, the company can now develop its assets and focus on the profitable farming operations. I would like to thank all involved stakeholders and advisors for a good cooperation during these tough times and welcome our new shareholders". Following such conversion 1,598,730,000 new shares each of nominally EUR 0.01, corresponding to an aggregate nominal amount of EUR 15,987,300, have been issued and delivered to the accounts of the bondholders of Trigon Agri A/S who have now become the shareholders of Trigon Agri A/S. As of today, the total number of shares issued by Trigon Agri A/S is 1,728,357,479 each of nominally EUR 0.01 corresponding to an aggregate nominal amount of EUR 17,283,574.79. The share capital increase and the amended Articles of Association have been registered with the Danish Business Authority. All new shares will be listed and admitted to trading on Nasdaq OMX Stockholm shortly after they have been delivered to the shareholders account. Further information to the shareholders entitled to warrants The shareholders that are entitled to warrants are reminded that the acceptance period for warrants has commenced. The forms containing detailed instruction on further actions necessary for acceptance of the warrants shall be sent to the shareholders registered in the register of shareholders (the forms will include pre-printed information to the extent possible). The blank acceptance form both in Swedish and English languages is available for download here: http://www.trigonagri.com/investor-relations/warrants/. Investor enquiries: Mr. Simon Boughton, CEO of Trigon Agri A/S, Tel: +372 6191 500, E-mail:  mail@trigonagri.com About Trigon Agri A/S Trigon Agri A/S is an integrated soft commodities production, storage and trading company with operations in Ukraine, Russia and Estonia. Trigon Agri A/S shares are traded on the main market of Nasdaq Stockholm. For subscription to Company announcements please contact us: mail@trigonagri.com If you do not want to receive Trigon Agri A/S press releases automatically in the future please send an e-mail to the following address: unsubscribe@trigonagri.com. This information is information that Trigon Agri A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 17:00 CET on 5 December 2016.

Trigon Agri A/S: Major Shareholder Announcement

Following the conversion of Bond Loan into equity in Trigon Agri A/S (CVR no. 29801843) ("Trigon Agri") on 5 December 2016, Trigon Agri hereby pursuant to Section 29 of the Danish Securities Trading Act announces receipt of the following major shareholder’s notifications: Trigon Agri A/S has received the following information: Mr. Gaurav Dhawan now indirectly through Phoenix Commodities Pvt. Ltd (company reg. no. 464110) owns 207,834,900 shares and voting rights in Trigon Agri, corresponding to 12.02% of the total share capital and of the total voting rights of Trigon Agri. Gaurav Dhawan controls Phoenix Commodities Pvt. Ltd who is the direct owner of the shares. Mr. Mats Nilsson now directly holds 126,050,000 shares and voting rights in Trigon Agri, corresponding to 7.29% of the total share capital and of the total voting rights of Trigon Agri. Mr. Joakim Johan Helenius now directly and indirectly via Trigon Capital AS (company reg. 10179709) holds shares and voting rights corresponding to less than 5% of the total share capital and of the total voting rights of Trigon Agri. In addition to his direct shareholding, Joakim Johan Helenius controls Trigon Capital AS, who is also a direct shareholder in Trigon Agri. Mr. Henrik Østenkjær Lind now indirectly through Lind Invest ApS (CVR no. 26559243) and Lind Value ApS (CVR no. 31767156) holds less than 5% of the total share capital and of the total voting rights of Trigon Agri. Lind Value ApS, the direct shareholder and owner of the shares, is controlled by Lind Invest ApS which, in turn, is controlled by Mr. Henrik Østenkjær Lind. Hunter Hall International Limited (ACN 059 300 426) now indirectly via Hunter Hall Investment Management Limited (ACN 063 081 612), holds shares and voting rights corresponding to less than 5% of the total share capital and of the total voting rights of Trigon Agri. Hunter Hall International Limited controls Hunter Hall Investment Management Limited (ACN 063 081 612), its wholly owned subsidiary company.  Hunter Hall Investment Management Limited has the power to control the exercise of the right to vote attached to the shares, and the power to exercise control over the disposal of the shares as Responsible Entity of various managed investment schemes registered in Australia. Sparinvest S.A via ID Sparinvest, Filial af Sparinvest S.A., Luxembourg ("Sparinvest") now holds 418,867,260 voting rights corresponding to 24.235 % of the total voting rights of Trigon Agri. Further information: Sparinvest S.A. is a UCITS and AIFM approved management company/alternative fund manager and portfolio manager for the following: Investeringsforeningen Sparinvest (a Danish UCITS) from 5 December 2016 owning 97,979,310 shares corresponding to 5.669% of the issued shares in Trigon Agri. Sparinvest SICAV (a Luxembourgish UCITS) from 5 December 2016 owning 60,431,994 shares corresponding to 5.611% of the issued shares in Trigon Agri. Sparinvest SICAV-SIF (a Luxembourgish SIF) from 5 December 2016 owning 120,224,496 shares corresponding to 6.956% of the issued shares in Trigon Agri. Undisclosed discretionary mandates from 5 December 2016 owning totally 5.999% of the issued shares in Trigon Agri A/S, none of the single mandates exceeding the threshold of 5% for disclosure of shareholding. Sparinvest exercises the voting rights on behalf of the funds listed above. Ownership structure of Sparinvest Companies: ID Sparinvest is the Danish branch of the Luxembourg based management company/alternative fund manager called Sparinvest S.A. which manages UCITS and AIFs in Luxembourg and Denmark. Sparinvest S.A. is 100% owned by the Luxembourg based SE company called Sparinvest Holding SE. Sparinvest Holding SE is owned by 60 financial companies ranging from banks to insurance companies and pension funds. Investor enquiries: Mr. Simon Boughton, CEO of Trigon Agri A/S, Tel: +372 6191 500, E-mail:  mail@trigonagri.com About Trigon Agri Trigon Agri is an integrated soft commodities production, storage and trading company with operations in Ukraine, Russia and Estonia. Trigon Agri’s shares are traded on the main market of Nasdaq Stockholm. For subscription to Company announcements please contact us: mail@trigonagri.com If you do not want to receive Trigon Agri press releases automatically in the future please send an e-mail to the following address: unsubscribe@trigonagri.com. This information is information that Trigon Agri A/S is obliged to make public pursuant to the Danish Securities Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 21:30 CET on 5 December 2016.

Nordic Nanovector: Betalutin® in combination with rituximab demonstrates synergistic anti-tumour effect in preclinical non-Hodgkin lymphoma model

Oslo, Norway, 6 December 2016 Nordic Nanovector ASA (OSE: NANO) announces that it has presented a poster describing the synergistic therapeutic effect of Betalutin® (177Lu-satetraxetan-lilotomab) in combination with rituximab in a preclinical model of non-Hodgkin lymphoma (NHL) (abstract 4189). The new data was presented at the 58th Annual American Society of Hematology (ASH) meeting (San Diego, CA, USA). These results build on previously presented data showing that treatment with Betalutin® increased binding of rituximab to NHL cells and uptake of rituximab in NHL tumours. The study found that Betalutin® in combination with rituximab showed a stronger anti-tumour effect compared to control groups and each of the treatments alone. The median survival time of mice given the combination was statistically significantly longer (>222 days, p < 0.05) than the survival of those receiving either of the treatments alone (31 days with rituximab and 60 days with Betalutin®). Betalutin® targets the CD37 antigen on NHL cells while rituximab targets CD20, and is the current gold standard therapy for NHL. Jostein Dahle, Nordic Nanovector’s Chief Scientific Officer, commented: “These preclinical results with Betalutin® in combination with rituximab are very encouraging and suggest that there is a strong synergistic effect against non-Hodgkin lymphoma tumours. Should this effect be confirmed in clinical studies, it would represent a very promising development and an important new dual immunotherapy approach for the treatment of NHL.” The poster (abstract 4189) was presented on Monday, 5 December 2016, between 6:00PM-8:00PM Pacific Standard Time (Oslo: Tuesday 6 December, 3:00AM–5:00AM CET) and is available at: http://www.nordicnanovector.com/product-info/scientific-posters. For further information, please contact: IR enquiries: Luigi Costa, Chief Executive OfficerCell: +41 79 124 8601 Tone Kvåle, Chief Financial OfficerCell: +47 91 51 95 76Email: ir@nordicnanovector.com Media enquiries:Mark Swallow/David Dible (Citigate Dewe Rogerson)Tel: +44 207 282 2948/+44 207 282 2949Email: nordicnanovector@citigatedr.co.uk About Nordic Nanovector: Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously referred to as HH1), conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications. Further information about the Company can be found at www.nordicnanovector.com This information is subject to the disclose requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Wihlborgs signs lease with Folktandvården Skåne in Lund

The premises will comprise a large modern clinic with 38 treatment rooms for general and specialist dentistry; a knowledge arena focused on research, developing care and training; and Folktandvården Skåne’s head office. Occupancy is scheduled for 1 April 2018 and the lease extends for 15 years. “Folktandvården are making an exciting investment and we are delighted that they have chosen to partner with Wihlborgs. These premises are ultra-modern in a strategic location adjacent to Lund Central Station,” says Anders Jarl, CEO of Wihlborgs Fastigheter. “Daily contact and proximity will increase between the clinic, research and management, which means that clinical research project findings can be incorporated more rapidly in practical healthcare operations. This will benefit all residents of Skåne,” explains Marika Qvist, CEO of Folktandvården Skåne. Demand for modern office space in central Lund is substantial and negotiations are ongoing with a number of interested parties for the remaining space at Posthornet. The property has a total of around 11,000 m2 of office space which will be ready in spring 2018. The building will have a clear environmental profile with a roof-top solar cell facility and environmental certification to SGBC Gold. More information is available at www.wihlborgs.se/en/projects/lund/posthornet-lund/ (https://www.wihlborgs.se/en/projects/lund/postterminalen-lund/) Wihlborgs Fastigheter AB (publ)

Jörgen Lantto proposed to join myFC’s board of directors and invest in myFC

Björn Westerholm, CEO of myFC and Jörgen Lantto The Nomination Committee and the Board of myFC Holding AB, have communicated that they will support the election of Jörgen Lantto as a new member of the board of myFC Holding AB during the extraordinary shareholders meeting on December 21, 2016. The Board also supports the motion to issue not more than 263 158 shares through a directed shares program to Jörgen Lantto without the preferential right of existing shareholders. This means an increase in the share capital of not more than 15 389,36 Swedish krona, whereby 5 MSEK before issue cost is added to the company. Payment will be made in connection with the election to the Board. The price for the directed shares will be based on the price at market closing time, minus 5,9 percent, on December 5, 2016 for myFC. Lantto was most recently CEO of Fingerprint Cards AB, a Swedish high-technology company developing and selling biometric systems for smartphones and other applications. Fingerprint Cards is traded on Large Cap, Nasdaq OMX. During Lantto’s leadership, Fingerprint Cards established a world-leading position in fingerprint sensors and during 2015 the company grew its revenues more than 1100 percent. In addition to Fingerprint Cards, Lantto has an extensive background in the telecom industry, primarily in the Ericsson group. "I am very pleased that myFC’s nomination committee and the board have proposed for me to join the board of directors of myFC Holding AB. myFC has during an extended period developed a technology that has the potential to help consumers get uninterrupted access to power in smartphones and other devices, thereby also contributing to a sustainable society. I am really looking forward to supporting myFC’s management in enabling a global expansion of the company, its technology and products, with the ambition to create yet another leading Swedish technology company in a truly global market", says Jörgen Lantto. "Jörgen has exceptional knowledge and experience from the telecom and component industry through a number of leading roles in Fingerprint Cards, Ericsson and other companies.In these roles, he has had profound relations with mobile operators and smartphone manufacturers with the associated world-wide ecosystems. As previously announced, myFC signed a multiyear framework agreement for the delivery of myFC’s fuel cell technology to China, while also receiving an initial order. We are now planning to ramp up our capability of meeting demand from existing customers, and we will also further develop our business model and product portfolio to further exploit our technology’s potential. This means that we are entering a very exciting phase where Jörgen’s previous experiences become highly relevant, and I am really looking forward to starting this work together with him", says Björn Westerholm, CEO of myFC. "I am very pleased that Jörgen Lantto has elected myFC Holding AB to be the only public company he sees fit to currently join. As a member of the board of directors, I am convinced that Jörgen’s input and direction will be of great use for us now that we are about to create and execute upon our future strategy on a global level", says Carl Palmstierna, Chairman of the Board of myFC Holding AB. For press inquiries, please contact: My Ernevi, Head of Marketing Email: my.ernevi@myfc.se  (my.ernevi@myfc.se%C2%A0)Phone: +46 (0) 703 83 63 43 This information is information that myFC is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07:55 CET on 6 of December 2016.  

Mycronic adjusts the outlookupwards for full year sales in 2016

Täby, 6 December, 2016 - Mycronic AB (publ), today adjusts the outlook upwards for full year sales in 2016 to the level of SEK 2,200 million, excluding effects from acquisitions.   The background for the upward adjustment is a combination of earlier delivery of a Prexision-80 mask writer, an order received in December 2015, the change in product mix within Mycronic’sboth business areas as well as currency effects.The current assessment for sales in 2016 has been at the level of SEK 1,900 million, excluding effects from acquisitions.Mycronic’s mask writer Prexision-80 is an advanced system for cost-effective manufacturing of the most advanced photomasks for display applications. At the time of the order it was agreed with the customer that delivery would take place during first quarter of 2017 at the latest. A successful completion of the project and agreement with the customer has enabled delivery in December 2016. Contacts at Mycronic:Lena Olving                         VD och koncernchef            Tel: +46 8 638 52 00lena.olving@mycronic.com                                         Per EkstedtCFO                                   Tel: +46 8 638 52 00per.ekstedt@mycronic.com                                         About Mycronic ABMycronic AB is a Swedish high-tech company engaged in the development, manufacture and marketing of production equipment with high precision and flexibility requirements for the electronics industry. Mycronic headquarters are located in Täby, north of Stockholm and the Group has subsidiaries in China, France, Germany, Japan, Singapore, South Korea, the Netherlands, United Kingdom and the United States. For more information see our web site at: www.mycronic.com  Mycronic AB (publ) is listed on NASDAQ Stockholm, Mid Cap: MYCR.  The information is of the type that Mycronic is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication, through the contact persons stated above, on 6 December, 2016, at 8.00 am.

Gant gains more efficient IT operations with solution from Proact

The international clothing brand Gant has updated its IT infrastructure with support from Proact. Gant, with its corporate headquarters and enterprise IT management in Sweden, had previously implemented a virtualised environment in its data centres, using VMware software platforms. The company has recently taken this initiative one step further by updating IT infrastructure with Proact’s assistance, complemented by consulting and support services. “We now operate a fully redundant environment, which delivers higher system availability and makes our business operations less vulnerable,” says Kenneth Karlsson, Global IT Infrastructure Manager at Gant. “The new infrastructure is also easier to manage, supporting our efforts for more efficient IT operations.” Gant operates its own data centres in three European countries and in the United States, all of which have implemented the new solution. In the UK, a new converged solution has been installed to replace the entirety of the former systems environment, including servers, storage and networking. Gant has also deployed a new backup solution using snapshot technology, and backup management has been centralised to Sweden. “We have a long-term relationship with Gant, a company with a well-designed strategy to actively engage inhouse IT resources and skills to develop its business,” says Lena Eskilsson, Managing Director Proact IT Sweden AB. “Gant has demonstrated how an international enterprise can successfully build and manage a high-performance, state-of-the-art IT infrastructure.”

NTTBP Appoints Clavister to Secure Its Public Wi-Fi Services Network in Japan

Clavister (Nasdaq: CLAV), a supplier of high-performance network security, today announced that NTTBP, Japanese provider of carrier grade Wi-Fi service, highly customized Wi-Fi services for transportation facilities, vehicles, convenience stores and local government, high-density WiFi in studiums and convention centers, and value added services, and a group company of NTT Group, a leading company in the communications industry, has selected Clavister and its integrator partner MIRAIT to implement security on NTTBP’s extensive public Wi-Fi network which has over 220,000 access points across Japan. In Japan, Wi-Fi is recognized as an important infrastructure that is one of the fundamental broadband networks,  such as optical fiber internet access and LTE internet access. It has also evolved to become an essential social foundation providing not only LTE traffic offload, but also providing social and business values to make difference for enterprise and public sectors not only with high quality WiFi but also with value-added services over WiFi.  Japan is one of the top four global LTE markets, with over 90 million LTE subscriptions*. LTE traffic has been rapidly growing, and further rapid growth is expected as more smart Internet of Things (IoT) devices connect to networks. NTTBP aims to offload LTE traffic to its high performance Wi-Fi networks to optimise LTE performance, and enhance subscribers’ mobile internet experience with fast Wi-Fi access. Clavister will deliver its security solution to ensure that NTTBP stays in control of its network, and to support the potential for new value-added services and revenue streams.  The Clavister solution is highly scalable, and can be integrated quickly and effectively with the NTTBP network infrastructure.  The security deployment will also support NTTBP’s network plans ahead of the 2020 Olympics in Tokyo. “Due to the increasing LTE traffic load and the demand for efficient, secure, high quality Wi-Fi Services, it is important to work with a security supplier that can deliver a high-performance and scalable security solution.  We are confident the Clavister solution implemented by MIRAIT will meet not only these demands across our growing network but also something we have seen in the market, which will be profitable service in security issue over free Wi-Fi. Clavister is the fastest company among candidates, that adapts the strategy of NTTBP” said Toshiya Masuzawa, Executive Manager, Senior Vice President, NTTBP. Jim Carlsson, CEO of Clavister, said: “Working with our partner MIRAIT, we are enhancing NTTBP users’ mobile internet experience, giving them the fast Web access, performance and security they expect across the country.  The solution relieves pressure on LTE networks in areas of dense population, while enabling seamless mobile browsing.  It also supports roll-out of targeted, value-added services for subscribers.  The scalability of our solution gives it the capability to secure country-wide Wi-Fi networks, enabling the provision of resources and public services to subscribers and tourists – the possibilities really are endless.” “NTTBP has sole responsibility for the Wi-Fi business as one of the NTT Group companies, whose core business is telecoms and is one of the leading enterprise groups in Japan.  NTT Group views cloud services as its core business for growth, and places great expectations on the Wi-Fi business as one of the key success factors.  MIRAIT is fully aware that NTTBP in accordance with NTT Group companies’ strategy, plans to strengthen security in their Wi-Fi business. Clavister’s solution for operators offers a high level performance and security.” Says Shigeru Yanagisawa, Managing Executive Officer, Head of Solution Business Headquarter MIRAIT. *  Ericsson North East Asia Mobility Report:  https://www.ericsson.com/res/docs/2015/mobility-report/emr-nov-2015-regional-report-north-east-asia.pdf //ENDS About NTTBP (and NTT)  NTT Broadband Platform Inc. (NTTBP) is a group corporation of Nipon Telegraph and Telephone Corp which provides fiber-optic broadband services and mobile broadband services as well as telecommunication services through its group companies, such as  NTT East corp., NTT West corp., NTT Communications, and NTT docomo. NTTBP has 15 years experience in Wi-Fi businesses since July of 2002 in business domains of Wi-Fi businesses, such as Wi-Fi whole-sale for telecommunication carriers, enterprise Wi-Fi provider for transportation, convenience stores, and public sectors, and value-addes services in advertisement, marketing oriented contents management services, and data analytics. It has also provided Wi-Fi in high-density traffic venues such as Convention centers and Sports Studiums with venue-dedicated visitor services including video streaming, 360 degree viewing and 3D AR services. About MIRAIT MIRAIT Corporation (MIRAIT), a leading ICT integrator in Japan, has conducted business creating communication infrastructures for over 70 years as partners of telecommunications carriers. MIRAIT Holdings, its parent company, had net sales of 270 billion yen in the FYE March 2016, growing into the industry's leading groups. The Group conducts business in a wide range of areas including ICT, the environment and energy, based on the creation of communication infrastructure (fixed communication and mobile communication) that is its main business, accounts for about 60% of net sales.  With nationwide business expansion and multi-carrier compatibility, MIRAIT is actively expanding new growing markets, such as network security, cloud solution and other innovative areas. MIRAIT share is listed on 1st Section of Tokyo Stock Exchange and has approximately 24,056 shareholders. For more information about MIRAIT, visit www.mrt.mirait.co.jp/english.

German media group signs agreement with Cxense for personalization offering

Oslo, Norway – 6 December 2016 – Cxense ASA (OSE: CXENSE) today announced that Rhein Main Digital GmbH has signed an agreement with Cxense for the use of its Data Management and Personalization Software.Rhein Main Digital is a subsidiary of Verlagsgruppe Rhein Main, a leading media group publishing 29 daily newspapers in the Hessen and Rheinland-Pfalz regions of Germany, reaching close to 1 million readers. The company is responsible for all group internet activities including publishing content across the various group sites covering newspapers, video news and events. Rhein Main Digital also handles all online marketing for the group, as well as acting as an independent digital agency for external customers.  The company has licensed Cxense Insight, Cxense DMP and Cxense Content. The target is to use online personalization to increase user engagement and drive subscriber conversion.About Cxense:Cxense (pronounced "see-sense") enables the world's leading media, e-commerce and consumer brands to take control of their audience data to deliver more engaging and personalized user experiences. Businesses using Cxense's advanced real-time analytics, data management (DMP), advertising, search and personalization technology gain more engaged users, increased digital revenue and higher sales conversions. Cxense is headquartered in Oslo, Norway, with offices worldwide.Customers include the Wall Street Journal, USA Today (Gannett), Grupo Clarin, El Pais, Bonnier, Naspers, Ebay, The Golf Channel, PGA, NBA, NFL, ABC News, FOX Sports, Singapore Press Holdings, South China Morning Post, AEON, DMM, Rakuten and many more. For more information: www.cxense.com, Twitter: @Cxense. Cxense is listed on the Oslo Stock Exchange with the ticker 'CXENSE.'Investor Relations Contact:Jørgen Loeng, Chief Financial OfficerEmail: jorgen.loeng@cxense.comMobile: +47 906 60 062

Mr. Trond Myklebust appointed as new CEO of Viking Supply Ships AB

The Board of Directors of Viking Supply Ships AB has appointed Mr. Trond Myklebust as Chief Executive Officer (CEO). Mr. Myklebust will also act as CEO in Viking Supply Ships A/S, and will take over the responsibilities as CEO in both companies ultimo January. Mr. Myklebust is currently employed as CEO of Fjord Shipping AS. He has extensive experience from the Offshore industry, most notably from his position as Managing Director of Bourbon Norway and ship broker and General Manager within Seabrokers. He has also been Managing Director of Kongsberg Evotec and has a long career as Chief Officer and Master within the Norwegian Coastguard and Remøy/Havila. Mr. Myklebust is a Master Mariner from Aalesund University College. With effect as of the same date, Mr. Bengt A. Rem will be reinstated as Chairman of the Board of Viking Supply Ships AB. Mr. Folke Patriksson will return to his previous position as Deputy Chairman. For further information please contact:   Bengt A. Rem, Interim CEO, tel. +47 94 01 71 71, e-mail bengt.rem@kistefos.no  Morten G. Aggvin, IR & Treasury Director, tel: +47 41 04 71 25, mga@vikingsupply.com. Viking Supply Ships AB is the parent company of a Swedish shipping group with its main office in Gothenburg, Sweden. The Group conducts its business in four segments: Anchor Handling Tug Supply ships (AHTS), Platform Supply Vessels (PSV), Services and Ship Management. The business is focused within offshore and ice-breaking primarily in Arctic and subarctic areas. The Group has approximately 500 employees and its revenue for 2015 amounted to MSEK 1.114. The Company’s series B share is listed at Nasdaq Stockholm, Small Cap segment. www.vikingsupply.com. This information is information that Viking Supply Ships AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 a.m. CET on 6 December 2016. 

The leading media house in Malaysia signs agreement with Cxense

Oslo, Norway – 6 December 2016 – Cxense ASA (OSE: CXENSE) today announced that Media Prima Berhad has signed an agreement with Cxense for the use of its Data Management and Personalization Software.Media Prima is Malaysia’s leading fully-integrated media company and one of the top 100 listed companies in the country by revenue. The group has a complete repertoire of media-related businesses including television, print, radio, out-of-home, as well as content and digital media.Media Prima has licensed Cxense Insight, Cxense DMP and Cxense Content. The personalization offering will be used to increase user engagement on Media Prima’s digital sites and applications, to strengthen user loyalty and to build richer user profiles in order to improve editorial planning and increase digital revenue.About Cxense:Cxense (pronounced "see-sense") enables the world's leading media, e-commerce and consumer brands to take control of their audience data to deliver more engaging and personalized user experiences. Businesses using Cxense's advanced real-time analytics, data management (DMP), advertising, search and personalization technology gain more engaged users, increased digital revenue and higher sales conversions. Cxense is headquartered in Oslo, Norway, with offices worldwide.Customers include the Wall Street Journal, USA Today (Gannett), Grupo Clarin, El Pais, Bonnier, Naspers, Ebay, The Golf Channel, PGA, NBA, NFL, ABC News, FOX Sports, Singapore Press Holdings, South China Morning Post, AEON, DMM, Rakuten and many more. For more information: www.cxense.com, Twitter: @Cxense. Cxense is listed on the Oslo Stock Exchange with the ticker 'CXENSE.'Investor Relations Contact:Jørgen Loeng, Chief Financial OfficerEmail: jorgen.loeng@cxense.comMobile: +47 906 60 062

Sectra enters the African market with new partnership

“Healthcare in Africa is entering a phase of modernization. This partnership with Tecmed Africa enables Sectra to be part of that transformation and, based on our extensive experience from markets where similar modernization has taken place, help African hospitals to tackle their challenges,” says Dr. Torbjörn Kronander, President and CEO of Sectra. The partnership agreement with Tecmed Africa includes distribution of Sectra’s Enterprise Image Management solutions comprising PACS (Picture Archiving and Communication System) for imaging-intense departments, VNA (Vendor Neutral Archive) and Cross Enterprise Workflow.  “Through this partnership with Sectra, we can now offer our customers solutions with higher availability and better integration possibilities. This will allow our customers to improve collaboration across the clinical pathway, thereby improving patient care,” says Peter Thome, Business Development Manager at Tecmed Africa, Informatics/IT. About Tecmed AfricaTecmed Africa operates in South Africa and has representation in several other countries in the Sub-Saharan region. The company has been in the market for more than 20 years and provides leading medical equipment and solutions to the healthcare sector. It also supplies locally developed solutions for African market, conditions and customer requirements. For more information about Tecmed Africa, http://www.tecmedafrica.com/.

Unibet Group becomes Kindred Group

The shareholders of Unibet Group plc today voted to change the name of the holding company from Unibet Group plc to Kindred Group plc. The strategic business rationale behind this decision relates to the fact that Unibet Group is a growing and changing company that today has ten consumer facing brands in the portfolio, many of them acquired. Unibet Group has operated with a multi-brand strategy since the acquisition of Maria Casino in 2007, a strategy which is now fully adopted with the Kindred Group brand. “Changing our group name from Unibet Group to Kindred Group marks an historic step for our company, founded almost twenty years ago. We are now in a position to move Kindred Group into the future with enhanced clarity and flexibility, creating better conditions for future growth in a dynamic and changing business environment”, says Anders Ström, Chairman of the Board of Directors of Unibet Group. “As Kindred we can create a greater distinction between our consumer facing brands and the group brand, providing us with the necessary strategic flexibility to ensure we remain at the very forefront of our industry. As a group we have played an important part in driving the industry forward, and we intend to continue to do so in the future”, says Henrik Tjärnström, CEO of Unibet Group. The chosen name is based on an extensive analysis of the Group culture and identity. If you look up the word kindred in the dictionary, you will find that it refers to a relationship between people with similar beliefs, values and attitudes. The Unibet Group are proud of their strong culture and great people, and this proposed name truly describes the people of the Group.

EQT Infrastructure to acquire Delta Comfort

· EQT Infrastructure to acquire Delta Comfort, the leading telecom infrastructure company and supplier of energy in the Dutch province of Zeeland  · EQT Infrastructure to support Delta Comfort in further strengthening its position as the preferred telecommunication infrastructure access provider for the Zeeland community  · New Board of Directors will be composed of a highly relevant set of industry leaders from the telecom and energy sectors to support management of Delta Comfort The EQT Infrastructure investment strategy (“EQT Infrastructure”) has signed definitive transaction documentation to acquire Delta Comfort B.V. (”Delta Comfort” or “the Company”) from Delta N.V., the municipality and province owned integrated utility company of the Dutch province of Zeeland. The purchase price amounts to EUR 488 million. Delta Comfort is the leading telecom infrastructure owner and operator, provider of multimedia services (broadband, TV, telephony) and supplier of energy, serving over 140,000 households and businesses mainly in the Dutch province of Zeeland. Delta Comfort’s hybrid fiber-coaxial (HFC) network of over 6,000km passes 192,000 homes, which corresponds to ~90% of the total number of homes in Zeeland. Delta Comfort employs approximately 370 people and generated sales of EUR 214 million in 2015. Going forward, the strategy is to further develop the Company’s unique multi-utility approach, invest in its network to provide the most advanced solutions to residential and business clients and therefore strengthen its position as the preferred telecommunication infrastructure access provider in Zeeland. The growth of the Company will be supported by an industrial board of directors who will have significant telecom and energy expertise. Harko Buringh, CEO of Delta Comfort, said: “We are excited to join EQT Infrastructure, one of the world’s most respected infrastructure funds, with a strong heritage in the telecom sector. They have a growth focused strategy, a responsible and hands-on ownership approach and will provide us with access to an extensive network of industry specialists.” Matthias Fackler, Partner at EQT Partners and Investment Advisor to EQT Infrastructure, said: “We are impressed with Delta Comfort’s superior network infrastructure, unique multi-utility product offering and leading position in Zeeland. We are very enthusiastic about the future of Delta Comfort and the opportunities the EQT industrial investment approach will bring to the Company’s next development phase.” The transaction is subject to customary conditions, such as completion of a works council consultation procedure, approval of the shareholders of Delta N.V. and the Autoriteit Consument & Markt (ACM). It is expected to close in the first quarter of 2017. ING acted as sole financial advisor and Clifford Chance as legal advisor to EQT Infrastructure. Contacts:Matthias Fackler, Partner at EQT Partners, Investment Advisor to EQT Infrastructure, +49 89 2554 99520Kerstin Danasten, EQT Press Officer, +46 8 506 55 334 About EQTEQT is a leading alternative investments firm with approximately EUR 31 billion in raised capital across 21 funds. EQT Funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 15 billion and approximately 100,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. EQT Funds current investments in the Netherlands include TransIP, Bureau van Dijk and 3D Hubs More info: www.eqtpartners.com About Delta ComfortDelta Comfort offers multimedia and energy solutions to residential and business clients in the province of Zeeland. Delta Comfort owns and operates a hybrid fiber-coaxial (HFC) network of 3,400km of fiber and 3,000km of coaxial cables, which passes 192,000 households in the region. Delta Comfort employs approximately 370 people and generated sales of EUR 214 million in 2015. It is headquartered in Middelburg, the capital of Zeeland, Netherlands. More info: www.delta.nl/en/about-delta

OrganoClick - one of Sweden's fastest growing technology company!

Affärsvärlden, Sweden’s leading business magazine, has recently published an article on this year's "Sweden Technology Fast 50", Deloitte's independent ranking of the fastest growing technology companies. The ranking show continued strong sales growth in the Swedish technology industry. Among the 10 fastest technology companies are among others Fingerprint Cards, iZettle and Q-channel. OrganoClick meets all the formal requirements for the list and would be placed on a 6th place, with its growth rate of 2828%, but was not on the list because the activity code (SIC code) OrganoClick has was not included in the Deloitte survey. The article in Affärsvärlden told of the ranking of the Fast50 companies. The ranking is based on Sweden's 50 fastest growing technology companies, in terms of sales performance during the past four years. Deloitte does the rankings based on a number of formal criteria that companies must meet (see below). Selecting technology companies from going through the companies operating codes from the Swedish Tax Agency. Unfortunately, the operating code that OrganoClick® is registered under, was not included this year but Deloitte confirms in writing that OrganoClick® meets all the formal requirements for the list. - At OrganoClick we are incredibly proud that we have grown so quickly but clearly we are a bit disappointed that we were not published on the Fast50 official list. A potential 6th place in the competition with Sweden's fastest growing IT companies is even better than we have hoped. The most important of all, however, is that all our growth contributes to a better environment. In coming years, we accelerate even more - because we see great potential for green chemistry and renewable materials, says Mårten Hellberg, CEO of OrganoClick AB. Fast50 – The entire list: http://www.fast50.se/ Deloitte’s own press release: https://www2.deloitte.com/se/sv/footerlinks/pressreleasespage/deloitte-sweden-technology-fast-50-20151.html ......................................................................................... For more information, please contact: Mårten Hellberg, CEO 0707 - 16 48 90, marten.hellberg@organoclick.com ......................................................................................... About OrganoClick OrganoClick AB (publ) is a public Swedish cleantech company listed on Nasdaq First North. The company develops, produces and markets functional materials based on environmentally friendly fiber chemistry. Examples of products that are marketed by OrganoClick are the water repellent fabric treatment OrganoTex®, the flame and rot-resistant timber OrganoWood® and biocomposite materials. OrganoClick was founded in 2006 as a commercial spin-off company based on research performed at Stockholm University and the Swedish University of Agricultural Sciences within environmentally friendly fiber chemistry. OrganoClick has won a number of prizes, such as "Sweden's Most Promising Start -up" and "Sweden's Best Environmental Innovation", and has also received a number of awards, such as the WWF "Climate Solver" award and has also appeared for two years on the Affärsvärldens and NyTekniks list of Sweden's top 33 hottest technology companies. OrganoClick has its head office, production and R&D located in Täby, north of Stockholm. OrganoClick's Certified Adviser on Nasdaq First North is Erik Penser Bank.  The information in this press release contains information that OrganoClick AB (publ) is obliged to release according to the EU's market regulation law number 596/2014. The information was published, of the contact person above, 6th December 2016 at 15:30. 

Nordic Nanovector launches a private placement of new shares

THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN Oslo, Norway, 6 December 2016Nordic Nanovector ASA (OSE: NANO) (“Nordic Nanovector” or the “Company”), announces the launch of an undocumented private placement of up to 4,374,244 new shares, representing approximately 10% of the outstanding share capital of the company (the “Offering”). DNB Markets, Jefferies International Limited and ABG Sundal Collier are acting as joint bookrunners (the “Joint Bookrunners”) in connection with the Offering. Nordic Nanovector intends to use the net proceeds of the Offering: To fund a Phase 2 combination study of Betalutin® and Rituximab CD20 To fund a Phase 1 study and GMP manufacturing for 177Lu-conjugated chimeric antibody (anti-CD37 ARC) Develop new proprietary antibody production technology Accelerate pipeline of pre-clinical assets to clinical trials Prepare for commercial launch of Betalutin® General corporate purposes The subscription price and the number of shares to be issued in the Offering will be determined through an accelerated bookbuilding process.The bookbuilding period for the Offering opens today at 16:30 CET and closes 7 December 2016 at 08:00 CET. The Company and the Joint Bookrunners may, however, at any time resolve to close or extend the bookbuilding period at their sole discretion and on short notice. The minimum subscription and allocation amount in the Offering will be the NOK equivalent of EUR 100,000, provided that the Company may, at its sole discretion, allocate an amount below EUR 100,000 to the extent applicable exemptions from the prospectus requirement pursuant to applicable regulations, including the Norwegian Securities Trading Act and ancillary regulations, are available. Allocation of the new shares will be determined at the end of the bookbuilding process, and final allocation will be made by the Company's Board of Directors at its sole discretion, following advice from the Joint Bookrunners. The shares to be issued in connection with the Offering will be issued based on the board authorisation granted at the Company's annual general meeting on 19 May 2016. In line with the shareholders’ approval, pre-emption rights of the existing shareholders are excluded. The Offering will be directed towards Norwegian and international investors, in each case subject to and in compliance with applicable exemptions from relevant prospectus or registration requirements. Notification of allotment and payment instructions will be sent to the applicants on or about 7 December 2016 through a notification to be issued by the Joint Bookrunners.Offer shares will be settled with existing and unencumbered shares in the Company that are already listed on the Oslo Stock Exchange, pursuant to a share lending agreement between DNB Markets (on behalf of the Joint Bookrunners) and HealthCap VI L.P., in order to facilitate delivery of listed shares to investors on a delivery versus payment basis. The offer shares delivered to the subscribers will thus be tradable from allocation. The Joint Bookrunners will settle the share loan with new shares in the Company to be issued by the Board of Directors pursuant to the aforementioned authorisation granted at the annual general meeting held on 19 May 2016. The Company, its board members, executive management and major shareholder have all agreed with the Joint Bookrunners to a lock-up on future share issuances and existing shareholdings, as applicable, for a period of 180 days from the closing date, subject to customary and de minimis exceptions. The Company will announce the final number of offer shares placed and the final subscription price in the Offering in a stock exchange announcement expected to be published before opening of trading on the Oslo Stock Exchange tomorrow, 7 December 2016. The Offering is subject to final approval by the Company’s Board of Directors. For further information, please contact:For Nordic NanovectorIR enquiries:Luigi Costa, Chief Executive OfficerCell: +41 79 124 8601Tone Kvåle, Chief Financial OfficerCell: +47 91 51 95 76Email: ir@nordicnanovector.com Media enquiries:Mark Swallow/David Dible (Citigate Dewe Rogerson)Tel: +44 207 282 2948/+44 207 282 2949Email: nordicnanovector@citigatedr.co.uk About Nordic Nanovector:Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab, conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its pipeline of innovative targeted immunoconjugate therapies for multiple selected cancer indications. Further information about the Company can be found at www.nordicnanovector.com This information is subject to the disclose requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Important NoticesThis document is not an offer to sell or a solicitation of offers to purchase or subscribe for shares. Copies of this document may not be sent to jurisdictions, or distributed in or sent from jurisdictions, in which this is barred or prohibited by law. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction.This document is not for publication or distribution in the United States of America, Canada, Australia or Japan and it does not constitute an offer or invitation to subscribe for or purchase any securities in such countries or in any other jurisdiction. In particular, the document and the information contained herein should not be distributed or otherwise transmitted into the United States of America or to U.S. persons (as defined in the U.S. Securities Act of 1933, as amended (the “Securities Act”)) or to publications with a general circulation in the United States of America. This document is not an offer for sale of securities in the United States. The securities referred to herein have not been and will not be registered under the Securities Act, or the laws of any state, and may not be offered or sold in the United States of America absent registration under or an exemption from registration under Securities Act. Nordic Nanovector does not intend to register any part of the offering in the United States, There will be no public offering of the securities in the United States of America. Any public offering in the United States would be made by means of a prospectus containing detailed information about the company and management, as well as financial statements.The information contained herein does not constitute an offer of securities to the public in the United Kingdom. No prospectus offering securities to the public will be published in the United Kingdom. This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.Any offer of securities to the public that may be deemed to be made pursuant to this communication in any member state of the European Economic Area (each an “EEA Member State”) that has implemented Directive 2003/71/EC (together with the 2010 PD Amending Directive 2010/73/EU, including any applicable implementing measures in any Member State, the “Prospectus Directive”) is only addressed to qualified investors in that Member State within the meaning of the Prospectus Directive.Investing in securities involves certain risks. You should read the Risk Factors contained in the prospectus dated 10 March 2015 (available at http://www.nordicnanovector.com/investor-relations/reports-and-presentations/prospectus), but they should be read in light of any new or additional information contained in any further publicly available information since the date of the prospectus.This publication may contain specific forward-looking statements, e.g. statements including terms like “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Nordic Nanovector and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. Nordic Nanovector assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Moberg Pharma considers an acquisition of a brand from Prestige Brands and evaluates the preconditions for carrying out a directed new shares issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, NEW ZEELAND, SOUTH AFRICA, HONG KONG OR SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL Summary of the considered acquisition and its overall effects•    Moberg Pharma has an exclusive option to acquire DermoPlast® from Prestige Brands (“Prestige”). Moberg Pharma considers to, on or around December 7th, 2016, enter into a binding acquisition agreement with Prestige to acquire DermoPlast® for a purchase price of USD 47.6M plus stock value. A final decision on such acquisition and the entering into an acquisition agreement is dependent on the Company first being able to secure financing. A potential transaction is expected to be completed during December 2016.•    Based on Moberg Pharma’s cost structure and accounting principles, the purchase price corresponds to approximately 8.9 times the estimated EBITDA for DermoPlast® for the period 1 October 2015–31 September 2016.•    DermoPlast® will be sold through Moberg Pharma’s established sales channels in the U.S., primarily in chain drugstores such as CVS, Walgreens and Rite Aid and in mass retailers, such as Walmart and Target and directly to hospitals.•    DermoPlast® is an anesthetic spray used externally for relief of pain and itching from skin chaps and skin injuries. The hospital sales are primarily focused on women, for usage on skin chaps and vaginal injuries and surgery in connection with or after childbirth.•    DermoPlast® will be included among Moberg Pharma’s strategic brands, and is expected to be the Company’s second largest product.•    At a completed acquisition of DermoPlast® it is expected that the brand, immediately following completion, will contribute positively to both the Company’s profit and cash flow per share, also considering financing costs.•    Moberg Pharma intends to partially finance the acquisition through a directed share issue of up to 2,843,504 shares through a so-called "accelerated book-building", and has mandated Carnegie Investment Bank to assess the preconditions therefor. “The acquisition of DermoPlast® is in line with our strategy and leverages our existing infrastructure and sales channels in the U.S. in an excellent way. The acquisition brings increased economies of scale and complements our portfolio with a strong and profitable dermatology brand. We are very pleased with this transaction, which is expected to contribute positively to both our sales and profitability and thereby to our long term financial target to deliver profitable growth and an EBITDA margin of 25 per cent”, says Peter Wolpert, CEO of Moberg Pharma. Background to the acquisition of DermoPlast® A central part of Moberg Pharma’s strategy is to acquire Over-the-Counter brands that complement the Company’s existing portfolio. Moberg Pharma is continuously evaluating possible acquisition of such complementary brands. One such possible acquisition is the brand DermoPlast® from Prestige. In June 2016, Moberg Pharma announced its acquisition of the three well-established U.S. Over-The-Counter brands New Skin®, Fiber Choice® and PediaCare® (under divestment) from Prestige. Subsequently, Moberg Pharma has secured an exclusive right to also acquire DermoPlast® from Prestige for an USD 1.25M option fee. The option provides Moberg Pharma with a one-time right to perform an evaluation of DermoPlast® on exclusive basis and following which evaluation Moberg Pharma, at its own discretion, can decide to complete an acquisition of DermoPlast® at an agreed multiple of the contribution margin of the product. Moberg Pharma has performed such an evaluation of DermoPlast® and on the basis thereof Moberg Pharma considers to complete the acquisition. A final decision is however dependent on that the Company has secured financing before any binding acquisition agreement is entered into. In addition to a directed issue of ordinary shares, Moberg Pharma intends to finance the contemplated acquisition of DermoPlast® by available cash resources and a tap issue to Moberg Pharma’s outstanding bond loan (ISIN: SE0007953989) of approximately SEK 215M. In the event of an acquisition of DermoPlast® the product will be included among Moberg Pharma’s strategic brands, and is expected to be the Company’s second largest product. DermoPlast® in shortDermoPlast® is an anesthetic spray used externally for relief of pain and itching from skin chaps and skin injuries. DermoPlast® will be sold through Moberg Pharma’s established sales channels in the U.S., via chain drugstores such as CVS, Walgreens and Rite Aid and in mass retailers such as Walmart and Target and directly to hospitals. The hospital sales is primarily focused on women, for usage on skin chaps and vaginal injuries and surgery in connection with or after childbirth. Prestige does not report DermoPlast® separately. However, based on information from Prestige’s public financial statements and Prestige’s internal accounting and reporting system, Moberg Pharma has made certain appraisals of the financial effects of an acquisition of DermoPlast®. These estimates are uncertain and have not been audited and should thus be treated with caution. Nonetheless, based on available information, the Company estimates that DermoPlast® during the period 1 October 2015-30 September 2016, and with application of IFRS and the Company’s accounting principles, experienced net sales of USD 12.0M and an EBITDA of USD 5.4M, equivalent to a EBITDA margin of approximately 45 per cent. Furthermore, the Company estimates that DermoPlast® has during recent years, with application of IFRS and the Company’s accounting principles, experienced increased net sales as follows: ·  2016/2015: USD 12.0M (12 months until 30 September 2016) ·  2015: USD 10.4M ·  2014: USD 9.8M ·  2013: USD 9.8M The EBITDA margin of the product has been stable during the period 2013-2016. In the event of an acquisition of DermoPlast®, the purchase price will amount to USD 47.6M plus stock value and with deduction of the already paid USD 1,25M option fee. The purchase price is intended to be financed partially by a tap issue to the Company’s outstanding bond loan, which bears annual interest equivalent to STIBOR 3M plus 6.00 per cent, of approximately SEK 215M and partially by available cash resources and also through the net proceeds from a directed new shares issue. Assuming completion of these transactions, the Company’s net debt is estimated to increase by approximately SEK 300M if the acquisition of DermoPlast® is carried out. A potential acquisition of DermoPlast® is expected to be completed during December 2016 and DermoPlast® will be consolidated in Moberg Pharma’s accounts thereafter. A potential acquisition of DermoPlast® is expected to, immediately following completion, contribute positively to both the Company’s profit and cash flow per share, also considering financing costs and additional shares. Engagement of Carnegie to evaluate the preconditions for a private placementMoberg Pharma intends to partially finance the contemplated acquisition of DermoPlast® through a direct issue of up to 2,843,504 shares. Therefore Moberg Pharma has, based on the authorization to issue shares granted by the Company’s annual general meeting on 18 May 2016, mandated Carnegie Investment Bank to assess the preconditions for a private placement of up to 2,843,504 shares, through a so-called “accelerated book-building” procedure. In addition hereto, the Company has mandated Carnegie Investment Bank and Swedbank to assess the preconditions for a tap issue to the Company’s outstanding bond loan of approximately SEK 215M. AdvisorsCarnegie Investment Bank has been engaged as financial advisor regarding the directed share issue and Carnegie Investment Bank and Swedbank have been engaged as financial advisors regarding the tap issue to the Company’s outstanding bond loan. Hansen Law has been engaged as legal advisor regarding the potential acquisition of DermoPlast® and Gernandt & Danielsson as legal advisor regarding the financing. About this information              This information is information that Moberg Pharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out above, at 17.30 p.m. (CET) on December 6th, 2016. Disclaimer/NoticeThis communication is not an offer of securities for sale in the United States or any other jurisdiction. Any securities referred to in this communication may not be offered or sold in the United States or any other jurisdiction absent registration under applicable securities laws or an exemption from registration.

Vattenfall enters the Danish consumer market

Vattenfall has a strategy to enter new markets through small and innovative sales companies with an existing customer base. The acquisition of Vindstød.dk and the entry into the Danish consumer sales market is a part of this. “The demand in the market makes it a natural step for us to move from being a wind power developer and operator to also start providing Danish customers with 100% renewable energy. Vindstød.dk is an innovative, successful and fast-growing company which has pioneered the Danish consumer market”, says Martijn Hagens, Head of Customers & Solutions, Vattenfall. Following three successful bids for major Danish offshore wind farms, Vattenfall is now also able to offer wind power to private customers. This is in line with Vattenfall´s strategy to be leading in sustainable energy production and consumption. “The acquisition in Denmark provides us with an attractive customer base, a strong IT-platform and an efficient organisation. We will now speed up the Vindstød.dk success-story even further, building on the 100% local wind power promise and scalable setup. We aim to grow the business significantly”, says Martijn Hagens. Vattenfall has a strong position in Denmark as the biggest onshore wind developer and operator and will soon be the biggest in offshore as well. Offering customers sustainable energy supply from a company such as Vindstød.dk is an attractive complement to the existing business in Denmark. “The Danish consumer market has large growth potential. The acquisition of Vindstød.dk is a start, and we want to open up a dialogue with similar companies to discuss their business with us”, says Martijn Hagens. Vattenfall and Vindstød.dk have agreed not to disclose the financial details of the transaction. Facts:Vindstød.dk was started in 2012 by Morten Nissen Nielsen and supplies 100% wind power that is bought from Danish wind power producers. The founder of Vindstød.dk, Morten Nissen Nielsen, will stay on as Managing Director. More information:Wind power in Vattenfall (https://corporate.vattenfall.com/about-energy/renewable-energy-sources/wind_power/wind-power-at-vattenfall/)Vindstød.dk (https://www.vindstoed.dk/) For further information, please contact:Heidi Stenström, Press Officer, +46 70 611 81 92,   (heidi.stenstrom@vattenfall.com)heidi.stenstrom@vattenfall.com (heidi.stenstrom@vattenfall.comVattenfall’s)Vattenfall’s Press Office, telephone: +46 8 739 5010, press@vattenfall.com

Senior management changes at Handelsbanken

Rolf Marquardt has been appointed CFO of Handelsbanken. He has been a member of the Bank’s Senior Management since 2015, and since September this year he has been Acting CFO.  Pål Bergström has been appointed Head of Handelsbanken’s Group Compliance. He has been a member of the Bank’s Senior Management since 2016, and since September this year he has been Acting Head of Group Compliance.  Stina Petersson has been appointed Head of Group Human Resources at Handelsbanken. She will also be a member of the Group’s Senior Management. Stina Petersson is currently responsible for management succession planning and leadership development within Group Human Resources.  All the above take up their new positions on 7 December 2016.  Stina Petersson succeeds Anders Öhman, who will reach his contractual age of retirement in the first half of 2017. He is therefore leaving Senior Management on 7 December 2016. During the period until his retirement, he will be working in an advisory capacity at Group Human Resources.  For further information, please contact:  Anders Bouvin, President and Group Chief Executive, +46 8–22 92 20Johan Lagerström, Chief Communications Officer,+46 8–701 13 95,+ 46 70–265 80 14Johan Wallqvist, Head of Group Media Relations, +46 8–701 80 47,+46 72–206 34 50 This information is of the type that Handelsbanken is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication through the agency of the contact person set out above, at 8.00 CET on 7 December 2016.For more information about Handelsbanken, see: www.handelsbanken.com (http://media.ne.cision.com/l/fbpxcdcv/www.handelsbanken.se/)

Mexican publisher signs agreement with Cxense for personalization offering

Oslo, Norway – 7 December 2016 – Cxense ASA (OSE: CXENSE) today announced that Empresas El Debate, SA de C.V. has signed an agreement with Cxense for the use of its Data Management and Personalization Software.El Debate is the biggest publisher in northern Mexico with daily coverage of local news for the states of Mazatlán, Sinaloa, Sonora, Durango, Baja California and Nayarit. The company also provides international-, sports- and entertainment news, as well as classifieds. El Debate has been active in reaching out to digital readers introducing app-based services in 2011.The company has licensed Cxense DMP and Cxense Content. El Debate will use the personalization offering to improve audience selling, enhance the group’s advertising strategy and drive user engagement. Cxense will in addition provide digital strategy consulting services.About Cxense:Cxense (pronounced "see-sense") enables the world's leading media, e-commerce and consumer brands to take control of their audience data to deliver more engaging and personalized user experiences. Businesses using Cxense's advanced real-time analytics, data management (DMP), advertising, search and personalization technology gain more engaged users, increased digital revenue and higher sales conversions. Cxense is headquartered in Oslo, Norway, with offices worldwide.Customers include the Wall Street Journal, USA Today (Gannett), Grupo Clarin, El Pais, Bonnier, Naspers, Ebay, The Golf Channel, PGA, NBA, NFL, ABC News, FOX Sports, Singapore Press Holdings, South China Morning Post, AEON, DMM, Rakuten and many more. For more information: www.cxense.com, Twitter: @Cxense. Cxense is listed on the Oslo Stock Exchange with the ticker 'CXENSE.'Investor Relations Contact:Jørgen Loeng, Chief Financial OfficerEmail: jorgen.loeng@cxense.comMobile: +47 906 60 062

SAS traffic figures - November 2016

Market developmentAlthough the demand is growing, the operating environment has become more challenging. As noted previously, the yield has declined more than anticipated during 2016. In addition, during the autumn jet fuel prices have started to increase combined with an unfavorable USD appreciation versus the SEK. This has had a negative effect on working capital and earnings. In addition, the introduced aviation tax in Norway has had a negative effect on the yield development. The total capacity increase in 2015/16 amounts to 10%. In 2016/2017, SAS’s total capacity increase will be lower. The increase will primarily be driven by a full-year effect from the new intercontinental routes that commenced during 2015/2016, increased capacity on leisure routes and the fact that the Airbus A320neo is larger than the aircraft it will replace. SAS scheduled traffic development in NovemberSAS increased its scheduled capacity in November by 10.4% and the traffic grew 17.3%. The overall load factor was 73.7%, the highest November load factor recorded for SAS. The improvement was driven by positive development on SAS’s intercontinental routes and international routes within Europe. SAS intercontinental traffic increased 29.4% and the capacity was up 21.8%. The growth was driven by the new routes to/from Los Angeles and Miami. The traffic on the European/Intrascandinavian routes increased by 13.6%. The growth was strongest on leisure oriented routes. On domestic routes, the capacity was increased by 1.6% and the traffic was up by 3.5%.

EQT Infrastructure enters strategic partnership with GETEC

· EQT Infrastructure to acquire a majority shareholding in three subsidiaries of GETEC ENERGIE HOLDING GmbH · EQT Infrastructure to support continued development of the subsidiaries GETEC heat & power AG, GETEC WÄRME & EFFIZIENZ AG und GETEC media AG · Partnership creates strong platform to build upon market position and continue geographical expansion The EQT Infrastructure investment strategy (“EQT Infrastructure”) has entered a strategic partnership with GETEC. The partnership will jointly develop the companies GETEC heat & power AG, GETEC WÄRME & EFFIZIENZ AG und GETEC media AG (together ”the Companies”) under a newly formed joint venture company. EQT Infrastructure will own 60 percent of the joint venture company. GETEC was founded by Dr Karl Gerhold in 1993 and is today one of the market leaders in energy services in Germany. The GETEC brand stands for tailor-made, efficient and sustainable energy solutions, implemented by a group of highly qualified engineers. The group currently operates around 1,050 decentralized energy production plants in Germany. In 2015, GETEC reported sales of EUR 783 million and employed 1,165 people. The aim of the partnership is to further strengthen and expand the activities of the jointly owned Companies. The strategy includes identifying and capturing growth opportunities both in Germany and by expanding into neighboring markets. Dr Karl Gerhold, owner and Managing Director of GETEC said: ”We are happy to partner with such an experienced investor and owner such as EQT Infrastructure. They have a stellar track record of developing companies and their experience and network of industrial experts in the energy sector is impressive. Together, we believe we now have the very best prerequisites to make the Companies even stronger.” Matthias Fackler, Partner at Investment Advisor EQT Partners, said: “Decentralized energy production is a crucial element of the new energy market and its importance will continue to increase in the future. GETEC is very well placed to profit from this trend thanks to a strong market position and outstanding technical capabilities. We are very much looking forward to support further development of the Companies and to explore expansion opportunities together with Dr Gerhold and the existing GETEC management team.” The transaction is subject to merger clearance from European competition authorities and is expected to close in the first quarter of 2017. Contacts: Matthias Fackler, Partner at EQT Partners in Germany, Investment Advisor to EQT Infrastructure, +49 89 2554 99520 Kerstin Danasten, EQT Press Officer, +46 8 506 55 334 About EQT EQT is a leading alternative investments firm with approximately EUR 30 billion in raised capital. EQT Funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 15 billion and approximately 100,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. More info: www.eqtpartners.com About the GETEC companies GETEC heat & power AG offers energy service solutions for industrial customers, municipalities and large complex real estate owners. As part of its business the company develops, builds, finances and operates innovative and highly efficient energy production plants. GETEC WÄRME & EFFIZIENZ AG offers energy service solutions for real estate owners and operators. This includes residential, commercial and public real estate, hotels as well as social buildings such as hospitals or care homes. GETEC media AG offers telecom services as well as implementation and operation of data transport infrastructure for the real estate sector. More info: www.getec.de

Vattenfall’s wireless charging station inaugurated on new electric bus route

This is the first time in the Nordic region that a hybrid electric bus running on a regular route is being provided with invisible inductive charging. Seven minutes of wireless charging is enough for bus route 755 to run its entire distance of ten kilometres. The experience gained in this project will be important for the public transport of the future. “This cooperation is a tangible example of realising Vattenfall’s strategy. The further electrification of the transport sector is one of the most important contributions to a climate-neutral Sweden. A hundred years ago, Vattenfall electrified Sweden and the railways, and now we are electrifying the road transports,” says Magnus Hall, CEO and President of Vattenfall. Vattenfall owns and operates the charging station and supplies it with renewable electricity. Wireless bus stop charging means that the bus parks over a charging segment hidden in the road where charging takes place automatically. This charging solution is based on wireless inductive technology which is safe, efficient and environmentally friendly. Sweden aims to have a fossil-free vehicle fleet by 2030. The electrification of public transport, and buses in particular, is crucial to reach this goal. The hybrid electric bus is 70 per cent more energy-efficient than a corresponding conventional diesel bus."Vattenfall wholeheartedly supports the objective of reducing emissions from the transport sector and it is a part of the company’s future to offer customised charging infrastructure for electric buses,” says Hall.  For further information, please contact:Michelle von Gyllenpalm, Head of PRA & Media Relations, phone: +46 70-531 63 11 From Vattenfall’s Press Office, telephone: +46 8 739 5010

Scania tests fast wireless charging in urban traffic

  This is the first time the technology is being tested in the Nordic region and both the bus and bus stop solution are part of a research project where Scania, the public transport operator for the Stockholm region SL, Vattenfall, Södertälje Municipality and the Royal Institute of Technology (KTH) are cooperating to develop a silent and sustainable public transport system. The project is partly financed by the Swedish Energy Agency.   For the first time ever, this type of technology is also being tested for a more extreme climate, which this type of infrastructure must also cope with to be relevant in more northerly parts of the world. Wireless bus stop charging means that the bus parks over a charging segment located under the road surface at the charging station, where charging occurs automatically. The design of the inductive technology has been adapted so as not to disturb existing urban environments and is essentially invisible. Seven minutes of wireless charging is enough to cover the entire 10 km-long route, which the bus will operate in Södertälje. “The electric hybrid bus in this project demonstrates a technology track for a more sustainable transport solution. The inductive charging technology is both silent and invisible. The field test in Södertälje is important ahead of the choices facing both society and the automotive industry with regard to eliminating emissions and reducing noise from traffic in sensitive urban environments,” says Hedvig Paradis, who is a project manager at Scania and responsible for the company’s participation in the research project. The cost of the Wireless bus stop charging project amounts to just over SEK 38 million, of which Scania is investing SEK 22 million. The Swedish Energy Agency has granted almost SEK 10 million in research funding, which will be divided among the Royal Institute of Technology, Scania and SL. “This is one of several projects Scania is conducting in order to find solutions for future sustainable transport services in cities,” says Anders Grundströmer, Head of recently started Scania Sustainable City Solutions. “We are working on identifying the needs of cities and on creating systems for eco-friendly, fast, secure and cost-effective transport solutions, which are based on locally-produced alternative fuels including electrification.”   Electrification of the transport sector will demand various technologies and solutions – both in terms of where and how vehicles are charged. Charging can either occur when vehicles are stationary at depots and bus stops or during operation. For charging during operation the alternatives are conductive charging via a pantograph or inductive charging – or a combination of these techniques. The choice of solution depends on what transport task will be performed. The size and weight of the batteries, which can be carried on board the vehicle, for example, determines how much of the charging must occur while in service. The bus that Scania will test in Södertälje’s urban traffic is a hybrid bus, i.e. featuring technology, which means that the bus’s batteries are also charged during operation by utilising braking power. Charging may also occur using the bus’s combustion engine, which operates on fossil-free fuel. More information about Scania’s electrification is available on www.scania.com/electrification For further information, please contact Karin Hallstan, Public Relations Manager,  tel. +46 76 842 81 04. Technical facts about the bus: Model: Scania Citywide LE4x2Powertrain: Parallel hybrid, integrated with the   gearbox (GRS895)Electrical 130 kWengine,capacity:Battery: Li-Ion 56 kWhCombustion 9-litre 320 hp diesel engine (operates on biodiesel)engine:

Sobi and Horizon Pharma enter five-year distribution agreement for Ravicti® and Ammonaps® outside the United States

Swedish Orphan Biovitrum AB (publ) (http://www.sobi.com/) (Sobi™) and Horizon Pharma plc (NASDAQ: HZNP) (“Horizon”) today announced that the companies have entered into a five-year distribution agreement for Ravicti® (glycerol phenylbutyrate) in European countries, including United Kingdom, Germany, France, Italy and Spain and for Ammonaps® (sodium phenylbutryate) in the same European countries and certain Middle Eastern countries.  Under the agreement, Sobi will have exclusive marketing, sales and distribution rights for the two medicines in the territory until 31 December 2021. Horizon has the ability to terminate the agreement after two years subject to certain pre-defined termination fees.  Sobi currently distributes Ravicti in certain Middle Eastern countries and Ammonaps in certain European and Middle Eastern countries. Ravicti and Ammonaps are authorised by the European Commission and are indicated for the treatment of Urea Cycle Disorders (UCD). “We are happy to build on our successful relationship with Horizon Pharma to support providing treatment to people living with UCDs”, says Alan Raffensperger, Chief Operating Officer of Sobi and continues:  “This distribution agreement will allow us to leverage our existing expertise and extensive experience within the area of UCDs.  Our main focus now will turn to implementing patient access activities with the objective to launch Ravicti in Europe during 2017.” “Sobi has been a trusted partner in Europe and the Middle East for the last three years,” says Francoise de Craecker, group vice president and general manager, EMEA, orphan business unit, Horizon Pharma plc.  “We believe that Sobi's current distribution of Ammonaps uniquely qualifies it to effectively provide Ravicti to people living with UCDs in European markets.” _________ About Ravicti® Ravicti is indicated for use in all 28 Member States of the European Union and 3 Member States of the European Economic Area as a nitrogen-binding agent for chronic management of adult and pediatric patients two months of age and older with UCDs who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. Important Safety Information LIMITATIONS OF USE:  · Ravicti is not indicated for the treatment of acute hyperammonemia in patients with UCDs because more rapidly acting interventions are essential to reduce plasma ammonia levels. · The safety and efficacy of Ravicti for the treatment of patients with N-acetylglutamate synthase (NAGS) and CITRIN (citrullinaemia type 2) deficiency has not been established. · The use of Ravicti in patients <2 months of age is not recommended as the safety and efficacy of Ravicti in this age group has not been established. CONTRAINDICATIONS:  · Hypersensitivity to the active substance. · Treatment of acute hyperammonaemia.  WARNINGS AND PRECAUTIONS:  · Phenylacetate acid (PAA), the major metabolite of Ravicti, may be toxic at levels ≥500 µg/mL. Reduce Ravicti dosage if symptoms of neurotoxicity, including vomiting, nausea, headache, somnolence, confusion, or sleepiness are present in the absence of high ammonia or other intercurrent illnesses. · Low or absent pancreatic enzymes or intestinal disease resulting in fat malabsorption may result in reduced or absent digestion of Ravciti and/or absorption of phenylbutyrate and reduced control of plasma ammonia. Monitor ammonia levels closely. · Studies in animals have shown reproductive toxicity (see section 5.3). There are limited data regarding the use of glycerol phenylbutyrate in pregnant women. Glycerol phenylbutyrate is not recommended during pregnancy and in women of childbearing potential not using contraception. · It is unknown whether glycerol phenylbutyrate or its metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from glycerol phenylbutyrate therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. ADVERSE REACTIONS:  · Assessment of adverse reactions was based on exposure in 114 UCD patients (65 adults and 49 children between the ages of 2 months and 17 years) with deficiencies in CPS, OTC, ASS, ASL, ARG, or HHH across 4 short term and 3 long term clinical studies, in which 90 patients completed 12 months duration (median exposure = 51 weeks). · At the beginning of the treatment, abdominal pain, nausea, diarrhoea, and/or headache may occur; these reactions usually disappear within a few days even if treatment is continued. The most frequently reported adverse reactions (>5%) during glycerol phenylbutyrate treatment were diarrhoea, flatulence, and headache (8.8% each); decreased appetite (7.0%), vomiting (6.1%); and fatigue, nausea and, skin odour abnormal (5.3% each). DRUG INTERACTIONS:  · Concomitant use of medicinal products known to inhibit lipase should be given with caution as glycerol phenylbutyrate is hydrolysed by digestive lipase into phenylbutyrate acid and glycerol. This may be associated with increased risk of medicinal product interactions with lipase inhibitors and with lipase contained in pancreatic enzyme replacement therapies. · A potential effect on CYP2D6 isoenzyme cannot be excluded and caution is advised for patients who receive medicinal products that are CYP2D6 substrates. · Glycerol phenylbutyrate and/or its metabolites, PAA and PBA, have been shown to be weak inducers of CYP3A4 enzyme in vivo. In vivo exposure to glycerol phenylbutyrate has resulted in decreased systemic exposure to midazolam of approximately 32% and increased exposure to the 1-hydroxy metabolite of midazolam, suggesting that steady-state dosing of glycerol phenylbutyrate results in CYP3A4 induction. The potential for interaction of glycerol phenylbutyrate as a CYP3A4 inducer and those products predominantly metabolised by the CYP3A4 pathway is possible. Therefore, therapeutic effects and/or metabolite levels of medicinal products, including some oral contraceptives that are substrates for this enzyme may be reduced and their full effects cannot be guaranteed, following coadministration with glycerol phenylbutyrate. · Corticosteroids, valproic acid, haloperidol and probenecid may have the potential to affect ammonia levels. About Ammonaps®Ammonaps (sodium phenylbutyrate) is used to treat Urea Cycle Disorders (UCD). UCD is a group of serious conditions in which patients suffer from deficiencies in the enzymes required to remove ammonia from the blood stream.Ammonaps is used to reduce levels of ammonia and glutamine in the blood. Ammonaps is used with other treatments and a special diet for the long-term management of patients with urea cycle disorders where there is lack of one or more of the following enzymes: carbamyl phosphate synthetase, ornithine transcarbamylase, or argininosuccinate synthetase. Ammonaps is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy. Important Safety Information  CONTRAINDICATIONS:  · Pregnancy. · Breast-feeding. · Hypersensitivity to the active substance or to any of the excipients WARNINGS AND PRECAUTIONS: · Ammonaps tablets should not be used in patients with dysphagia due to the potential risk of oesophageal ulceration if tablets are not promptly delivered to the stomach. Each Ammonaps tablet contains 62 mg (2.7 mmol) of sodium, corresponding to 2.5 g (108 mmol) of sodium per 20 g of sodium phenylbutyrate, which is the maximum daily dose. Ammonaps should therefore be used with caution in patients with congestive heart failure or severe renal insufficiency, and in clinical conditions where there is sodium retention with oedema.  · Ammonaps granules contain 124 mg (5.4 mmol) of sodium per gram of sodium phenylbutyrate, corresponding to 2.5 g (108 mmol) of sodium per 20 g of sodium phenylbutyrate, which is the maximum daily dose. Ammonaps should therefore be used with caution in patients with congestive heart failure or severe renal insufficiency, and in clinical conditions where there is sodium retention with oedema.  · Since the metabolism and excretion of sodium phenylbutyrate involves the liver and kidneys, Ammonaps should be used with caution in patients with hepatic or renal insufficiency.  · Serum potassium should be monitored during therapy since renal excretion of phenylacetylglutamine may induce a urinary loss of potassium.  · Even on therapy, acute hyperammonaemic encephalopathy may occur in a number of patients.  · Ammonaps is not recommended for the management of acute hyperammonaemia, which is a medical emergency.  · In children unable to swallow tablets, it is recommended to use Ammonaps granules instead.                         ADVERSE REACTIONS:  · In clinical trials with Ammonaps, 56 % of the patients experienced at least one adverse event and 78 % of these adverse events were considered as not related to Ammonaps. · Adverse reactions mainly involved the reproductive and gastrointestinal system. DRUG INTERACTIONS:  · Concurrent administration of probenecid may affect renal excretion of the conjugation product of sodium phenylbutyrate. · There have been published reports of hyperammonaemia being induced by haloperidol and by valproate. Corticosteroids may cause the breakdown of body protein and thus increase plasma ammonia levels. More frequent monitoring of plasma ammonia levels is advised when these medications have to be used. About Sobi™ Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and   Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and about 700 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.   About Horizon Pharma plc Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs.  The Company markets 11 medicines through its orphan, rheumatology and primary care business units.  For more information, please visit www.horizonpharma.com (http://file///C:/Users/e011271/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/FHXQBXL5/www.horizonpharma.com).  Follow @HZNPplc (http://ctt.marketwire.com/?release=1199271&id=6291790&type=1&url=https%3a%2f%2ftwitter.com%2fhznpplc) on Twitter or view careers on our LinkedIn (http://ctt.marketwire.com/?release=1199271&id=6291793&type=1&url=https%3a%2f%2fwww.linkedin.com%2fcompany%2fhorizon-pharma) page.  Forward Looking StatementsThis press release contains forward-looking statements, including statements regarding the potential benefits that may be derived from the distribution agreement between Horizon Pharma and Sobi, and plans and expected timing with respect to launching Ravicti in Europe.  These forward-looking statements are based on management expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors.  These factors include risks that the distribution agreement is terminated early, that either party does not comply with its obligations under the distribution agreement, that adequate pricing and reimbursement for Ravicti in Europe is not available, and those factors described in Horizon Pharma's filings with the United States Securities and Exchange Commission, including those discussed under the caption "Risk Factors" in those filings.  Forward-looking statements speak only as of the date of this press release and Horizon does not undertake any obligation to update or revise these statements, except as may be required by law.  For more informationplease contact:Media relations Investor relationsLinda Holmström, Senior Jörgen Winroth, ViceCommunications Manager  President, Head of Investor RelationsT: + 46 708 73 40 95, + T: +1 347-224-0819, +1 21246 8 697 31 74   -579-0506, +46 8 697 2135linda.holmstrom@sobi.com jorgen.winroth@sobi.com  Horizon Pharma contacts:Media  Investor relations Geoff Curtis  Tina Ventura Senior Vice President, Senior Vice President,Corporate Investor Relations Communications media@horizonpharma.com  Investor -relations@horizonpharma.com

EQT Mid Market invests in Fertin Pharma A/S

· EQT Mid Market acquires Fertin Pharma, the world’s largest independent developer and manufacturer of medicated chewing gum · The founding Bagger-Sørensen family will reinvest and enter into a partnership with EQT Mid Market with the view to further develop and accelerate the growth of Fertin Pharma · The management team of Fertin Pharma, led by CEO Søren Birn, will remain with the Company and invest alongside the Bagger-Sørensen family and EQT Mid Market EQT Mid Market has agreed to acquire Fertin Pharma (“Fertin Pharma” or the “Company”) from the Bagger-Sørensen family. The Bagger-Sørensen family will reinvest part of their proceeds and will following the transaction own 30% of the Company. The Company is the leading independent B2B developer and manufacturer of medicated chewing gum, primarily within Nicotine Replacement Therapy (“NRT”), a pharmaceutical product used for withdrawal management in the process of tobacco cessation. Furthermore, Fertin develops pharmaceutical chewing gum with different APIs (MediChew) and nutraceutical chewing gum products (Nutraceuticals). Rikke Kjær Nielsen, Director at EQT Partners and Investment Advisor to EQT Mid Market, said: “We are truly impressed by Fertin Pharma’s strong management team and its unparalleled market position based on a unique combination of more than 100 years of chewing gum heritage, profound nicotine knowledge and strong pharma manufacturing capabilities. Fertin is a global market leader within NRT gum with a strong financial track record operating in one of EQT’s core sectors and core geographies. As such we see an excellent match with EQT, which is further underpinned by the EQT track record in healthcare investments and experience in supporting companies to drive growth across different avenues. We are therefore extremely pleased about the partnership with the founding family to jointly develop Fertin into an even stronger company”. Søren Birn, CEO of Fertin Pharma, said: “Fertin has developed a global stronghold with its leading NRT gum product portfolio and realized above market growth for several years.We are very pleased to have EQT as our new majority owner and partner in this exciting phase for Fertin. We share the same vision and ambitions for Fertin’s great potential. Under the new partnership, we look very much forward to  continue growing the core business while exploring new avenues of growth for the Company”. Steen and Claus Bagger-Sørensen, main shareholders of Fertin Pharma, said: “We are pleased to have EQT as the new majority owner of Fertin, and we believe they are a great fit with Fertin, both in terms of core values, visions and long-term ambitions for the Company. Furthermore, we are excited about entering a partnership with them, and we look forward to working alongside EQT and contributing knowledge, experience and history”.   Financial terms of the transaction are not disclosed. Contacts: Rikke Kjær Nielsen at EQT Partners, Investment Advisor to EQT Mid Market, +45 4021 1216 Kerstin Danasten, EQT Press Officer, +46 8 506 55 334 About the Bagger-Sørensen family The Bagger-Sørensen family founded Vejle Caramel og Tablet Fabrik in 1915 and launched the Dandy chewing gum brand in 1939. In 1978, the Swedish company Fertin, known for their V6 chewing gum, was acquired by the Bagger-Sørensen Group. Following the acquisition the company was renamed Fertin Pharma and in 2000 Fertin Pharma launched the world’s first coated nicotine gum. Today, the family brothers Steen and Claus Bagger-Sørensen, along with the family fund, comprise the owners of Fertin Pharma prior to the transaction. About EQT EQT is a leading alternative investments firm with approximately EUR 31 billion in raised capital. EQT Funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 15 billion and approximately 100,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. More info: www.eqtpartners.com About Fertin Pharma Fertin Pharma A/S is a family-owned company based in Vejle, Denmark, with additional facilities in India. Fertin is the world’s leading B2B developer/manufacturer of medicated chewing gum, specialising in Nicotine Replacement Therapy gum. Fertin has 715 employees and an estimated 2016 revenue of DKK 851m and EBITDA of DKK 250m. More info: www.fertin.com 

Enersize selects Sedermera Fondkommission as advisor for planned listing on Nasdaq Stockholm First North during 2017

The listing process starts directly and exact information will follow in an investor memorandum to be published later. Enersize recently added one large Chinese glass manufacturer to its project list after previously announcing orders in both the Chinese vehicle and electronics sector. Christian Merheim, Chairman of the Board Enersize, comments: “With an attractive case we had a large selection of advisors to choose from. We are very happy to announce that we choose Sedermera. We had our initial discussions with them over a year ago and we have been impressed with their thoroughness, professionality and integrity all along the way. Enersize team is really looking forward working together with Sedermera for the 2017 IPO". Sami Mykkänen, Enersize CEO, comments: “The timing to start our IPO process could not have been better. During the last year, we have more than tripled the size of our sales pipeline and closed several significant customers. The upcoming IPO gives us the possibility to take on even more projects".  Cleantech Invest, the largest owner of Enersize, CEO Alexander Lidgren comments: “We are happy to be one step closer to offering a listed share in what we think is a carbon cutting champion. After hard and systematic efforts building a big customer pipeline, Enersize is now delivering what can only be labelled drastic energy savings to the Chinese manufacturing industry.” Sedermera Fondkommission’s Head of Corporate Finance, Andreas Sandgren, comments: ”We are delighted to have been appointed Enersize’s advisor and look forward to initiating the listing process of the company.” About Sedermera Fondkommission: Sedermera Fondkommission offers services for listed companies or companies with the target of being listed at a trading platform. Sedermera’s services includes corporate finance, certified adviser, M&A’s, financial communications, issue management and market making. Sedermera is a secondary name of ATS Finans AB, an investment firm under the supervision of the Swedish FSA (Finansinspektionen). Sedermera’s headquarter is in Malmö, Sweden. The company also have offices in Lund (Medicon Village) and Norrköping (Norrköping Science Park). The organisation consists of approximately fifteen co-workers. Sedermera’s ambition is to create long term client and investing relations.

Ripasso Energy AB – license applications information and revenue forecast for 2018

At the time of the information memorandum, i.e. November 23, 2016, Horizon had submitted applications for 16 projects with an aggregated sales potential of 106 hybridized Stirling engines (“engines”). Since that date until December 6, 2016, Horizon has submitted additional applications. This means that as of today, there are pending applications for 22 projects, including 125 engines. In addition to the pending applications, Horizon expects to submit applications for an additional 20 projects including 67 engines before end of 2016.  With respect to the pending applications: · 8 projects including 55 engines have been approved for grid connection. · 4 projects including 39 engines have been declined grid connection. · 10 projects including 31 engines await decision.  The grid connection approval is an important step in the application process. The projects approved for grid connection now await decisions from regional authorities. Declined projects are not likely to materialize. Approved projects are expected to be fully ready for investment between April and August 2017. A firm order to Ripasso Energy is expected in September 2017. Final delivery of the first projects is planned for Q1 2018. During 2018, Ripasso Energy forecasts completed delivery of at least 100 engines, resulting in Ripasso Energy’s share of revenues being 4.8 MEUR with a positive gross margin. During 1H 2017, Ripasso Energy and Horizon will construct a demonstration unit on the grounds of University of Palermo. The objective is to attract interest to invest in projects with Ripasso Energy technology and transfer EPC-knowledge to Horizon in preparation for commercial projects. The target date for completion is May 31, 2017. Part of the construction process will be recorded by Finwire Media and published on YouTube.   For additional information with respect to this press release, please contact Ripasso Energy’s CEO and founder Gunnar Larsson, e-mail: ir@ripassoenergy.com. For more information about the company, visit: www.ripassoenergy.com. This information is information that Ripasso Energy is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 8:30 on December 8, 2016.

Change in the reporting of costs related to growth of biological assets

Costs related to the development of biological assets are capitalised on the balance sheet during the growth cycle (i.e. until the time of harvesting). At harvesting, the capitalised costs are transferred from biological assets to inventory. Prior to the change, Stora Enso has included the costs related to the growth of biological assets in its operational EBITDA. Starting from the fourth quarter of 2016, these growth costs will be excluded from operational EBITDA and presented as Operational decrease in the value of biological assets. The reason for the change is to align the reporting of the growth costs with industry benchmarks. This change will affect the following key figures: · operational EBITDA · operational EBITDA margin · net debt to last 12 months’ operational EBITDA ratio There will be no impact on operational EBIT, the subtotals of the official Condensed Consolidated Income Statement or the group’s other IFRS figures. The new definition of the non-IFRS measure of operational EBITDA is: operating profit/loss excluding operational decrease in the value of biological assets, fixed asset depreciation and impairment, share of results of equity accounted investments, IAC and fair valuations. The historical figures are restated according to the new reporting structure and presented in the tables below. RECONCILIATION OF OPERATIONAL PROFITABILITY As published  EUR million Q3/16 Q2/16 Q1/16 2015  Q4/15 Q3/15  Q2/15  Q1/15         Operational 326 333 356 1 352 341 353 318 340EBITDAEquity 17 16 16 80 22 21 24 13accountedinvestments(EAI),operationalDepreciation -124 -123 -124 -517 -121 -128 -135 -133andimpairmentexcl. IACOperational 219  226  248  915  242  246  207  220 EBIT Fair -14 -15 -26 378 401 -25 15 -13valuationsand non-operationalitemsItems -9 37 -28 -234 -250 16 -8 8affectingcomparability(IAC)Operating 196  248  194  1 059  393  237  214  215 profit(IFRS)  Restated  EUR million Q3/16 Q2/16 Q1/16 2015  Q4/15 Q3/15 Q2/15 Q1/15             Operational 343 355 363 1 408 351 369 337 351EBITDAEquity 17 16 16 80 22 21 24 13accountedinvestments(EAI),operationalOperational -17 -22 -7 -56 -10 -16 -19 -11decrease inthevalue ofbiologicalassetsDepreciation -124 -123 -124 -517 -121 -128 -135 -133andimpairmentexcl. IACOperational 219  226  248  915  242  246  207  220 EBIT Fair -14 -15 -26 378 401 -25 15 -13valuationsand non-operationalitemsItems -9 37 -28 -234 -250 16 -8 8affectingcomparability(IAC)Operating 196  248  194  1 059  393  237  214  215 profit(IFRS)  Change  EUR million Q3/1 Q2/1 Q1/1 2015  Q4/1 Q3/15  Q2/15  Q1/15  6  6  6  5 Operational 17 22 7 56 10 16 19 11EBITDAEquity 0 0 0 0 0 0 0 0accountedinvestments(EAI),operationalOperational -17 -22 -7 -56 -10 -16 -19 -11decrease inthevalue ofbiologicalassetsDepreciation 0 0 0 0 0 0 0 0andimpairmentexcl. IACOperational 0  0  0  0  0  0  0  0 EBIT Fair 0 0 0 0 0 0 0 0valuationsand non-operationalitemsItems 0 0 0 0 0 0 0 0affectingcomparability(IAC)Operating 0  0  0  0  0  0  0  0 profit(IFRS)  OPERATIONAL EBITDA BY SEGMENTS  As published  EUR million Q3/16 Q2/16 Q1/16 2015 Q4/15 Q3/15 Q2/15 Q1/15Consumer Board 109 113 108 434 89 116 114 115Packaging Solutions 37 33 23 147 37 32 38 40Biomaterials 71 84 110 420 108 125 87 100Wood Products 30 41 23 111 26 30 32 23Paper 77 74 83 231 74 44 52 61Other 2 -12 9 9 7 6 -5 1Total 326 333 356 1 352 341 353 318 340 Restated  EUR million Q3/16 Q2/16 Q1/16 2015 Q4/15 Q3/15 Q2/15 Q1/15Consumer Board 118 127 110 466 94 128 124 120Packaging Solutions 37 33 23 147 37 32 38 40Biomaterials 79 92 115 444 113 129 96 106Wood Products 30 41 23 111 26 30 32 23Paper 77 74 83 231 74 44 52 61Other 2 -12 9 9 7 6 -5 1Total 343 355 363 1 408 351 369 337 351 Change  EUR million Q3/16 Q2/16 Q1/16 2015 Q4/15 Q3/15 Q2/15 Q1/15Consumer Board 9 14 2 32 5 12 10 5Packaging Solutions 0 0 0 0 0 0 0 0Biomaterials 8 8 5 24 5 4 9 6Wood Products 0 0 0 0 0 0 0 0Paper 0 0 0 0 0 0 0 0Other 0 0 0 0 0 0 0 0Total 17 22 7 56 10 16 19 11 OPERATIONAL EBITDA MARGIN BY SEGMENTS As published  % Q3/16 Q2/16 Q1/16 2015 Q4/15 Q3/15 Q2/15 Q1/15Consumer Board 18.2% 18.9% 19.1% 18.5% 15.9% 19.1% 18.9% 20.2%Packaging Solutions 14.3% 12.8% 9.4% 16.1% 15.4% 14.2% 16.8% 18.1%Biomaterials 21.3% 24.6% 31.3% 28.3% 28.9% 31.9% 23.9% 28.2%Wood Products 7.8% 9.5% 6.0% 6.9% 6.6% 8.0% 7.3% 5.9%Paper 9.7% 8.8% 9.7% 6.4% 8.3% 4.8% 5.7% 6.7%Other 0.4% -1.9% 1.4% 0.4% 1.1% 1.1% -0.8% 0.2%Total 13.6% 13.2% 14.6% 13.5% 13.7% 14.1% 12.4% 13.6% Restated  % Q3/16 Q2/16 Q1/16 2015 Q4/15 Q3/15 Q2/15 Q1/15Consumer Board 19.7% 21.2% 19.5% 19.9% 16.8% 21.1% 20.6% 21.1%Packaging Solutions 14.3% 12.8% 9.4% 16.1% 15.4% 14.2% 16.8% 18.1%Biomaterials 23.7% 26.9% 32.8% 29.9% 30.2% 32.9% 26.4% 29.9%Wood Products 7.8% 9.5% 6.0% 6.9% 6.6% 8.0% 7.3% 5.9%Paper 9.7% 8.8% 9.7% 6.4% 8.3% 4.8% 5.7% 6.7%Other 0.4% -1.9% 1.4% 0.4% 1.1% 1.1% -0.8% 0.2%Total 14.3% 14.1% 14.8% 14.0% 14.1% 14.8% 13.2% 14.1% Change  Percentage point Q3/16 Q2/16 Q1/16 2015 Q4/15 Q3/15 Q2/15 Q1/15Consumer Board 1.5 2.3 0.4 1.4 0.9 2.0 1.7 0.9Packaging Solutions 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0Biomaterials 2.4 2.3 1.5 1.6 1.3 1.0 2.5 1.7Wood Products 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0Paper 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0Other 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0Total 0.7 0.9 0.2 0.5 0.4 0.7 0.8 0.5 NET DEBT/LAST 12 MONTHS' OPERATIONAL EBITDA RATIO As published  Q3/1 Q2/16 Q1/16 2015 Q4/15 Q3/15 Q2/15 Q1/15 6Net debt/last 12 months' 2.1 2.3 2.3 2.4 2.4 2.5 2.7 2.6operational EBITDA ratio Restated  Q3/1 Q2/16 Q1/16 2015 Q4/15 Q3/15 Q2/15 Q1/15 6Net debt/last 12 months' 2.1 2.2 2.2 2.3 2.3 2.3 2.6 2.5operational EBITDA ratio Change  Q3/1 Q2/16 Q1/16 2015 Q4/15 Q3/15 Q2/15 Q1/15 6Net debt/last 12 months' 0.0 -0.1 -0.1 -0.1 -0.1 -0.2 -0.1 -0.1operational EBITDA ratio For further information, please contact: Ulrika Lilja, EVP Communications, tel. +46 72 221 9228 Investor enquiries:Ulla Paajanen-Sainio, SVP, Investor Relations, tel. +358 40 763 8767  Stora Enso is a leading provider of renewable solutions in packaging, biomaterials, wooden constructions and paper on global markets. Our aim is to replace fossil based materials by innovating and developing new products and services based on wood and other renewable materials. We employ some 26 000 people in more than 35 countries, and our sales in 2015 were EUR 10.0 billion. Stora Enso shares are listed on Nasdaq Helsinki (STEAV, STERV) and Nasdaq Stockholm (STE A, STE R). In addition, the shares are traded in the USA as ADRs (SEOAY) on the International OTCQX over-the-counter market. storaenso.com (http://www.storaenso.com/)  STORA ENSO OYJ

Cleantech Invest portfolio company Swap.com raises 19M€ round

Cleantech Invest portfolio company Swap.com (Swap.com Services Oy) has closed a 19M€ investment round. The round was led by eEquity from Sweden and joined by other investors. This investment brings Swap.com’s total equity funding to 46M€. The funding will be used to further accelerate the growth of Swap.com. The effective ownership of Cleantech Invest Plc in Swap.com is 5.3% after this investment round. Cleantech Invest Plc and all of its affiliated companies own a total of 16.1% of Swap.com after the transaction. The ownership does not take into account possible dilution from performance based options. Swap.com is an online consignment store that was founded in Finland. The company has been growing 180 % year-over-year, and the company operates a state-of-the-art logistics center of 360,000 square feet in Bolingbrook, Illinois. It has over 1.5 million unique items in stock. CEO of Cleantech Invest, Alexander Lidgren: ”We warmly welcome the new shareholders on board Swap.com. Swap.com aims to become the category leader in the rapidly growing online pre-owned retail market, which is emerging between the traditional online shops such as Amazon and peer-to-peer marketplaces such as eBay. Swap.com is redefining the pre-owned market and changing the way people consume. The investment round is among the largest in the Nordic start-up scene, and reflects the opportunity for a multi-billion dollar business.“ CEO & Co-Founder of Swap.com Services Oy, Dr. Juha Koponen: “As an industry, we’re only scratching the surface. There’s a staggering amount of unused, pre-owned merchandise with an estimated value of more than one hundred billion dollars annually. And while there is a large demand for secondhand items, the merchandise has not been moving mostly because there hasn’t been a practical or convenient way to purchase these items online. With more than 30% of Americans shopping in thrift and consignment stores each year, we have an incredible opportunity to make an impact. This round lead by e-commerce focused eEquity provides us with the resources to scale and become a household name in the United States.” Carnegie Investment Banking acted as a sole financial advisor to Swap.com Services Oy in the private placement. For more information see Swap.com’s press release here (https://www.dropbox.com/s/hxvyi219f9q59bi/2016FundingPressReleaseFI.pdf?dl=0).

TalkPool and Sigma sign global framework agreement within IoT

TalkPool works with advanced technologies and has created a unique leading position in the Low Power Wide Area Technologies (LPWA). This requires credible and stable partners. Sigma Technology is a reliable supplier of technology and software development, with a strong focus on the needs of their customers and high delivery quality. “The new radio technology, optimized for long range and low power consumption, allows for more units to be connected than what was up until now economically viable or even possible. For example, smart homes, containers of various types, pallets and parking lots. It will be fascinating to see what new and exciting areas we will develop that improves our society and gives companies even better offerings”, says Robert Spertina, Head of IoT. Earlier this year, Tele2 and TalkPool entered into a partnership with the goal of building an IoT network based on LoRaWAN Technology in Gothenburg. This will enable many exciting customer projects in the Gothenburg region. "We are very happy and proud for the opportunity to help TalkPool with the development of the IoT solutions of tomorrow. For 30 years, Sigma has built a strong competence in software development and in recent years we have focused a lot on strengthening our expertise within IoT. Therefore, we look forward to cooperating with TalkPool and follow them in their ambitious goal to create innovative IoT services." said Robert Åberg, Head of IoT Solutions at Sigma Technology. For further information, please contact:Robert Spertina, Head of IoTTel: +46 70 797 6788robert.spertina@talkpool.com Erik Strömstedt, CEO Talkpool AGTel: +41 81 250 2020erik.stromstedt@talkpool.com    About TalkpoolTalkPool builds, maintains and improves telecommunication networks globally. Through its cutting-edge technical expertise, long experience and agile business model, TalkPool offers global telecom vendors and operators high-quality services on short notice no matter the location. Moreover, TalkPool is one of few companies with actual solutions and contracts in place in the exciting IoT-market. Remium Nordic AB is TalkPool’s Certified Advisor.   About Sigma Technology Group and SigmaSigma Technology Group is a global provider of product information, embedded & software design and offshore development. We are experts with a passion for technology and information and we take pride in always improving our deliveries. Our delivery philosophy is "Local Drive - Global Strength", which is why we have offices in many places around the world to be close to our customers. Sigma is owned by Danir AB and has about 3000 employees in eleven countries. For more information, visit www.sigmatechnology.se.